WO2013082317A2 - Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof - Google Patents

Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof Download PDF

Info

Publication number
WO2013082317A2
WO2013082317A2 PCT/US2012/067123 US2012067123W WO2013082317A2 WO 2013082317 A2 WO2013082317 A2 WO 2013082317A2 US 2012067123 W US2012067123 W US 2012067123W WO 2013082317 A2 WO2013082317 A2 WO 2013082317A2
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant
vaccine
vector
gene
virus
Prior art date
Application number
PCT/US2012/067123
Other languages
French (fr)
Other versions
WO2013082317A3 (en
WO2013082317A8 (en
Inventor
Michael Bublot
Teshome Mebatsion
Joyce Pritchard
Perry LINZ
Original Assignee
Merial Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013082317(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to HRP20190525TT priority Critical patent/HRP20190525T4/en
Priority to PL12805843.5T priority patent/PL2785374T5/en
Priority to ES12805843T priority patent/ES2719409T5/en
Priority to MEP-2019-103A priority patent/ME03433B/en
Priority to LTEP12805843.5T priority patent/LT2785374T/en
Priority to MX2014006361A priority patent/MX361893B/en
Priority to IN4833CHN2014 priority patent/IN2014CN04833A/en
Priority to CN201280066324.4A priority patent/CN104159605B/en
Priority to RS20190443A priority patent/RS58610B1/en
Priority to JP2014544892A priority patent/JP6149301B2/en
Priority to KR1020147017914A priority patent/KR102013135B1/en
Priority to SI201231570T priority patent/SI2785374T1/en
Priority to EP12805843.5A priority patent/EP2785374B2/en
Priority to DK12805843.5T priority patent/DK2785374T3/en
Application filed by Merial Limited filed Critical Merial Limited
Publication of WO2013082317A2 publication Critical patent/WO2013082317A2/en
Publication of WO2013082317A3 publication Critical patent/WO2013082317A3/en
Publication of WO2013082317A8 publication Critical patent/WO2013082317A8/en
Priority to HK15100455.1A priority patent/HK1200018A1/en
Priority to CY20191100394T priority patent/CY1121528T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/125—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use as safe immunization vehicles to protect against a variety of pathogens. It also relates to multivalent composition or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making and using the recombinant viral vectors.
  • ND Newcastle disease
  • IBD infectious bursal disease
  • MD infectious bronchitis
  • IB infectious laryngotracheitis
  • AI avian influenza
  • ND is caused by the avian paramyxovirus 1 (APMV-1) also designated ND virus (NDV) belonging to the Paramyxoviridae family.
  • MD is caused by Gallid herpesvirus 2 ⁇ Herpesviridae family) also designated as MD virus serotype 1 (MDV1).
  • IB is caused by IB virus (IBV) belonging to the Coronaviridae family
  • ILT is caused by Gallid herpesvirus 1 ⁇ Herpesviridae family) also designated ILT virus (ILTV)
  • AI is caused by AI virus (AIV) belonging to the Orthomyxoviridae family.
  • avipox viruses especially fowlpox (EP-A-0,517,292), Marek's virus, such as serotypes 2 and 3 (HVT) (WO-A-87/04463), or alternatively the ITLV, NDV and avian adenovirus.
  • HVT serotypes 2 and 3
  • ITLV avian adenovirus
  • HVT herpesvirus of turkeys
  • MDV serotype 3 herpesvirus 1 or MDV serotype 3 vectors expressing antigens from various pathogens
  • IBDV IBDV
  • NDV NDV
  • ILTV ILTV
  • AIV antigens from various pathogens
  • HVT vector- expressing IBDV VP2 protective gene that has shown clear advantages over classical IBD vaccines (Bublot et al J.Comp. Path.2007, Vol.137, S81-S84).
  • Other HVT vectors of interest are those expressing either NDV (Morgan et al 1992, Avian dis.
  • BAC chromosome
  • Herpesvirus-3 (MDV-2) viral vector protecting against a poultry pathogen beyond Marek's disease virus.
  • the present invention showed surprising result when multivalent vaccines were used to protect animals against a variety of avian pathogens.
  • the present invention relates to a recombinant Gallid Herpesvirus-3 (MDV-2) vector comprising one or more heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen.
  • the present invention further relates to a recombinant Gallid Herpesvirus-3 (MDV-2) vector comprising a mutated glycoprotein C (gC) gene.
  • the present invention provides a composition or vaccine comprising one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors comprising one or more
  • heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen.
  • the present invention further provides a composition for vaccine comprising one or more Gallid Herpesvirus-3 (MDV-2) vectors comprising a mutated glycoprotein C (gC) gene.
  • MDV-2 Gallid Herpesvirus-3
  • the present invention provides a polyvalent composition or vaccine comprising: i) a recombinant Gallid Herpesvirus-3 (MDV-2) vector comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen, or comprising a mutated glycoprotein C (gC) gene; and ii) at least one of: a recombinant HVT vector (or MDV-3 or Meleagrid herpesvirus- 1) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; or wild type HVT (MDV-3); or recombinant MDV serotype 1 vector (i.e., MDV-1, Gallid herpesvirus-2) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; or any wild type MDV-1.
  • MDV-2 Gallid Herpesvirus-3
  • the present invention relates to a method of vaccinating an animal, or inducing an immunogenic or protective response in an animal, comprising at least one administration of the composition or vector of the present invention.
  • the present invention further provides specific insertion loci for the introduction of one or more isolated polynucleotide into nonessential regions of the SB-1 genome.
  • Figure 1 is a table showing the SEQ ID NO assigned to each DNA and protein sequence.
  • Figure 2 depicts a schematic diagram of SB-1 genome organization.
  • Figure 3 depicts the immuno fluorescent staining of recombinant vSB 1-004 virus expressing NDV-F protein.
  • Figure 4 depicts the schematic representation of primer binding sites.
  • Figure 5 shows the PCR results of identifying vSB 1 -004.
  • Figure 6 shows the immuno fluorescent staining of recombinant vSB 1-006 virus expressing NDV-F protein.
  • Figure 7 depicts the schematic representation of primer binding sites on vSBl-
  • Figure 8 shows the PCR results of vSBl-006.
  • Figure 9 depicts the immuno fluorescent staining of recombinant SB 1-007 virus expressing NDV-F protein.
  • Figure 10 depicts the schematic diagram of primer location on pSBl 44 cds
  • Figure 11 shows the PCR results of vSB 1-007.
  • Figure 12 depicts the immuno fluorescent staining of recombinant SB 1-008 virus expressing NDV-F protein.
  • Figure 13 depicts the schematic representation of primer binding sites.
  • Figure 14 shows the PCR results of vSBl-008.
  • Figure 15 depicts the Western blot analysis of immunoprecipitated sample from vSB 1-009 infected cells.
  • Figure 16 depicts the Immunoprecipitation and Western Blot of vHVTl 14.
  • Figure 17 depicts the clinical analysis (percentage of birds shedding challenge virus) of the recombinants against CA02 and ZJ1 NDV challenge.
  • Figure 18 depicts the clinical analysis (oropharyngeal shedding) of the
  • Figure 19 shows the sequence alignment and sequence identity percentage.
  • Figure 20 shows the DNA and protein sequences.
  • animal is used herein to include all mammals, birds and fish.
  • the animal as used herein may be selected from the group consisting of equine (e.g., horse), canine (e.g., dogs, wolves, foxes, coyotes, jackals), feline (e.g., lions, tigers, domestic cats, wild cats, other big cats, and other felines including cheetahs and lynx), bovine (e.g., cattle), porcine (e.g., pig), ovine (e.g., sheep, goats, lamas, bisons), avian (e.g., chicken, duck, goose, turkey, quail, pheasant, parrot, finches, hawk, crow, ostrich, emu and cassowary), primate (e.g., prosimian, tarsier, monkey, gibbon, ape), humans, and fish.
  • equine e.g.,
  • polypeptide and “protein” are used interchangeably herein to refer to a polymer of consecutive amino acid residues.
  • nucleic acid refers to any organic acid
  • nucleotide refers to any organic compound
  • RNA, DNA, cDNA, or cRNA and derivatives thereof such as those containing modified backbones.
  • the invention provides polynucleotides comprising sequences complementary to those described herein.
  • the "polynucleotide” contemplated in the present invention includes both the forward strand (5' to 3') and reverse complementary strand (3' to 5').
  • Polynucleotides according to the invention can be prepared in different ways (e.g. by chemical synthesis, by gene cloning etc.) and can take various forms (e.g. linear or branched, single or double stranded, or a hybrid thereof, primers, probes etc.).
  • genomic DNA refers to the heritable genetic information of a host organism.
  • the genomic DNA comprises the DNA of the nucleus (also referred to as chromosomal DNA) but also the DNA of the plastids (e.g., chloroplasts) and other cellular organelles (e.g., mitochondria).
  • the genomic DNA or genome contemplated in the present invention also refers to the RNA of a virus.
  • the RNA may be a positive strand or a negative strand RNA.
  • genomic DNA contemplated in the present invention includes the genomic DNA containing sequences complementary to those described herein.
  • the term “genomic DNA” also refers to messenger RNA (mRNA), complementary DNA (cDNA), and complementary RNA (cRNA).
  • genes or polynucleotides include introns and exons as in genomic sequence, or just the coding sequences as in cDNAs , such as an open reading frame (ORF), starting from the start codon (methionine codon) and ending with a termination signal (stop codon). Genes and polynucleotides can also include regions that regulate their expression, such as transcription initiation, translation and transcription termination.
  • ORF open reading frame
  • promoters and ribosome binding regions in general these regulatory elements lie approximately between 60 and 250 nucleotides upstream of the start codon of the coding sequence or gene; Doree S M ei al; Pandher K et al; Chung J Y et al), transcription terminators (in general the terminator is located within approximately 50 nucleotides downstream of the stop codon of the coding sequence or gene; Ward C K et al).
  • Gene or polynucleotide also refers to a nucleic acid fragment that expresses mRNA or functional RNA, or encodes a specific protein, and which includes regulatory sequences.
  • heterologous DNA refers to the DNA derived from a different organism, such as a different cell type or a different species from the recipient.
  • the term also refers to a DNA or fragment thereof on the same genome of the host DNA wherein the heterologous DNA is inserted into a region of the genome which is different from its original location.
  • the term "antigen" or "immunogen” means a substance that induces a specific immune response in a host animal.
  • the antigen may comprise a whole organism, killed, attenuated or live; a subunit or portion of an organism; a recombinant vector containing an insert with immunogenic properties; a piece or fragment of DNA capable of inducing an immune response upon presentation to a host animal; a polypeptide, an epitope, a hapten, or any combination thereof.
  • the immunogen or antigen may comprise a toxin or antitoxin.
  • immunogenic protein or peptide includes polypeptides that are immunologically active in the sense that once administered to the host, it is able to evoke an immune response of the humoral and/or cellular type directed against the protein.
  • the protein fragment is such that it has substantially the same immunological activity as the total protein.
  • a protein fragment according to the invention comprises or consists essentially of or consists of at least one epitope or antigenic determinant.
  • An "immunogenic" protein or polypeptide, as used herein, includes the full-length sequence of the protein, analogs thereof, or immunogenic fragments thereof.
  • immunological fragment is meant a fragment of a protein which includes one or more epitopes and thus elicits the immunological response described above.
  • Such fragments can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996).
  • epitope mapping techniques well known in the art. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996).
  • linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports.
  • conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, supra.
  • immunological response denotes the replacement of an amino acid residue by another biologically similar residue, or the replacement of a nucleotide in a nucleic acid sequence such that the encoded amino acid residue does not change or is another biologically similar residue.
  • conservative substitutions will generally be conservative in nature, i.e., those substitutions that take place within a family of amino acids.
  • amino acids are generally divided into four families: (1) acidic—aspartate and glutamate; (2) basic— lysine, arginine, histidine; (3) non-polar— alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar— glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids.
  • conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another hydrophobic residue, or the substitution of one polar residue for another polar residue, such as the substitution of arginine for lysine, glutamic acid for aspartic acid, or glutamine for asparagine, and the like; or a similar conservative replacement of an amino acid with a structurally related amino acid that will not have a major effect on the biological activity.
  • Proteins having substantially the same amino acid sequence as the reference molecule but possessing minor amino acid substitutions that do not substantially affect the immunogenicity of the protein are, therefore, within the definition of the reference polypeptide. All of the polypeptides produced by these modifications are included herein.
  • the term "conservative variation” also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.
  • epitope refers to the site on an antigen or hapten to which specific B cells and/or T cells respond.
  • the term is also used interchangeably with "antigenic determinant” or "antigenic determinant site”.
  • Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.
  • an "immunological response" to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to a composition or vaccine of interest.
  • an "immunological response” includes but is not limited to one or more of the following effects: the production of antibodies, B cells, helper T cells, and/or cytotoxic T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest.
  • the host will display either a therapeutic or protective immunological response such that resistance to new infection will be enhanced and/or the clinical severity of the disease reduced. Such protection will be demonstrated by either a reduction or lack of symptoms normally displayed by an infected host, a quicker recovery time and/or a lowered viral titer in the infected host.
  • polynucleotide or protein in its native environment or surrounding.
  • the modification, alteration or engineering of a polynucleotide or protein may include, but is not limited to, deletion of one or more nucleotides or amino acids, deletion of an entire gene, codon- optimization of a gene, conservative substitution of amino acids, insertion of one or more heterologous polynucleotides.
  • polyvalent vaccine or composition refers to a composition or vaccine containing more than one composition or vaccines.
  • the polyvalent vaccine or composition may contain two, three, four or more compositions or vaccines.
  • the polyvalent vaccine or composition may comprise recombinant viral vectors, active or attenuated or killed wild-type viruses, or a mixture of recombinant viral vectors and wild-type viruses in active or attenuated or killed forms.
  • One embodiment of the present invention provides a recombinant Gallid
  • mutated gC gene refers to the gC gene of Gallid herpesvirus 3 (MDV- 2) that is altered or engineered which results in a non-functional gC protein upon expression.
  • the alteration or engineering of the gC gene includes mutation or deletion of a segment of the gC gene which is essential for the expression of a functional gC protein.
  • mutated gC gene also includes deletion of the entire gC gene of Gallid herpesvirus 3 (MDV-2) wherein gC protein is not expressed.
  • Another embodiment of the present invention provides a recombinant Gallid herpesvirus 3 (MDV-2) wherein the Glycoprotein C (gC) gene in the native (wild-type) Gallid herpesvirus 3 (MDV-2) genome encoding the gC protein is deleted.
  • Glycoprotein C (gC) gene includes any gene or polynucleotide that encodes the Glycoprotein C (gC) of Gallid herpesvirus 3 (MDV-2), and homologs, fragments or variants thereof.
  • the gC gene may encode a gC protein having at least 75%, 80%, 85%, 90%, 95%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity to SEQ ID NO: 35, or a variant thereof.
  • the gC gene having at least 75%, 80%, 85%, 90%, 95%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity to SEQ ID NO:34 is also encompassed in the present invention.
  • Another embodiment of the invention provides a recombinant Gallid herpesvirus 3 (MDV-2) viral vector comprising one or more heterologous polynucleotides coding for and expressing at least one antigen or polypeptide of an avian pathogen.
  • the Gallid herpesvirus 3 (MDV-2) strains used for the recombinant viral vector may be any SB-1 strains, including, but not limited to, the commercial Marek's Disease Vaccine (SB-1 vaccine) (Merial Select Inc., Gainesville, GA 30503, USA), the SB-1 strain having the genome sequence as defined by GenBank Accession Number HQ840738.1.
  • the Gallid herpesvirus 3 (MDV-2) strains used for the recombinant viral vector may be any other Gallid herpesvirus 3 isolate including the HPRS24 strain having the genome sequence as defined by GenBank Accession Number AB049735.1 , or the HPRS24 strain having the genome sequence as defined by GenBank Accession Number NC_002577.1.
  • the genomes of HPRS24 and SB-1 share 98.4% sequence identity (Spatz and Schat, 201 1 ; Virus Gene 42, 331-338).
  • the Gallid herpesvirus 3 (MDV-2) strains used for the recombinant viral vector may be the 301B/1 isolate described by Witter (1987 Avian Dis 31 , 752-765) or by Witter et al.
  • the Gallid herpesvirus 3 (MDV-2) strains may be any Gallid herpesvirus 3 (MDV-2) strains comprising the genome sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence as defined in GenBank Accession Number HQ840738.1 (SEQ ID NO: 14), AB049735.1 , or NC 002577.1.
  • the genes coding for antigen or polypeptide may be those coding for Newcastle Disease Virus fusion protein (NDV-F), Newcastle Disease Virus hemagglutinin neuraminidase (NDV-HN), Marek's Disease Virus glycoprotein C (gC), Marek's Disease Virus glycoprotein B (gB), Marek's Disease Virus glycoprotein E (gE), Marek's Disease Virus glycoprotein I (gl), Marek's Disease Virus glycoprotein H (gH) or Marek's Disease Virus glycoprotein L (gL), IBDV VP2, IBDV VPX, IBDV VP3, IBDV VP4, ILTV glycoprotein B, ILTV glycoprotein I, ILTV UL32, ILTV glycoprotein D, ILTV glycoprotein E, ILTV glycoprotein C, influenza hemaglutinin (HA), influenza neuraminidase (NA), protective genes derived from Mycoplasma gallisepticum (MG), or Mycoplasma synovi
  • the antigen or polypeptide may be any antigen from the poultry pathogen selected form the group consisting of avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian metapneumo virus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, chick anemia virus, avian astrovirus, avian parvovirus, coccidiosis (Eimeria sp.), Campylobacter sp., Salmonella sp., Pasteurella sp., Avibacterium sp., Mycoplasma gallisepticum, Mycoplasma synoviae, Clostridium sp., and E. coli.
  • avian encephalomyelitis virus avian reovirus
  • avian paramyxovirus avian metapneumo virus
  • avian influenza virus avian a
  • homologs of aforementioned antigen or polynucleotides are intended to be within the scope of the present invention.
  • the term “homologs” includes orthologs, analogs and paralogs.
  • the term “analogs” refers to two
  • orthologs encode polypeptides having the same or similar functions.
  • the term "paralogs" refers to two polynucleotides or polypeptides that are related by duplication within a genome. Paralogs usually have different functions, but these functions may be related. Analogs, orthologs, and paralogs of a wild-type polypeptide can differ from the wild-type polypeptide by post-translational modifications, by amino acid sequence differences, or by both.
  • homologs of the invention will generally exhibit at least 80-85%, 85-90%, 90-95%, or 95%, 96%, 97%), 98%), 99%o sequence identity, with all or part of the polynucleotide or polypeptide sequences of antigens described above, and will exhibit a similar function.
  • the present invention provides a recombinant Gallid
  • Herpesvirus-3 (MDV-2) viral vector comprising one, two or more heterologous polynucleotides coding for and expressing the NDV-F antigen or polypeptide.
  • the NDV-F antigen or polypeptide has at least 70%>, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2, 9, 50, 52, or 54, or a conservative variant, an allelic variant, a homolog or an immunogenic fragment comprising at least eight or at least ten consecutive amino acids of one of these polypeptides, or a combination of these polypeptides.
  • the heterologous polynucleotide encoding an NDV-F antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%), 96%), 97%), 98%) or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2, 9, 50, 52, or 54.
  • the heterologous polynucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%o or 99%) sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO: l, 8, 49, 51, or 53.
  • Variants include allelic variants.
  • allelic variant refers to a nucleic acid sequence that corresponds to a nucleic acid sequence that corresponds to a nucleic acid sequence that corresponds to a nucleic acid sequence that corresponds to a nucleic acid sequence that corresponds to a nucleic acid sequence.
  • polynucleotide or a polypeptide containing polymorphisms that lead to changes in the amino acid sequences of a protein and that exist within a natural population (e.g., a virus species or variety).
  • a natural population e.g., a virus species or variety.
  • Such natural allelic variations can typically result in 1- 5% variance in a polynucleotide or a polypeptide.
  • Allelic variants can be identified by sequencing the nucleic acid sequence of interest in a number of different species, which can be readily carried out by using hybridization probes to identify the same gene genetic locus in those species. Any and all such nucleic acid variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity of gene of interest, are intended to be within the scope of the invention.
  • sequence identity with respect to sequences can refer to, for example, the number of positions with identical nucleotides or amino acids divided by the number of nucleotides or amino acids in the shorter of the two sequences wherein alignment of the two sequences can be determined in accordance with the Wilbur and Lipman algorithm (Wilbur and Lipman).
  • the sequence identity or sequence similarity of two amino acid sequences, or the sequence identity between two nucleotide sequences can be determined using Vector NTI software package (Invitrogen, 1600 Faraday Ave., Carlsbad, CA).
  • RNA sequences are within the scope of the invention and can be derived from DNA sequences, by thymidine (T) in the DNA sequence being considered equal to uracil (U) in RNA sequences.
  • the polynucleotides of the disclosure include sequences that are degenerate as a result of the genetic code, e.g., optimized codon usage for a specific host.
  • optimized refers to a polynucleotide that is genetically engineered to increase its expression in a given species.
  • the DNA sequence of the NDV-F protein gene can be modified to 1) comprise codons preferred by highly expressed genes in a particular species; 2) comprise an A+T or G+C content in nucleotide base composition to that substantially found in said species; 3) form an initiation sequence of said species; or 4) eliminate sequences that cause destabilization, inappropriate polyadenylation, degradation and termination of RNA, or that form secondary structure hairpins or RNA splice sites.
  • Increased expression of NDV F protein in said species can be achieved by utilizing the distribution frequency of codon usage in eukaryotes and prokaryotes, or in a particular species.
  • frequency of preferred codon usage refers to the preference exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the disclosure as long as the amino acid sequence of the NDV-F polypeptide encoded by the nucleotide sequence is functionally unchanged.
  • the present invention provides a method for producing a recombinant Gallid Herpesvirus-3 or SB-1 viral vector comprising the introduction into the SB-1 genome of one, two or more isolated polynucleotides in a nonessential region of the SB-1 genome.
  • the present invention provides a method for producing a recombinant Gallid Herpesvirus-3 or SB-1 viral vector comprising the steps of altering, engineering, or deleting the gC gene from the SB-1 genome.
  • the term "nonessential region” refers to a region of a virus genome which is not essential for replication and propagation of the virus in tissue culture or in chickens.
  • any nonessential region or portion thereof can be deleted from the SB-1 genome or a foreign sequence can be inserted in it, and the viability and stability of the recombinant Gallid Herpesvirus-3 or SB-1 vector resulting from the deletion or insertion can be used to ascertain whether a deleted region or portion thereof is indeed nonessential.
  • the non-essential regions are located in the unique long (UL) and unique short (US) regions of the SB-1 genome (see Spatz et al, Virus Genes 42:331-338, 2011).
  • the UL region of SB-1 is about 109,744 bp to about 109,932 bp in length and may extend from positions 12,209 to 121,952 of SEQ ID NO: 14 (GenBank accession No, HQ840738.1) or equivalent positions of other SBl-genomes, for example, from 11,826 bp to 121,757 bp of HPRS24 genome.
  • the US region of SB-1 is about 12,109 bp to about 12,910 bp in length and may extend from positions 143,514 to 156,423 of SEQ ID NO: 14 (GenBank accession No, HQ840738.1) or equivalent positions of other SB 1 -genomes, for example from 142,681bp to 154,789 bp of HPRS24 genome (Spatz et al, 2011).
  • the non-essential region is between ORF of UL55 and ORF of LORF5 in the unique long (UL) region of SB-1.
  • the polynucleotide is inserted into or to replace SB-1 glycoprotein C gene (also designated UL44).
  • the use of the gC locus may allow the generation of recombinant virus unable to produce a functional gC protein and unable to be transmitted horizontally.
  • the nonessential region may be in the intergenic regions between UL7 and UL8, between UL 21 and UL22, between UL40 and UL41, between UL50 and UL51, between UL54 and LORF4, between USIO and SORF4, or within the UL43, US2, USIO or US6 (coding for gD) gene (see GenBank accession No, HQ840738.1).
  • the nonessential regions may be in the region of nucleotide positions 118057-118306 (intergenic UL55-LORF5), 98595-100031 (gC or UL44), 25983-26038 (intergenic UL7- UL8), 49865-50033 (intergenic UL21-UL22), 75880-75948 (intergenic UL35-UL36), 93928-93990 (intergenic UL40-UL41), 109777-109847 (intergenic UL50-UL51), 116466-116571 (intergenic UL54-LORF4), 146548-146697 (intergenic US 10-SORF4), 97141-98385 (UL43), 147857-148672 (US2), 145853..146548 (US10) or 150322-151479 (gD or US6) of SEQ ID NO: 14.
  • recombinant virus is well known in the art as described in, e.g., US patent Nos. 4,769,330, 4,722,848, 4,603, 112, 5,174, 993, and 5,756,103, 6,719,979.
  • a recombinant Gallid Herpesvirus-3 (MDV-2) viral vector may be constructed in two steps. First, the Gallid Herpesvirus-3 (MDV-2) or SB-1 genomic regions flanking the locus of insertion are cloned into an E.coli plasmid construct;
  • unique(s) restriction site(s) is (are) placed between the two flanking regions (insertion plasmid) in order to allow the insertion of the donor expression cassette DNA.
  • the cDNA or DNA gene sequence to be inserted is preceded by a promoter region (gene start region) and a terminator (or poly-adenylation,poly-A) sequence which is specific for the Gallid Herpesvirus-3 (MDV-2) or SB-1 vector and/or eukaryotic cells.
  • the whole expression cassette (promoter-foreign gene-poly-A) is then cloned into the unique(s) restriction site(s) of the insertion plasmid to construct the "donor plasmid" which contains the expression cassette flanked by Gallid Herpesvirus-3 (MDV-2) or SB-1 "arms" flanking the insertion locus.
  • the resulting donor plasmid construct is then amplified by growth within E.coli bacteria and plasmid DNA is extracted.
  • This plasmid is then linearized using a restriction enzyme that cut the plasmid backbone (outside the Gallid Herpesvirus-3 (MDV-2) or SB-1 arms and expression cassette).
  • Chicken embryo fibroblasts are then co-transfected with parental Gallid Herpesvirus-3 (MDV-2) or SB-1 DNA and linearized donor plasmid DNA.
  • the resulting virus population is then cloned by multiple limiting dilution steps where viruses expressing the foreign gene are isolated from the non-expressing viral population.
  • another foreign cassette can be inserted in another locus of insertion to create a double Gallid Herpesvirus-3 (MDV-2) or SB-1 recombinant expressing two genes.
  • the second cassette can also be inserted into the same locus.
  • the Gallid Herpesvirus-3 (MDV-2) or SB-1 recombinant is produced in primary chicken embryo fibroblasts similarly to the parental Gallid Herpesvirus-3 (MDV- 2) or SB-1 MD vaccine. After incubation, infected cells are harvested, mixed with a freezing medium allowing survival of infected cells, and frozen usually in cryovial or glass ampoules and stored in liquid nitrogen.
  • promoter promoter, enhancer, donor and acceptor splicing sites and intron, Kozak translation initiation consensus sequence, polyadenylation signals, untranslated sequence elements).
  • the promoters include, but are not limited to, an immediate early cytomegalovirus (CMV) promoter, guinea pig CMV promoter, an SV40 promoter, Pseudorabies Virus promoters such as that of glycoprotein X promoter, Herpes Simplex Virus- 1 such as the alpha 4 promoter, Marek's Disease Viruses (including MDV-1, MDV-2 and HVT) promoters such as those driving glycoproteins gC, gB, gE, or gl expression, Infectious Laryngotracheitis Virus promoters such as those of glycoprotein gB, gE, gl, gD genes, or other herpesvirus promoters.
  • CMV immediate early cytomegalovirus
  • guinea pig CMV promoter such as the alpha 4 promoter
  • Marek's Disease Viruses including MDV-1, MDV-2 and HVT
  • the foreign gene can be inserted into the vector with no additional promoter sequence since the promoter of the deleted gene of the vector will drive the transcription of the inserted foreign gene.
  • the present invention relates to a pharmaceutical composition or vaccine comprising one or more recombinant Gallid Herpesvirus-3 (MDV-2) rival vectors of the present invention and a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant.
  • the Gallid herpesvirus 3 (MDV-2) strains used for the recombinant Gallid Herpesvirus-3 viral vector may be any SB-1 strains, the HPSR24 strains, or the 301B/1 strains.
  • the Gallid Herpesvirus-3 (MDV-2) strains may also include those described in Witter et al (Avian Diseases 34, 944-957; 1990), Witter (Avian Pathology 21, 601-614, 1992) and Witter (Avian Pathology 24, 665-678, 1995): 280-5/1, 281MI/1, 287C/1, 298B/1, 301A/1, 401/1, 437A/1, 437B/1, 468A/1, 468A/2, 468B/1, 471B/l, or HN-l/l .
  • the present invention provides a composition or vaccine comprising: i) a recombinant Gallid Herpesvirus-3 vector (MDV-2) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; and ii) at least one of: a recombinant HVT vector (or MDV-3 or Meleagrid Herpesvirus- 1) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; or wild type MDV-3; or recombinant MDV-1 vector (or Gallid herpesvirus-2) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; or wild type MDV-1.
  • MDV-2 Gallid Herpesvirus-3 vector
  • composition or vaccine may further comprise a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant.
  • This composition may further contain a recombinant fowlpox vector comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; or wild type fowlpox.
  • the composition or vaccine comprises one (or more) recombinant Gallid Herpesvirus-3 (MDV-2) vectors and one or more wild type HVT (MDV-3).
  • the composition or vaccine comprises one (or more) recombinant Gallid Herpesvirus-3 (MDV-2) vectors and one or more recombinant HVT (MDV-3).
  • the composition or vaccine comprises one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors and one or more wild type or genetically modified MDV-1.
  • the composition or vaccine comprises one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors and one or more recombinant MDV-1.
  • composition or vaccine comprises one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors, one or more wild type HVT (MDV-3) and one or more wild type MDV-1.
  • composition or vaccine comprises one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors, one or more recombinant HVT (MDV-3) and one or more wild type MDV-1.
  • composition or vaccine comprises one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors, one or more recombinant HVT (MDV-3) and one or more wild type MDV-1.
  • composition or vaccine comprises one or more recombinant Gallid
  • composition or vaccine comprises one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors, one or more recombinant HVT (MDV-3) and one or more recombinant MDV-1.
  • the wild type HVT (MDV-3) or wild type MDV-1 may be live, attenuated or genetically modified.
  • the heterologous polynucleotides in recombinant Gallid Herpesvirus-3 (MDV-2) vectors, recombinant HVT (MDV-3) vectors, and recombinant MDV-1 vectors may encode same or different antigens from the same or different avian pathogens.
  • a pharmaceutically or veterinarily acceptable carrier or adjuvant or vehicle or excipient can be Marek's disease vaccine diluent used for MD vaccines.
  • Other pharmaceutically or veterinarily acceptable carrier or adjuvant or vehicle or excipients that can be used for methods of this invention include, but are not limited to, 0.9% NaCl (e.g., saline) solution or a phosphate buffer, poly-(L-glutamate) or polyvinylpyrrolidone.
  • the pharmaceutically or veterinarily acceptable carrier or vehicle or excipients may be any compound or combination of compounds facilitating the administration of the vector (or protein expressed from an inventive vector in vitro), or facilitating transfection or infection and/or improve preservation of the vector (or protein). Doses and dose volumes are herein discussed in the general description and can also be determined by the skilled artisan from this disclosure read in conjunction with the knowledge in the art, without any undue experimentation.
  • other compounds may be added as pharmaceutically or veterinarily acceptable carriers or adjuvant or vehicles or excipients, including, but not limited to, alum; CpG oligonucleotides (ODN), in particular ODN 2006, 2007, 2059, or 2135 (Pontarollo R.A.
  • compositions and vaccines according to the invention may comprise or consist essentially of one or more adjuvants.
  • Suitable adjuvants for use in the practice of the present invention are (1) polymers of acrylic or methacrylic acid, maleic anhydride and alkenyl derivative polymers, (2) immunostimulating sequences (ISS), such as oligodeoxyribonucleotide sequences having one or more non-methylated CpG units (Klinman et al, 1996; W098/16247), (3) an oil in water emulsion, such as the SPT emulsion described on p 147 of "Vaccine Design, The Subunit and Adjuvant Approach" published by M. Powell, M.
  • cation lipids containing a quaternary ammonium salt e.g., DDA (5) cytokines, (6) aluminum hydroxide or aluminum phosphate, (7) saponin or (8) other adjuvants discussed in any document cited and incorporated by reference into the instant application, or (9) any combinations or mixtures thereof.
  • a quaternary ammonium salt e.g., DDA (5) cytokines, (6) aluminum hydroxide or aluminum phosphate, (7) saponin or (8) other adjuvants discussed in any document cited and incorporated by reference into the instant application, or (9) any combinations or mixtures thereof.
  • Another aspect of the invention relates to a method for inducing an
  • immunological response in an animal against one or more antigens or a protective response in an animal against one or more avian pathogens which method comprises inoculating the animal at least once with the vaccine or pharmaceutical composition of the present invention.
  • Yet another aspect of the invention relates to a method for inducing an immunological response in an animal to one or more antigens or a protective response in an animal against one or more avian pathogens in a prime -boost administration regimen, which is comprised of at least one primary administration and at least one booster administration using at least one common polypeptide, antigen, epitope or immunogen.
  • the immunological composition or vaccine used in primary administration may be same, may be different in nature from those used as a booster.
  • the avian pathogens may be Newcastle Disease Virus (NDV), Infectious Bursal Disease Virus (i.e., IBDV or Gumboro Disease virus), Marek's Disease Virus (MDV), Infectious Laryngotracheitis Virus (ILTV), avian encephalomyelitis virus and other picornavirus, avian reovirus, avian paramyxovirus, avian metapneumovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, avian parvovirus, avian astrovirus and chick anemia virus, coccidiosis (Eimeria sp.), Campylobacter sp., Salmonella sp., Mycoplasma gallisepticum, Mycoplasma synoviae, Pasteurella sp., Avibacterium sp., E. coli or Clostridium sp
  • one administration of the vaccine is performed either at one day-of-age by the subcutaneous or intramuscular route or in ovo in 17-19 day-old embryo.
  • a second administration can be done within the first 10 days of age.
  • the animals are preferably at least 17-day-embryo or one day old at the time of the first administration.
  • a variety of administration routes in day-old chicks may be used such as subcutaneously or intramuscularly, intradermally, transdermally.
  • the in ovo vaccination can be performed in the amniotic sac and/or the embryo.
  • Commercially available in ovo and SC administration devices can be used for vaccination.
  • Example 1 Construction of recombinant vSBl-004 expressing NDV-F [0077] The aim of the work is to construct a recombinant SB-1 virus in which an expression cassette containing mouse cytomegalovirus (mCMV) promoter, Newcastle disease virus fusion protein (NDV-F), and Simian virus 40 (SV40) poly A tail is inserted into the intergenic site between US 10 and SORF4 site of SB-1 virus (Table 1 and Fig. 2).
  • mCMV mouse cytomegalovirus
  • NDV-F Newcastle disease virus fusion protein
  • SV40 Simian virus 40
  • NDV-F Newcastle disease virus Fusion Protein
  • SEQ ID NO:2 encoded by SEQ ID NO:3 genotype Vlld sequence
  • SEQ ID NO:3 encoded by SEQ ID NO:3 was chemically synthesized (GenScript, Piscataway, NJ, USA).
  • the F protein cleavage site of this synthetic gene was altered to match with a lentogenic F cleavage site sequence and the resultant NDV-F gene sequence has 99% nucleotide as well as 99% amino acid sequence identity to NDV-F sequence deposited in GenBank under accession number AY337464 (for DNA) and AAP97877.1 (for protein), respectively .
  • a fragment containing the synthetic NDV-F gene was excised from pUC57 NDV- F Vlld wt plasmid (synthesized by GeneScript) using NotI and inserted into the same site of pCD046 plasmid containing mCMV promoter and SV40 polyA tail.
  • the resultant plasmid, pCD046+NDV-F wt was digested with EcoRl and Sail and blunt ended with Klenow.
  • a 3.3kb fragment was gel extracted and ligated to a Smal digested and dephosphorylated (CIPed) vector (SB1 US10-SORF4 Sbfl pUC57) containing flanking arms.
  • Ligated material was transformed using Top 10 Oneshot kit (Invitrogen, CA, USA). Bacterial colonies were grown in LBamp broth, plasmid extracted by using Qiagens MiniSpin Prep kit, and screened for insert orientation using Pstl digestion. The correct donor plasmid was designated SB-1 lOmFwt Sbfl. Large scale cultures were grown and plasmid extraction was done using Qiagens Maxi Prep kit. Transient expression of the maxi preps was verified using Fugene Transfection Reagent in Chicken Embryo Fibroblast Cells (CEF's) and chicken polyclonal sera against NDV. Recombinant generation
  • a standard homologous recombination procedure was followed by co- electroporation of secondary CEF cells using SB-1 USIOmFwt Sbfl donor plasmid and viral DNA isolated from vaccine strain of SB-1 virus. Co-electroporation was performed using lxl 0 7 2° CEF in 300 ⁇ Opti-MEM and shocked at 150 volts with 950 capacitance in a 2 mm electroporation cuvette. The transfected cells were seeded into 96-well plate and incubated for 5-7 days. The cells grown in the 96-well plate were then treated with trypsin and transferred into two "sisters" 96-well plates and incubated for 5 more days. One set of 96-well plates was used for IFA using chicken polyclonal sera against NDV-F to identify positive wells containing recombinants and another set of 96-well plates was used for recovering the infected cells from the positive wells.
  • the recombinant viral purification methods were performed first by 96-well plate duplication and IFA selection for the wells containing the most IFA positive plaques with the least amount of IFA negative plaques. Wells matching those criteria were then harvested and adjusted to 1ml in DMEM+2% FBS. From the 1ml stock, 5-20 ⁇ 1
  • recombinant SB-1 expressing NDV-F protein was isolated and the purity of the recombinant virus was tested by IFA and PCR to confirm the absence of parental virus. Selected recombinant virus was then passed from one well of a 96-well plate (P0) to 2xT-25 flasks (PI), then 2xT-75 flasks (P2), 2xT-175 flasks (P3), and finally 2x850 cm 2 roller bottles (pre-MSV stock or P4). Vials with 2 ml aliquot were stored in liquid nitrogen. Titrations were performed in triplicate on CEFs and a titer of lxl 0 5 pfu/ml was obtained for SB 1-004.
  • the P3 material was diluted 1 : 100 in media. Approximately 50 ⁇ of the diluted virus was added to 10 ml of DMEM+2% FBS with lxl 0 7 CEFs and then aliquoted onto a 96 well plate (100 ⁇ /well). The plates were incubated for 5 days at 37°C+5%C0 2 until viral plaques were visible. The plates were fixed with 95% ice-cold acetone for three minutes and washed three times with PBS. Chicken anti-sera against Newcastle Disease Virus (lot#C0139, Charles Rivers
  • DNA was extracted from a stock virus by phenol/chloroform extraction, ethanol precipitated, and resuspended in 20mM HEPES.
  • PCR primers were designed to specifically identify the NDV-F Vlld gene, the promoter, the SV40 poly A and the SB-1 flanking arms (see Fig. 4).
  • Primers, specific to HVT (strain FC126), MDV serotype 3 (MB080 +MB081) were also included in the analysis to check the purity of the recombinant virus from SB-1 parental virus.
  • PCR was performed using 200 ⁇ g of DNA template along with the specified primers pairs.
  • vSB 1-004 is a
  • Recombinant SB-1 expressing a NDV-F gene under the control of mCMV promoter.
  • Recombinant vector vSB 1-004 is free of any detectable parental SB-1 virus or potential HVT contaminant.
  • Example 2 Construction of recombinant vSBl-006 expressing NDV-F
  • the aim of the work is to construct a recombinant SB-1 virus in which an expression cassette containing SV40 promoter, Newcastle disease virus fusion protein (NDV-F), and synthetic polyA tail is inserted between the UL55 and LORF5 site of SB-1 virus (Table 2).
  • NDV-F Newcastle disease virus fusion protein
  • NDV-F Newcastle disease virus Fusion Protein corresponding to a consensus codon-optimized genotype Vlld sequence (SEQ ID NO:2 encoded by SEQ ID NO: l) was chemically synthesized (Gene Art).
  • a synthetic SB-1 UL55-LOrf5 Sbfl plasmid covering approximately 1 kb sequence on each side of the insertion site (GenScript) was digested with Sbfi and dephosphorylated.
  • a synthetic SV OptF syn tail pUC57 plasmid (Genscript) was digested with Sbfi and a 2239 base pair fragment was gel extracted and ligated to the Sbfi digested vector to create the new SBl UL55 SVFopt syn tail Sbfl donor plasmid.
  • Genomic DNA of SB-1 virus was co-electroporated with SB-1 UL55 SV Fopt syn tail Sbfl donor plasmid to generate recombinant SB-1 using homologous recombination technique. Recombinant virus was separated from parental SB-1 virus by
  • a plaque purified recombinant SB-1 virus expressing the NDV-F protein designated vSB 1-006, was scaled up from tissue culture flasks to 2 x 850 cm 2 roller bottles. After about 72 hrs post infection in roller bottles, the infected CEFs were harvested. Aliquots were frozen in liquid nitrogen containing 10% FBS and 10% DMSO. Titrations were performed in triplicate on CEFs and a titer of 8xl0 5 pfu/ml was obtained for SB 1-006.
  • vSB 1-006 is a recombinant SB-1 expressing a codon-optimized NDV-F gene under the control of SV40 promoter.
  • Recombinant vector vSB 1-006 is free of any detectable amount of parental SB-1 virus and potential HVT contaminant.
  • the aim of the work is to construct a recombinant SB-1 virus in which an
  • NDV-F gene corresponding to the F sequence of genotype Vlld of NDV is used to replace the coding sequence of
  • glycoprotein C (gC or UL44) of SB-1 virus (Table 3).
  • NDV-F Newcastle disease virus Fusion Protein corresponding to a consensus codon-optimized genotype Vlld sequence (SEQ ID NO:2 encoded by SEQ ID NO: l) was chemically synthesized (Gene Art).
  • a synthetic pSBl 44 cds plasmid containing flanking arms was generated by gene synthesis (GenScript).
  • the pSBl 44 cds was digested with Sbfl, dephosphorylated.
  • SV-OptF-syn no polyA tail-pUC57 was digested with Sbfl and 2.1 kb fragment containing SV40 promoter and NDV-F gene was gel extracted, ligated into the Sbfl digested vector and transformed using the Top 10 Oneshot kit (Invitrogen). Bacterial colonies were grown in LB-ampicillin media (lOOug/ml), and plasmids were extracted by using Qiagen Mini Spin Prep kit, and screened for insertions by EcoRI and Ncol digestion. The resultant donor plasmid was designated pSBl 44 cds SVOptF.
  • the synthetic plasmid pSBl 44 cds (SEQ ID NO:36 in FIG. 20) can also be used as a donor plasmid without further modification (without inserting NDV-F expression cassette) to generate a recombinant SB-1 lacking the glycoprotein (gC) gene.
  • Immunofluorescents was performed using chicken anti-sera (lot# CO 139, Charles Rivers Laboratories) followed by a FITC labeled anti-chicken IgG (cat# 02-24-06, KPL). All examined plaques of vSB 1-007 were found to express NDV-F protein (Fig. 9).
  • Viral DNA was extracted from SB 1 -007 from P.1 through P.6 by QIA DNeasy Blood & Tissue Kit (Qiagen). PCR primers were designed to specifically identify the presence of NDV F (codon-optimized), the SV40 promoter and the flanking arms of UL44 (see Fig. 10). PCR amplifications were preformed using 200ng of DNA template along with the specified primer pairs.
  • vSB 1-007 is a recombinant SB-1 expressing a codon-optimized NDV-F gene under the control of SV40 promoter.
  • the NDV-F expression cassette was successfully used to replace the gC gene of SB 1 , demonstrating that gC is dispensable for in vitro propagation of SB-1 virus.
  • Recombinant vector vSB 1-007 is free of any detectable amount of parental SB-1 virus or HVT.
  • the aim of the work is to construct a recombinant SB-1 virus in which an
  • NDV-F corresponding to a codon-optimized genotype V (CA02 strain) sequence (SEQ ID NO: 9 encoded by SEQ ID NO: 8) was chemically synthesized (GeneArt). The F protein cleavage site of this synthetic gene was altered to match a lentogenic F cleavage site sequence and the resultant NDV-F gene sequence has 99% amino acid sequence identity to NDV-F sequence deposited in GenBank (ABS84266). Donor plasmid SB1 UL55 SV CaFopt syn tail Sbfl construction
  • a synthetic SV OptF syn tail pUC57 plasmid (Genscript) was digested with Sbfl and a 2239 base pair fragment containing syn tail was gel extracted and ligated to the Sbfl digested vector to create the new SB1 UL55 SVFopt syn tail Sbfl donor plasmid. This donor plasmid was then digested with Notl, CIPed, and a 5196 base pair fragment was gel extracted.
  • a synthetic NDV-F CA02 CSmut 0813005 pVRlOl donor plasmid (GeneArt) was digested with Notl and a 1677 base pair fragment was gel extracted and ligated to the Notl digested and CIPed UL55 vector resulting in donor plasmid SB1 UL55 SV CaFopt syn tail Sbfl.
  • Recombinant virus was separated from parental SB-1 virus by immuno fluorescent positive well selection and PCR screening in multiple rounds of plaque purification.
  • vSB 1-008 is a recombinant SB-1 expressing a codon-optimized NDV-F gene under the control of SV40 promoter.
  • Recombinant vector vSB 1-008 is free of any detectable parental SB-1 virus or HVT.
  • Example 5 Construction of recombinant vSBl-009 and vSBl-010 expressing NDV-F
  • the aim of the study is to construct a recombinant SB-1 viral vector vSB 1-009 in which an expression cassette containing SV40 promoter and Newcastle disease virus fusion (NDV-F) gene is inserted to replace UL44 coding (gC) sequence of SB-1 and to construct a recombinant SB-1 viral vector vSBl-010 in which an additional expression cassette containing guinea pig CMV promoter and NDV-F gene is inserted in SORF-US2 locus of SB 1-009 vector backbone.
  • NDV-F Newcastle disease virus fusion
  • a donor plasmid pSBl 44 cds SV FCAopt was constructed containing UL44 flanking arms of SBl virus, SV40 promoter and NDV F codon optimized gene sequence (SEQ ID NO:8, coding for SEQ ID NO:9) (Table 7).
  • Viral DNA was extracted from vSB 1-009 pre-master seed virus (pre-MSV) stock by QIA DNeasy Blood & Tissue Kit (Qiagen).
  • PCR primers were designed to identify the presence of the NDV F optimized, the NDV F wild type, the SV40 promoter, the mCMV promoter, the UL44 flanking arms of SB-1 virus and HVT virus.
  • PCR amplifications were performed using approximately 200ng of DNA template along with the primer pairs.
  • PCR amplification with various primers confirmed that the vSB 1-009 has the expected amplification patterns and amplicons.
  • Indirect immunofluorescent assay was performed on the vSB 1-009 pre- MSV stock to examine the expression of NDV F gene and SB-1 virus antigen.
  • the CEFs that were inoculated with vSB 1-009 were fixed with ice-cold 95% acetone for three minutes at room temperature and air-dried for 10 min.
  • the plates were washed with PBS, then two primary antibodies, chicken anti-Newcastle Disease Virus sera (Charles Rivers Laboratories cat#10100641, lot#C0117A) at 1 :500 dilution and Y5.9 monoclonal antibody against SB-1 virus (Merial Select, Gainesville, GA) at 1 :3000 dilution were added and the plates were incubated for 45 min at 37°C. After three washes with PBS, two secondary antibodies, goat anti-chicken IgG-fluorescein (KPL) at 1 :500 dilution and donkey anti-mouse IgG-Alexa Fluor 568 (Molecular Probe) at 1 :250 dilution were added.
  • KPL goat anti-chicken IgG-fluorescein
  • KPL donkey anti-mouse IgG-Alexa Fluor 568
  • the plates were incubated at 37°C for 45 min and followed by three washes with PBS.
  • the wells were screened for IFA positive plaques with a fluorescent microscope using fluorescein isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate (TRITC)- filters of Nikon Eclipse Ti inverted microscope.
  • FITC fluorescein isothiocyanate
  • TRITC tetramethylrhodamine isothiocyanate
  • NDV F Mab reactivity was confirmed by Dual IFA. Over 200 vSB 1 -009 plaques were examined for NDV F Mab reactivity as well as anti-MDV serum reactivity. The reactivity with NDV F Mab completely matched with anti-MDV serum reactivity in each virus plaque (Table 9).
  • Total genomic DNA was extracted from vSB 1-009 pre-MSV stock infected CEFs.
  • the genomic DNA of vSB 1-009, SB-1 virus (negative control), pSBl 44 cds SV FCA opt donor plasmid were digested at 37°C with EcoRI, Ncol, and Kpnl restriction endonucleases separately.
  • the restriction fragments were separated by a 0.8 % agarose gel electrophoresis and transferred onto a positively charged Nylon membrane. After transfer, the membrane was treated with 0.4M NaOH and then neutralized with 2XSSC- HC1 buffer. The membrane was then air dried and UV crosslinked.
  • the membrane was pre- hybridized for 1 hr and then hybridized with the probe at 55°C for overnight.
  • two probes were used; 1) the Sbfl fragment of pSBl 44 cds SV FCA opt as NDV F cassette probe, 2) the Smal-EcoRI fragment of pUC57 SB1 44 arm
  • the Southern blot results were as expected based on Vector NTI map analysis.
  • the NDV F cassette (SV40 promoter, NDV-F CA02 codon optimized gene) replaced the UL44 coding sequences of SB-1 virus.
  • vSB 1-009 pre-MSV stock was conducted by nucleotide sequence determination of the region of recombination arm as well as inserted gene cassette. Primers were designed and used to amplify the entire NDV-F gene cassette including the recombination arms.
  • vSB 1 -009 sequence (donor plasmid pSB 1 44 cds SV FCAopt) containing the recombinant arms, SV40 promoter and NDV F codon-optimized gene was confirmed to be correct as shown in SEQ ID NO:37 (FIG. 20).
  • the CEF monolayer was infected with vSB 1 -009 pre-MSV at MOI - 0.1. After a 5 -day incubation, the CEFs were pelleted and washed with PBS followed by lysis with IP Lysis/Wash buffer of Pierce Classic IP Kit (Thermo Scientific cat#26146) according to the manufacturers' protocols. The lysate was pre-cleared and incubated with 100 ul of anti-NDV F monoclonal antibody to make the immune complex. The immune complex was captured by Protein A/G Plus Agarose and after removing of the un-bounded immune complex by washing steps, the 50 ul of sample buffer was used to elute under non-reducing conditions.
  • the uninfected CEFs were included as a control.
  • the 20 ul of eluted samples were separated in 10% Bis-Tris gels by electrophoresis. After the electrophoresis, the separated proteins in a gel were transferred onto PVDF membrane.
  • the Protein Detection TMB Western Blot Kit (KPL cat#54-l 1-50) was used to detect the NDV antigens onto PVDF membrane with chicken anti-NDV serum (Charles River Laboratories Laboratories cat#l 0100641, lot#C0117A), and goat anti-chicken IgG- peroxidase conjugate (KPL cat#14-24-06) following the manufacturers' protocols.
  • NDV F protein expression of vSBl-009 was confirmed by two-step immunodetection.
  • the expressed NDV F proteins from vSB 1-009 infected CEF lysate were captured by the immunoprecipitation using anti-NDV F monoclonal antibody 001C3.
  • Western blot analysis using anti-NDV polyclonal serum (Charles River Laboratories cat#10100641, lot#C0117 A) was applied to detect the NDV F protein in the captured samples (NDV F protein-monoclonal antibody complex) (Fig.15).
  • An approximately 55 kDa protein in vSB 1-007 pre-MSV lysates was detected by anti-NDV serum that corresponding the expected size of NDV Fl fusion protein (Fig.15).
  • vSB 1-010 contains the correct sequences of guinea pig CMV promoter and the NDV-F Vlld wt gene as shown in the sequence of the donor plasmid SB1US2 gpVIIdwtsyn (SEQ ID NO: 57).
  • DNA was extracted from a stock virus by phenol/chloroform extraction, ethanol precipitated, and resuspended in 20mM HEPES.
  • PCR primers were designed to specifically identify the NDV-F Vlld wt gene, the promoter, the polyA, as well as, the purity of the recombinant virus from SBl parental virus.
  • PCR was performed using 200 ⁇ g of DNA template along with the specified primers pairs indicted in Table 1. PCR cycling conditions are as follows (unless otherwise noted): 94°C - 2 min; 30 cycles of 94°C - 30 sec, 55°C - 30 sec, 68°C - 3 min; 68°C - 5 min.
  • the P3 material was diluted 1 : 100 in media. Approximately 50 ⁇ of the diluted virus was added to 10 ml of DMEM+2% FBS with lxl 0 7 CEFs and then aliquoted onto a 96 well plate (100 ⁇ /well). The plates were incubated for 5 days at 37°C+5% C0 2 until viral plaques were visible. The plates were fixed with 95% ice-cold acetone for three minutes and washed three times with PBS. Chicken anti-sera against Newcastle Disease Virus (lot#C0139, Charles Rivers
  • vSBl-010 is a
  • vSBl-010 carries both Vlld and CA02 F genes of NDV genotypes and it is free of any detectable parental vSB 1-009.
  • the plasmid pHM103 (Merial Limited) containing the Intergenic I arms of HVT FC126, SV40 promoter and SV40 poly A was digested with NotI, dephosphorylated, and the 5.6kb fragment was gel extracted.
  • a NotI flanked 1.7 kb fragment of a chemically synthesized codon-optimized genotype Vlld NDV-F gene (SEQ ID NO: l, coding for SEQ ID NO:2) was also NotI digested and the 1.7kb fragment was gel extracted.
  • the 5.6 and 1.7kb fragments were ligated to create pHM103+Fopt (Table 10.2).
  • HVT viral vector A standard homologous recombination procedure was followed by co- electroporation of secondary CEF cells using donor plasmid pHM103+Fopt and viral DNA isolated from the HVT strain FC126 (Igarashi T. et al, J. Gen. Virol. 70, 1789- 1804, 1989). Essentially the procedure described in example 1 was followed to generate, plaque purify and characterize recombinants by immunofluorescence.
  • vHVTl 14 a recombinant virus designated as vHVTl 14 was isolated and the purity was tested by IF A and PCR to confirm NDV-F expression and the absence of parental virus.
  • DNA was extracted from vHVTl 14 by phenol/chloroform extraction, ethanol precipitated, and was resuspended in 20mM HEPES.
  • PCR primers were designed to specifically identify the presence of the codon optimized NDV-F, the SV40 promoter, as well as, the purity of the recombinant virus from FC126 CL2 parental virus.
  • vHVTl 14 contains the correct SV40 promoter, the codon-optimized NDV-F and the SV40 polyA sequences that match exactly the sequence described for the donor plasmid pHM103+Fopt in SEQ ID NO:38 (see Fig. 20).
  • the immune complex was washed three times to remove non-bound material and then eluted in 50ul volume using sample buffer elution under non-reducing condition. After boiling for 5 minutes, 10 ⁇ of the samples were loaded into a 10% Acrylamide gel (Invitrogen). The PAGE gel was run in MOPS buffer (Invitrogen) at 200volts for 1 hour. Then the gel was transferred onto a PVDF membrane.
  • the membrane was then rinsed three times in IX Wash Buffer, five minutes each and then soaked in blocking buffer containing 1 : 1000 dilution of chicken serum raised against NDV virus (Lot # CO 139, Charles River Laboratories). After washing three times in a washing buffer, the membrane was incubated with a peroxidase labeled goat anti-chicken IgG (KPL, cat# 14-24-06) at a dilution of 1 :2000 for 1 hour at room temperature. The membrane was then rinsed three times in IX Wash Buffer, five minutes each. 5ml of TMB membrane peroxidase substrate was added to the membrane and gently rocked for about 1 minute. The developing reaction was stopped by placing the membrane into water.
  • IX Wash Buffer 1 dilution of chicken serum raised against NDV virus
  • the immunoprecipitation and Western blot technique detected an approximately 55 kD protein in vHVTl 14 sample that corresponds to the expected size of Fl component ofthe NDV-F protein (Fig. 16).
  • HVT039 generation and characterization of other HVT recombinants, such as vHVT039, vHVTl 10, vHVTl 11, vHVTl 12, vHVTl 13, and vHVTl 16 were essentially done in the same way as for vHVTl 14 described above.
  • the generation and characterization of recombinant HVT viral vectors were also described in US patent application serial No.
  • the donor plasmid pHVT US2 SV- Fopt-synPA was constructed containing SV40 promoter, synthetic NDV F codon optimized VII gene, synthetic polyA tail flanked by the SORF3 and US2 arm sequences of HVT FC126.
  • example 1 The procedure described in example 1 was followed to generate, plaque purify and characterize recombinants by immunofluorescence.
  • VHVT306 pure recombinant virus
  • Viral DNA was extracted from vHVT306 pre-master seed virus (pre-MSV) stock by QIA DNeasy Blood & Tissue Kit (Qiagen). PCR primers were designed to identify the presence of the NDV F optimized, the NDV F wild type, the SV40 promoter, the mCMV promoter, the flanking arms of US2 HVT virus and SB-1 virus.
  • PCR amplification with various primers confirmed that the vHVT306 had the expected amplification patterns and amplicons.
  • Genomic analysis [0156] The genomic DNA of vHVT306 pre-MSV stock was sequenced to verify the sequence of the recombination arm region as well as inserted gene cassette.
  • Primers were designed to amplify the entire inserted gene cassette including recombination arm used in donor plasmid. Analysis of vHVT306 genomic DNA was performed by PCR amplification and followed by nucleotide sequence determination.
  • vHVT306 donor plasmid pHVT US2 SV- Fopt-synPA containing the recombinant arms, SV40 promoter and NDV F codon-optimized gene was confirmed to be correct as shown in SEQ ID NO:45 (Fig. 20).
  • NDV F protein-monoclonal antibody complex A 55 kDa protein in vHVT306 pre-MSV lysates was detected by anti-NDV serum which corresponds to the expected size of NDV Fl fusion protein.
  • Table 12 shows the features unique to each construct around the expression cassettes, including the respective sequences.
  • the objective of the study was to compare the level of viremia and horizontal transmission induced by the parental SB-1 with that of a recombinant SB-1 virus in which the gC gene was deleted (see example 3).
  • Two groups (A and B) of thirty one-day-old specific pathogen free (SPF) white Leghorn chicks were randomly constituted. Twenty birds from groups A were vaccinated (DO) by the subcutaneous route (nape of the neck; 0.2ml/bird) with 2000 PFU of parental SB-1 and twenty from groups B with 2000 PFU of the SB-1 gC-deleted mutant. Ten birds were kept unvaccinated in the same isolator as the vaccinated birds (groups Ac and Be). At 2-weeks-of-age (D14), the spleen as well as 2 feathers of twenty vaccinated birds of groups A and B were removed after euthanasia.
  • SPF pathogen free
  • the spleen of the 10 contact birds of groups Ac and Be were also removed for viral isolation.
  • White blood cells were collected from the buffy coat of ground spleens which had added to lymphocyte separation medium and centrifuged.
  • 10 6 leucocytes were added to a 60mm tissue culture dish that contained confluent monolayers of primary chicken embryo fibroblasts (CEF) prepared the day before.
  • CEF primary chicken embryo fibroblasts
  • MDV plaques were counted on each dish and the number of positive birds and mean number of plaques was calculated.
  • the feather pulp was added to SPGA medium and sonicated for 10 seconds before placing on confluent monolayers of primary CEF from which the media had been removed. The pulp suspension was allowed to absorb for 45 minutes prior to adding fresh media with 1% calf serum.
  • Results of virus isolation from spleen and from feather follicles of vaccinated birds at D14 are reported in Table 13. All birds from both groups were positive for virus isolation from spleen with a similar mean number of plaques of 142.5 and 176.0 for groups A and B, respectively. Virus could be isolated from feather follicles of all birds in group A and from 90% of birds in group B.
  • Results of virus isolation from spleen of unvaccinated contact birds at D28 are reported in Table 14. Seven out of ten birds from group Ac were positive for virus isolation from spleen indicating that the parental SB-1 spread horizontally to contact birds. Virus could not be isolated from birds of group Be suggesting that the gC-deleted mutant did not spread to contact birds.
  • Example 9 ND efficacy induced by SB-1 recombinant alone or in combination with an HVT-IBD vector vaccine in one day-old SPF chickens
  • IM intramuscular
  • EID50 Egg Infectious Dose 50
  • Oropharyngeal swabs were also sampled from 10 birds per group 5, 7 and 9 days after challenge.
  • the viral RNA load was evaluated in these swabs after RNA extraction by using a quantitative reverse transcriptase real time polymerase chain reaction (qRT-PCR) based on the M gene and described by Wise et al. (2004; Development of a Real-Time Reverse-Transcription PCR for Detection of Newcastle Disease Virus RNA in Clinical Samples; J. Clin. Microbiol. 42, 328-338). Shedding levels were expressed as loglO egg infectious dose 50% (EID50) per mL. Blood was also sampled at the time of challenge (D27). The serums were tested with the anti-IBD ELISA (Synbiotics ELISA ProFlok PLUS IBD) to evaluate the impact of vSBA-004 on the vHVT 13 -induced IBDV antibodies.
  • qRT-PCR quantitative reverse transcriptase real time polymerase chain reaction
  • Results of protection and serology are summarized in Table 15. All control birds died within 5 days after ND challenge. The vSB 1-004 recombinant virus induced full clinical protection either alone or when combined with vHVT13. The number of birds shedding detectable amount of challenge ND virus was very low in both vaccinated groups. The mean IBD ELISA titers in groups 1 and 3 were nearly identical indicating the lack of vSB 1-004 interference on vHVT 13 -induced IBDV antibodies.
  • the ND challenge model with the genotype V Chimalhuacan velogenic NDV is very severe. In these severe challenge conditions, vSB 1-004 induced full clinical protection and excellent protection against shedding of challenge virus by the oropharyngeal route. It is worth noting that the F gene inserted in vSB 1-004 is from a genotype Vlld NDV strain and the challenge strain used here is a genotype V. It shows therefore that the genotype Vlld F gene inserted into the SB-1 vector is cross-protecting birds against a genotype V challenge.
  • vHVT13 did not impair the ND protection induced by vSB 1-004 and the vSB 1-004 did not interfere on vHVT 13 -induced IBD antibody titers, demonstrating compatibility of SB-1 vector with HVT vector.
  • Results of protection are summarized in Table 16. All control birds died within 5 days after ND challenges. The vSB 1-004 recombinant virus induced partial protection against mortality (70% and 40% protection after challenge with Mai Vlld and Mex V, respectively) and against morbidity (50% and 30% protection after challenge with Mai Vlld and Mex V, respectively) in these severe early challenge conditions.
  • Example 11 ND efficacy induced by SB-1 recombinant alone or in combination with an HVT-IBD vector vaccine in 1 day-old broiler chickens with maternal antibodies
  • the challenge was performed by the intramuscular (IM) route using 10 5 Egg Infectious Dose 50 (EID50) diluted in 0.2 ml of physiological sterile water. Birds were observed daily during 14 days after challenge for clinical signs and mortality. Blood was also sampled from 5 birds in each group at the time of challenge (D28). The serums were tested with the anti-IBD ELISA (Synbiotics ELISA ProFlok PLUS IBD) to evaluate the impact of vSBl-004 on the vHVT 13 -induced IBDV antibodies in broilers.
  • Results of protection and serology are summarized in Table 17. All control birds died within 5 days after ND challenges.
  • the vSB 1-004 recombinant virus induced significant level of clinical protection when combined or not with vHVT13.
  • the number of birds shedding detectable amount of virus was very low in both vaccinated groups.
  • the mean IBD antibody titers in groups 2 was still high (3 log 10) at D27 indicating a high level of maternally-derived IBD antibodies; nevertheless, vHVT13 induced a clear IBD antibody response which was not affected when mixed with vSB 1-004.
  • vSB 1-004 did not interfere on vHVT 13 -induced IBD antibodies
  • the objective of the study was to evaluate the potential interference of the vSB l- 004 recombinant on the IBD efficacy induced by an HVT-IBD vector vaccine (vHVT13) in an early (D14) IBD challenge model in SPF chicks.
  • Chicks from group 2 were vaccinated with 2000 PFU of vHVT13 and birds from group 3 were vaccinated with 2000 PFU of vHVT13 and 2000 PFU of vSB 1-004.
  • All birds of each group were challenged by the ocular route with 50 ⁇ , containing 2.5 loglO EID50 of the IBDV classical strain Faragher 52/70. Birds were observed daily during 10 days after challenge for clinical signs and mortality. All birds were euthanized 10 days after challenge and body and bursa of Fabricius weights were recorded in order to evaluate the bursa/body weight ratio. Their bursa was also checked for histological lesions typical of IBD.
  • lymphoid depletion i.e., less than 50% of depletion in 1 affected follicle
  • the affected follicles show necrosis lesions and severe influx of heterophils may be detected 51% to 75% of the follicles show lymphoid depletion; affected follicles show necrosis lesions and a severe influx of heterophils is detected
  • Results of protection are summarized in Table 19. All control birds became sick and one died after challenge whereas all vaccinated birds remained healthy. The bursal body weight ratios of groups 2 and 3 were similar and significantly higher than that of group 1. All 8 birds that survived challenge from group 1 had bursa lesion scores of 4 or 5.
  • the aim of the study was to assess the efficacy of 2 single HVT recombinant constructs (vHVTl 14 and vHVTl 16), 2 SB1 recombinant constructs (vSB 1-007 & vSB 1-008) expressing the NDV F gene and a double HVT recombinant (vHVT304) against Newcastle disease challenge with NDV ZJ1 (genotype Vlld) and California/02 (genotype V) performed at 21 days of age in SPF chickens.
  • *vHVT13 is the active ingredient of the licensed Vaxxitek HVT-IBD vaccine based on an HVT vector expressing the IBDV VP2 gene (see US 5,980,906 and EP 0 719 864).
  • shedding was evaluated after challenge by real time RT-PCR in oral and cloacal swabs taken 2 and 4 days post-challenge. Percentage of positive (Ct ⁇ 40) birds are shown for both challenges in Figs. 17A and 17B. Note that all 6 birds were dead at 4 dpch in the control group challenged with the CA/02 isolate and only one bird (out of 6) was still alive at 4 dpch in the control group challenged with ZJl . Shedding was detected in all control birds. Reduction of the percentage of birds positive for shedding was observed in all vaccinated groups.
  • Marek's disease vector vaccines expressing the NDV F and/or the IBDV VP2 gene against Newcastle disease challenge performed at 28 days of age in SPF chickens.
  • the characteristics of the 5 recombinant vaccine candidates tested in this study are described in Table 22 below.
  • herpesvirus 2 and serotype 2 (SB-1 strain; gallid herpesvirus 3) vaccines were used also in combination with recombinant viruses in some of the groups.
  • the aim of the study was to assess the efficacy of one HVT recombinant construct (vHVTl 14) and two SBl recombinant constructs (vSB 1-007 and vSB 1-009) expressing the NDV F gene in combination with vHVT-IBD (vHVT13), as well as a double HVT vHVT307 expressing both NDV F and IBDV VP2 against Newcastle disease challenge (Chimalhuacan, genotype V) performed at 28 days of age in SPF chickens.
  • this example further illustrates the excellent ND protection induced by double HVT-IBD+ND recombinant or a combination of SB1-ND or HVT-ND and HVT-IBD (vHVT13) recombinant viruses.
  • a second HVT vaccine regular HVT vaccines or recombinant HVT vaccines
  • the present invention showed surprising result that vHVTl 14 in combination with vHVT13 offered excellent protection against NDV and no interference effect was observed.
  • Example 16 Efficacy of vHVT306, vSBl-008 in combination with vHVT13 administered by SC or in ovo route against challenge with NDV Chimalhuacan strain (genotype V) at D28 in SPF chickens
  • the aim of the study was to assess the efficacy of the vHVT306 double HVT expressing both NDV F and IBDV VP2 genes, and the vSB 1-008 SB1 recombinant expressing the NDV F gene in combination with vHVT-IBD (vHVT13), administered by the in ovo or by the subcutaneous route against Newcastle disease challenge
  • the birds were injected by subcutaneous (SC) injection in the neck at DO with 0.2 mL of recombinant vaccines containing a target dose of 2000 pfu as described in Table 26 below.
  • Ten birds per group were challenged by the intramuscular route on D28 with 5.0 loglO EID50 velogenic Chimalhuacan (genotype V) strain.
  • this example shows excellent ND protection induced by vHVT306 double HVT recombinant administered either by in ovo or by SC routes.
  • the performance of vSBl-008+vHVT13 was slightly lower especially after in ovo administration, but it may be at least partially due to egg incubator problems.
  • the in ovo safety testing of another SB1-ND recombinant (vSB 1-009) at 1000 or 4000 PFU associated with 6000 PFU of vHVT13 did not show any difference in hatchability and early survival with a group receiving 6000 PFU of vHVT13 only.
  • vSB 1-007 and vSB 1-008 expressing the NDV F gene in combination with vHVT-IBD (vHVT13) against Newcastle disease challenge (Chimalhuacan, genotype V) performed at 42 days of age in commercial broiler chickens.
  • the vSBl-007+vHVT13 performed better than vSBl-008+vHVT13.
  • the vSBl- 007 genomic structure differs from that of vSB 1-008 in different aspects: locus of insertion, promoter, poly-adenylation signal and F gene origin. The combination of these foreign sequences and locus of insertion in vSB 1-007 were likely responsible for its better ND protection performances.
  • this example illustrates the importance of the locus of insertion and other regulatory sequences of the NDV expression cassette in the ND protection induced by HVT and MDV serotype 2 vectors.
  • Example 18 Efficacy of double HVT-ND+IBD (vHVT304 and vHVT306) or SB1- ND (vSBl-008) in combination with vHVT13 recombinant vaccines, against challenge with a classical IBDV isolate on D14 in SPF chickens [0216]
  • the aim of the study was to assess the early IBD efficacy of double HVT recombinants vHVT304 and vHVT306 as well as that of vHVT13 co-administered with a SB1-ND (vSB 1-008) recombinant constructs against a virulent infectious bursal disease virus (vIBDV) challenge (Faragher 52/70 strain) performed at 14 days of age in SPF chickens.
  • vIBDV virulent infectious bursal disease virus
  • the bursal/body weight ratio of the unvaccinated/unchallenged group was 0.0047.
  • lymphoid depletion i.e. less than 50% of depletion in 1 affected follicle
  • affected follicles show necrosis and severe influx of heterophils may be detected
  • a bird was considered as affected if it died and/or showed notable sign of disease and/or severe lesions of the bursa of Fabricius (i.e., histology score >3).
  • Example 19 Efficacy of single HVT-ND (vHVT114) or SB1-ND (vSBl-007 and vSBl-009) in combination with vHVT13 recombinant vaccines, against challenge with a very virulent IBDV isolate on D23 in commercial broiler chickens
  • the aim of the study was to assess the IBD efficacy of vHVT13 co-administered with an HVT-ND (vHVTl 14) or SB1-ND (vSB 1-007 and vSB 1-009) recombinant constructs against a very virulent infectious bursal disease virus (wIBDV) challenge (91- 168/980702 isolate) performed at 23 days of age in commercial broiler chickens.
  • wIBDV infectious bursal disease virus
  • a bird was considered as affected if it died and/or showed notable signs of disease and/or severe lesions of the bursa of Fabricius (i.e., histology score >3).
  • the mean ELISA IBD+ serological titer at DO was 4.36 ⁇ 0.01 loglO indicating a very high level of IBD maternal antibody at hatch.
  • the mean ELISA IBD+ titer was still high (3.9) in the control Gl .
  • ELISA mean titers in the vaccinated groups were not significantly different from those of the control group.
  • Example 20 Efficacy of double HVT-ND+IBD (vHVT304 and vHVT306) associated or not with SB-1 and of SB1-ND (vSBl-007 and vSBl-008) in combination with vHVT13 recombinant vaccines, against challenge with a variant E IBDV isolate on
  • the aim of the study was to assess the efficacy of two double HVT (HVT- ND+IBD: vHVT304 and vHVT306) or two vSB-l-NDV in combination with vHVT13 (vSBl-007+vHVT13, vSBl-008+vHVT13) vectored vaccines administered subcutaneously (SC) to day-old SPF chicks and challenged with IBDV- Variant (VAR-E) 28 days post-vaccination.
  • SC subcutaneously
  • VAR-E IBDV- Variant
  • the mean bursal/body weight ratios are shown in Table 33.
  • the challenged control birds had a severe bursal atrophy compared to unchallenged ones.
  • the vSB 1-007 and vSB 1-008 vaccines did not interfere on vHVT 13 -induced protection (G4 and G5).
  • the bursal/body weight ratios of birds vaccinated with the double HVT (HVT-ND+IBD) were slightly lower than the unchallenged control group but were clearly higher than the challenged control groups.
  • the SB-1 serotype 2 Marek's disease vaccine did not interfere with vHVT304-induced IBD protection.
  • the mean bursal/body weight ratios are shown in Table 34.
  • the challenged control birds (G4 and G9) had a severe bursal atrophy compared to unchallenged ones.
  • the bursal/body weight ratios of the vaccinated groups (Gl to G3 and G6 to G8) were similar to those of the unchallenged control groups (G5 and G10) and well above those of the challenged control groups (G4 and G9).
  • the lack of interference of vHVTl 14 on vHVT 13 -induced IBD protection after both SC or in ovo routes was surprising and confirmed data obtained in examples 15 and 19.
  • the aim of this study was to evaluate the Marek's disease efficacy induced by different combinations of vaccines including vHVTl 14, vHVT13, SB-1 and/or vSB 1-009 administered by the SC route to one-day-old SPF chicks and challenged 4 days later with the very virulent plus Marek's disease virus (w+MDV) T-King isolate.
  • vHVTl 14, vHVT13, SB-1 and/or vSB 1-009 administered by the SC route to one-day-old SPF chicks and challenged 4 days later with the very virulent plus Marek's disease virus (w+MDV) T-King isolate.
  • Each group was monitored daily for any unfavourable reactions before and after challenge.
  • day 49 all live birds were terminated and necropsied to examine for gross lesions associated with Marek's disease.
  • Chickens were classified as positive for infection with Marek's disease if nervous signs, such as paralysis, locomotive signs attributable to the disease, and severe emaciation or depression are observed, if mortality directly attributable to Marek's Disease occurs, or if gross lesions are observed at necropsy. Lesions might include, but not be limited to, the following: liver, heart, spleen, gonads, kidneys, and muscle lesions
  • Marek's disease (MD) efficacy is also demonstrated for Marek's disease vectored recombinants either alone or in combination in other MD challenge models including virulent Marek's disease (vMD) challenge such as GA22, very virulent Marek's disease (wMD) challenge such as RB1B and/or very virulent plus Marek's disease (w+MD) challenge such as the T. King virus.
  • vMD virulent Marek's disease
  • wMD very virulent Marek's disease
  • w+MD very virulent plus Marek's disease
  • One-day-old chickens are inoculated subcutaneously or 18-19-day-old embryonated eggs are inoculated with a 0.2 ml dose or 0.05 ml dose, respectively, of the test viruses.
  • the vaccinated chickens and naive controls are challenged with the relevant Marek's challenge virus (v, w, or w+ MDV).
  • the challenged birds are observed until seven weeks of age. All birds are terminated and necropsied to observe for grossly visible lesions associated with Marek's disease as described in Example 22.
  • Example 24 Efficacy of vSBl-004, vSBl-006, vSBl-007, vSBl-008, SBl-vectored ND vaccine alone or in association with vHVT13 HVT-vectored IBD vaccine, and the vHVT302 and vHVT304 vaccines against challenges with NDV Texas GB strain at 14 and/or 28 days of age in SPF chickens
  • Marek's disease vector vaccines expressing the NDV F and/or the IBDV VP2 gene against Newcastle disease challenge performed at 14 and/or 28 days of age in SPF chickens.
  • vSB 1-008 and vSB 1-007 constructs performed slightly better than vSB 1-004 and vSB 1-006, and the vHVT304 performed slightly better than vHVT302, indicating that different characteristics of the constructs are playing a role in the performances of MDV-based vector vaccines.
  • ND protection levels induced by Marek's disease vectors expressing NDV F gene may depend on different parameters including the vector, the locus of insertion, the F gene, the promoter, the poly-adenylation site and the challenge conditions.
  • Example 25 Efficacy of double HVT-ND+IBD vHVT304 and vHVT306 vaccines against challenges with NDV Texas GB strain at 14 and/or 28 days
  • ND protection levels induced by Marek's disease vectors expressing NDV F gene depend on different parameters including the vector, the locus of insertion, the F gene, the promoter, the poly-adenylation site and the challenge conditions.
  • Example 26 ND early efficacy induced by double HVT-ND+IBD (vHVT302, VHVT303, and vHVT304) or SBl-vectors (vSBl-006 and vSBl-007) in one day-old
  • the objective of the study was to evaluate the efficacy of three double HVT- ND+IBD (vHVT302, vHVT303, and vHVT304) and two SB1-ND vectors (vSBl-006 and vSB 1-007) in one day-old SPF chickens against a velogenic genotype V
  • Results of protection are summarized in Table 41. All control birds died after ND challenge. Variable levels of ND protection were induced by the different tested vaccines ranging from 10% to 80% and from 0% and 60% in terms of protection against mortality and morbidity, respectively.
  • the vHVT304 candidate induced a better protection than the vHVT303 and vHVT302 candidates; this may be due to the exogenous SV40 promoter placed in front of the NDV F gene.
  • the vSB 1-007 performed slightly better than the vSB 1-006. Furthermore, performances obtained with vHVT304 were comparable to those obtained with vSB 1-007 indicating that different Marek's disease vectors can reach the same level of ND protection.
  • Example 27 ND efficacy induced by the double HVT-ND+IBD vHVT306 administered by in ovo or SC route to one day-old SPF chickens against a velogenic genotype V NDV challenge performed at D28
  • the objective of the study was to evaluate the efficacy of one double HVT- ND+IBD (vHVT306) administered by the in ovo or SC route to SPF chickens against a velogenic genotype V (Chimalhuacan) NDV challenge performed at 28 days of age.
  • vHVT302, vHVT303 and vHVT304 recombinant constructs against a virulent infectious bursal disease virus (vIBDV) challenge (Faragher 52/70 strain) performed at 15 days of age in SPF chickens.
  • vIBDV infectious bursal disease virus
  • the bursal/body weight ratio of the unvaccinated/unchallenged group was 0.0043. [0269] Each group was monitored before and after challenge. IBDV clinical signs were recorded for 11 days after challenge (from D15 to D25). At the end of the post-challenge observation period (D25), all the surviving birds were euthanized and necropsied. Body and bursal weights were recorded. Each bursa of Fabricius (BF) was weighted then stored in individual recipients containing 4% formaldehyde for histology. Histological lesions of the bursa were scored according to the scale presented in Table 46.
  • BF Fabricius
  • lymphoid depletion i.e. less than 50%
  • a bird was considered as affected if it died and/or showed notable sign of disease and/or severe lesions of the bursa of Fabricius (i.e., histology score >3).
  • the aim of the study was to assess the efficacy of 5 single HVT recombinant constructs (vHVT39, vHVTl 10, vHVTl 11, vHVTl 12 and vHVTl 13) expressing the NDV F gene against Newcastle disease challenge with velogenic NDV ZJ1 (genotype Vlld) isolate performed at 14 days of age in SPF chickens.
  • Wt means that the wild type velogenic F gene sequence was used but the cleavage site was modified to that of a lentogenic virus.
  • Wtnm means that the cleavage site of the wild type sequence was not modified.
  • the Texas velogenic strain belongs to genotype IV and YZCQ to the genotype Vlld.
  • Example 30 Evaluation of the Newcastle disease efficacy induced by double SB1 constructs expressing IBDV VP2 and NDV F [0280] The aim of the study is to assess the efficacy of double SB1 constructs expressing IBDV VP2 and NDV F against Newcastle disease challenge.
  • one-day-old SPF chickens are randomly allocated into several groups of 10-20 birds, including vaccinated and non- vaccinated groups.
  • the birds of the vaccinated groups are injected by subcutaneous injection in the neck at DO with 0.2 mL containing a target dose of 1000 to 5000 pfu of recombinant vaccines.
  • the same dose in 0.05 mL may be administered in ovo 2 or 3 days before hatch.
  • the birds are challenged by the intramuscular route at different time after vaccination: for instance, D14, D28 or D42 with about 4.0 loglO EID50 (0.1 mL) of a velogenic NDV strain such as Texas GB (genotype II), ZJ1 (genotype Vlld), Chimalhuacan (genotype V) strain.
  • a velogenic NDV strain such as Texas GB (genotype II), ZJ1 (genotype Vlld), Chimalhuacan (genotype V) strain.
  • Oropharyngeal and cloacal swabs can be samples at different times after challenge such as 3, 5, 7 and 9 days post-challenge and the viral load can be estimated by real-time RT- PCR.
  • the best candidates will be those who induced the highest level of clinical protection and the lowest level of viral load in the swabs.
  • a similar study can be performed in broilers containing NDV maternal antibodies; however, these maternal antibodies may potentially protect the non- vaccinated birds if the challenge is performed early.
  • the double SB1 construct may also be tested in combination with other Marek's disease vaccine or vector vaccines.
  • the aim of the study is to assess the IBD efficacy of double SB1 expressing both the IBDV VP2 and the NDV F.
  • One-day-old SPF chickens are randomly allocated into several groups of 10 to 20 birds including vaccinated and non- vaccinated controls.
  • Non- vaccinated controls will be separated into 2 subgroups including challenged and unchallenged birds.
  • the birds of vaccinated groups are injected by subcutaneous injection in the neck at DO with 0.2 mL of vaccines containing each a target dose of 1000 to 5000 pfu.
  • the same dose in 0.05 mL may be administered in ovo 2 or 3 days before hatch.
  • virulent IBDV such as the Faragher or the US standard strain
  • very virulent IBDV such as the 91-168 isolate or a variant IBDV isolate such as the US Delaware variant E isolate.
  • virulent IBDV such as the Faragher or the US standard strain
  • very virulent IBDV such as the 91-168 isolate or a variant IBDV isolate such as the US Delaware variant E isolate.
  • Each group is clinically monitored before and after challenge.
  • Birds can be necropsied 4 or 5 days post-challenge for bursal gross lesions evaluation. They can also be necropsied 10 to 11 days post-challenge. Gross and/or histological lesions can be evaluated.
  • bursal/body weight ratios (bursa weight/body weight ratio X 100) are calculated compared to those of the non- vaccinated unchallenged group.
  • Control SPF challenged birds must show clinical signs and/or have significant gross and/or histological lesions, and/or should have a bursal/body weight ratio significantly lower than the unvaccinated unchallenged control birds to validate the severity of challenge.
  • the efficacy of the vaccine is evaluated by comparing these parameters with unvaccinated/challenged and unvaccinated/unchallenged groups. Such study may be performed in broiler chickens containing IBDV maternal antibodies; however, these maternal antibodies may potentially protect the non-vaccinated birds if the challenge is performed early.
  • the double SB1 construct may also be tested in combination with other Marek's disease vaccine or vector vaccines.
  • the aim of the study is to evaluate Marek's disease efficacy induced by the SB1 vectors expressing both IBDV VP2 and NDVF.
  • One-day-old SPF chickens are randomly allocated into several groups of 20 to 50 birds including vaccinated and non- vaccinated controls.
  • Non- vaccinated controls may be separated into 2 subgroups including challenged and unchallenged birds.
  • the birds of vaccinated groups are injected by subcutaneous injection in the neck at DO with 0.2 mL of vaccines containing each a target dose of 1000 to 5000 pfu.
  • the same dose in 0.05 mL may be administered in ovo 2 or 3 days before hatch.
  • all birds from vaccinated groups and the challenged controls are challenged by the intraperitoneal route with 0.2 mL of a Marek's disease virus (MDV) strain.
  • MDV Marek's disease virus
  • MDV strain may be of several pathotypes such as virulent MDV (vMDV) including the JM or GA22 isolate, very virulent MDV (wMDV) such as the RB-1B or Md5 isolate, very virulent plus (w+MDV) such as the T-King or 648A isolate.
  • MDV challenge strain inoculum are prepared by infecting chickens, harvesting and freezing their blood cells into liquid nitrogen in presence of a
  • CID50 chicken infectious dose 50
  • the chicken infectious dose 50 is established for each challenge batch before performing vaccination/challenge studies. Each group is clinically monitored before and after challenge. Birds are necropsied after at least 7 weeks post-vaccination and the presence Marek's disease gross lesions is checked in each bird. Lesions might include, but not be limited to, the following: liver, heart, spleen, gonads, kidneys, nerve and muscle lesions. Such study may be performed in broiler chickens containing MDV maternal antibodies.
  • the double SB1 construct may also be tested in combination with other Marek's disease vaccine (for insance HVT and or CVI988 Rispens strains) or MD vector vaccines. MD challenge may also be performed by contact between vaccinated birds and MDV infected non- vaccinated SPF chicks.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors.

Description

RECOMBINANT GALLID HERPESVIRUS 3 (MDV SEROTYPE 2) VECTORS EXPRESSING ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. provisional application 61/564,877 filed on November 30, 2011 and U.S. provisional application 61/694,957 filed on August 30, 2012.
FIELD OF THE INVENTION
[0002] The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use as safe immunization vehicles to protect against a variety of pathogens. It also relates to multivalent composition or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making and using the recombinant viral vectors.
BACKGROUND OF THE INVENTION
[0003] Poultry vaccination is widely used to protect poultry flocks against devastating diseases including Newcastle disease (ND), infectious bursal disease (IBD), Marek's disease (MD), infectious bronchitis (IB), infectious laryngotracheitis (ILT) and avian influenza (AI). ND is caused by the avian paramyxovirus 1 (APMV-1) also designated ND virus (NDV) belonging to the Paramyxoviridae family. MD is caused by Gallid herpesvirus 2 {Herpesviridae family) also designated as MD virus serotype 1 (MDV1). IB is caused by IB virus (IBV) belonging to the Coronaviridae family, ILT is caused by Gallid herpesvirus 1 {Herpesviridae family) also designated ILT virus (ILTV) and AI is caused by AI virus (AIV) belonging to the Orthomyxoviridae family.
[0004] A number of recombinant avian viral vectors have been proposed with a view to vaccinating birds against these avian pathogens. The viral vectors used comprise avipox viruses, especially fowlpox (EP-A-0,517,292), Marek's virus, such as serotypes 2 and 3 (HVT) (WO-A-87/04463), or alternatively the ITLV, NDV and avian adenovirus. When some of these recombinant avian viral vectors were used for vaccination, they display variable levels of protection. [0005] Several recombinant herpesvirus of turkeys (HVT, also designated Meleagrid herpesvirus 1 or MDV serotype 3) vectors expressing antigens from various pathogens (US patent Nos. 5,980,906, 5,853,733, 6,183,753, 5,187,087) including IBDV, NDV, ILTV and AIV have been developed and licensed. Of particular interest is a HVT vector- expressing IBDV VP2 protective gene that has shown clear advantages over classical IBD vaccines (Bublot et al J.Comp. Path.2007, Vol.137, S81-S84). Other HVT vectors of interest are those expressing either NDV (Morgan et al 1992, Avian dis. 36, 858-70) or ILTV (Johnson et al, 2010 Avian Dis 54, 1251-1259) protective gene(s). One of the practical problems of using several HVT-based recombinant vaccines together is their interference. Lower protection is induced at least against one of the disease when two HVT recombinants expressing different antigens are mixed (Rudolf Heine 2011; Issues of the Poultry Recombinant Viral Vector Vaccines which May Cause an Effect on the Economic Benefits of those Vaccines; paper presented at the XVII World Veterinary Poultry Association (WVPA) Congress in Canciin, Mexico, August 14-18, 2011; Slacum G, Hein R. and Lynch P., 2009, The compatibility of HVT recombinants with other Marek's disease vaccines, 58th Western Poultry Disease Conference, Sacramento, CA, USA, March 23rd-25th, p 84).
[0006] The combination of HVT and SB-1, a Gallid herpesvirus 3 (MDV serotype 2 or MDV-2) vaccine strain, has shown a synergistic effect on MD protection (Witter and Lee, 1984, Avian Pathology 13, 75-92). To address the interference problem, it is of interest to evaluate the SB-1 virus as a vaccine vector to express protective antigen(s) that could be compatible with HVT vector and improve MD protection.
[0007] The SB-1 genome was cloned and characterized in bacterial artificial
chromosome (BAC) (Petherbridge, et al.,J. Virol. Methods 158, 11-17, 2009; Singh et al, Research in Veterinary Science 89, 140-145, 2010). The MDV2 SB-1 sequence was recently obtained and analyzed (Spatz and Schat, Virus Gene 42, 331-338, 2011). A glycoprotein E deletion of SB-1 virus was described by Petherbridge et al. (J. Virol. Methods 158, 11-17, 2009). However, no research has been reported using SB-1 as a viral vector expressing foreign protective genes.
[0008] It has been shown that both UL13 protein kinase and glycoprotein C (UL44) genes individually are essential for horizontal transmission of MDV in chickens (Jarosinski, et al, J. of Virology 81, 10575-10587, 2007; Jarosinski, et al, J. of Virology 84, 7911- 7916, 2010).
[0009] Considering the potential effect of animal pathogens, such as NDV and IBDV on veterinary public health and the economy, efficient methods of preventing infection and protecting animals are needed. There is a need for a solution of combined effective vector vaccines and a suitable method for making the vaccine that could alleviate the problem of interference observed between 2 HVT-based vector vaccines.
SUMMARY OF THE INVENTION
[0010] The present invention demonstrated for the first time a recombinant Gallid
Herpesvirus-3 (MDV-2) viral vector protecting against a poultry pathogen beyond Marek's disease virus.
[0011] The present invention showed surprising result when multivalent vaccines were used to protect animals against a variety of avian pathogens.
[0012] The present invention relates to a recombinant Gallid Herpesvirus-3 (MDV-2) vector comprising one or more heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen. The present invention further relates to a recombinant Gallid Herpesvirus-3 (MDV-2) vector comprising a mutated glycoprotein C (gC) gene.
[0013] The present invention provides a composition or vaccine comprising one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors comprising one or more
heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen. The present invention further provides a composition for vaccine comprising one or more Gallid Herpesvirus-3 (MDV-2) vectors comprising a mutated glycoprotein C (gC) gene.
[0014] The present invention provides a polyvalent composition or vaccine comprising: i) a recombinant Gallid Herpesvirus-3 (MDV-2) vector comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen, or comprising a mutated glycoprotein C (gC) gene; and ii) at least one of: a recombinant HVT vector (or MDV-3 or Meleagrid herpesvirus- 1) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; or wild type HVT (MDV-3); or recombinant MDV serotype 1 vector (i.e., MDV-1, Gallid herpesvirus-2) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; or any wild type MDV-1.
[0015] The present invention relates to a method of vaccinating an animal, or inducing an immunogenic or protective response in an animal, comprising at least one administration of the composition or vector of the present invention.
[0016] The present invention further provides specific insertion loci for the introduction of one or more isolated polynucleotide into nonessential regions of the SB-1 genome.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] The following detailed description, given by way of example, and which is not intended to limit the invention to specific embodiments described, may be understood in conjunction with the accompanying figures, incorporated herein by reference, in which:
[0018] Figure 1 is a table showing the SEQ ID NO assigned to each DNA and protein sequence.
[0019] Figure 2 depicts a schematic diagram of SB-1 genome organization.
[0020] Figure 3 depicts the immuno fluorescent staining of recombinant vSB 1-004 virus expressing NDV-F protein.
[0021] Figure 4 depicts the schematic representation of primer binding sites.
[0022] Figure 5 shows the PCR results of identifying vSB 1 -004.
[0023] Figure 6 shows the immuno fluorescent staining of recombinant vSB 1-006 virus expressing NDV-F protein.
[0024] Figure 7 depicts the schematic representation of primer binding sites on vSBl-
006.
[0025] Figure 8 shows the PCR results of vSBl-006.
[0026] Figure 9 depicts the immuno fluorescent staining of recombinant SB 1-007 virus expressing NDV-F protein.
[0027] Figure 10 depicts the schematic diagram of primer location on pSBl 44 cds
SVOptF donor plasmid.
[0028] Figure 11 shows the PCR results of vSB 1-007. [0029] Figure 12 depicts the immuno fluorescent staining of recombinant SB 1-008 virus expressing NDV-F protein.
[0030] Figure 13 depicts the schematic representation of primer binding sites.
[0031] Figure 14 shows the PCR results of vSBl-008.
[0032] Figure 15 depicts the Western blot analysis of immunoprecipitated sample from vSB 1-009 infected cells.
[0033] Figure 16 depicts the Immunoprecipitation and Western Blot of vHVTl 14.
[0034] Figure 17 depicts the clinical analysis (percentage of birds shedding challenge virus) of the recombinants against CA02 and ZJ1 NDV challenge.
[0035] Figure 18 depicts the clinical analysis (oropharyngeal shedding) of the
recombinants against NDV challenge.
[0036] Figure 19 shows the sequence alignment and sequence identity percentage.
[0037] Figure 20 shows the DNA and protein sequences.
DETAILED DESCRIPTION OF THE INVENTION
[0038] It is noted that in this disclosure and particularly in the claims, terms such as
"comprises", "comprised", "comprising" and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting essentially of and "consists essentially of have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.
[0039] Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes V. published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8). The singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicate otherwise. The word "or" means any one member of a particular list and also includes any combination of members of that list.
[0040] The term "animal" is used herein to include all mammals, birds and fish. The animal as used herein may be selected from the group consisting of equine (e.g., horse), canine (e.g., dogs, wolves, foxes, coyotes, jackals), feline (e.g., lions, tigers, domestic cats, wild cats, other big cats, and other felines including cheetahs and lynx), bovine (e.g., cattle), porcine (e.g., pig), ovine (e.g., sheep, goats, lamas, bisons), avian (e.g., chicken, duck, goose, turkey, quail, pheasant, parrot, finches, hawk, crow, ostrich, emu and cassowary), primate (e.g., prosimian, tarsier, monkey, gibbon, ape), humans, and fish. The term "animal" also includes an individual animal in all stages of development, including embryonic and fetal stages.
[0041] The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of consecutive amino acid residues.
[0042] The term "nucleic acid", "nucleotide", and "polynucleotide" are used
interchangeably and refer to RNA, DNA, cDNA, or cRNA and derivatives thereof, such as those containing modified backbones. It should be appreciated that the invention provides polynucleotides comprising sequences complementary to those described herein. The "polynucleotide" contemplated in the present invention includes both the forward strand (5' to 3') and reverse complementary strand (3' to 5'). Polynucleotides according to the invention can be prepared in different ways (e.g. by chemical synthesis, by gene cloning etc.) and can take various forms (e.g. linear or branched, single or double stranded, or a hybrid thereof, primers, probes etc.).
[0043] The term "genomic DNA", or "genome" is used interchangeably and refers to the heritable genetic information of a host organism. The genomic DNA comprises the DNA of the nucleus (also referred to as chromosomal DNA) but also the DNA of the plastids (e.g., chloroplasts) and other cellular organelles (e.g., mitochondria). The genomic DNA or genome contemplated in the present invention also refers to the RNA of a virus. The RNA may be a positive strand or a negative strand RNA. The term "genomic DNA" contemplated in the present invention includes the genomic DNA containing sequences complementary to those described herein. The term "genomic DNA" also refers to messenger RNA (mRNA), complementary DNA (cDNA), and complementary RNA (cRNA).
[0044] The term "gene" is used broadly to refer to any segment of polynucleotide associated with a biological function. Thus, genes or polynucleotides include introns and exons as in genomic sequence, or just the coding sequences as in cDNAs , such as an open reading frame (ORF), starting from the start codon (methionine codon) and ending with a termination signal (stop codon). Genes and polynucleotides can also include regions that regulate their expression, such as transcription initiation, translation and transcription termination. Thus, also included are promoters and ribosome binding regions (in general these regulatory elements lie approximately between 60 and 250 nucleotides upstream of the start codon of the coding sequence or gene; Doree S M ei al; Pandher K et al; Chung J Y et al), transcription terminators (in general the terminator is located within approximately 50 nucleotides downstream of the stop codon of the coding sequence or gene; Ward C K et al). Gene or polynucleotide also refers to a nucleic acid fragment that expresses mRNA or functional RNA, or encodes a specific protein, and which includes regulatory sequences.
[0045] The term "heterologous DNA" as used herein refers to the DNA derived from a different organism, such as a different cell type or a different species from the recipient. The term also refers to a DNA or fragment thereof on the same genome of the host DNA wherein the heterologous DNA is inserted into a region of the genome which is different from its original location.
[0046] As used herein, the term "antigen" or "immunogen" means a substance that induces a specific immune response in a host animal. The antigen may comprise a whole organism, killed, attenuated or live; a subunit or portion of an organism; a recombinant vector containing an insert with immunogenic properties; a piece or fragment of DNA capable of inducing an immune response upon presentation to a host animal; a polypeptide, an epitope, a hapten, or any combination thereof. Alternately, the immunogen or antigen may comprise a toxin or antitoxin.
[0047] The term "immunogenic protein or peptide" as used herein includes polypeptides that are immunologically active in the sense that once administered to the host, it is able to evoke an immune response of the humoral and/or cellular type directed against the protein. Preferably the protein fragment is such that it has substantially the same immunological activity as the total protein. Thus, a protein fragment according to the invention comprises or consists essentially of or consists of at least one epitope or antigenic determinant. An "immunogenic" protein or polypeptide, as used herein, includes the full-length sequence of the protein, analogs thereof, or immunogenic fragments thereof. By "immunogenic fragment" is meant a fragment of a protein which includes one or more epitopes and thus elicits the immunological response described above. Such fragments can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996). For example, linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Such techniques are known in the art and described in, e.g., U.S. Pat. No. 4,708,871. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, supra.
48] The term "immunogenic protein or peptide" further contemplates deletions, additions and substitutions to the sequence, so long as the polypeptide functions to produce an immunological response as defined herein. The term "conservative variation" denotes the replacement of an amino acid residue by another biologically similar residue, or the replacement of a nucleotide in a nucleic acid sequence such that the encoded amino acid residue does not change or is another biologically similar residue. In this regard, particularly preferred substitutions will generally be conservative in nature, i.e., those substitutions that take place within a family of amino acids. For example, amino acids are generally divided into four families: (1) acidic—aspartate and glutamate; (2) basic— lysine, arginine, histidine; (3) non-polar— alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar— glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another hydrophobic residue, or the substitution of one polar residue for another polar residue, such as the substitution of arginine for lysine, glutamic acid for aspartic acid, or glutamine for asparagine, and the like; or a similar conservative replacement of an amino acid with a structurally related amino acid that will not have a major effect on the biological activity. Proteins having substantially the same amino acid sequence as the reference molecule but possessing minor amino acid substitutions that do not substantially affect the immunogenicity of the protein are, therefore, within the definition of the reference polypeptide. All of the polypeptides produced by these modifications are included herein. The term "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.
[0049] The term "epitope" refers to the site on an antigen or hapten to which specific B cells and/or T cells respond. The term is also used interchangeably with "antigenic determinant" or "antigenic determinant site". Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.
[0050] An "immunological response" to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to a composition or vaccine of interest. Usually, an "immunological response" includes but is not limited to one or more of the following effects: the production of antibodies, B cells, helper T cells, and/or cytotoxic T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest. Preferably, the host will display either a therapeutic or protective immunological response such that resistance to new infection will be enhanced and/or the clinical severity of the disease reduced. Such protection will be demonstrated by either a reduction or lack of symptoms normally displayed by an infected host, a quicker recovery time and/or a lowered viral titer in the infected host.
[0051] The terms "recombinant" and "genetically modified" are used interchangeably and refer to any modification, alteration or engineering of a polynucleotide or protein in its native form or structure, or any modification, alteration or engineering of a
polynucleotide or protein in its native environment or surrounding. The modification, alteration or engineering of a polynucleotide or protein may include, but is not limited to, deletion of one or more nucleotides or amino acids, deletion of an entire gene, codon- optimization of a gene, conservative substitution of amino acids, insertion of one or more heterologous polynucleotides.
[0052] The terms "polyvalent vaccine or composition", "combination or combo vaccine or composition" and "multivalent vaccine or composition" are used interchangeably to refer to a composition or vaccine containing more than one composition or vaccines. The polyvalent vaccine or composition may contain two, three, four or more compositions or vaccines. The polyvalent vaccine or composition may comprise recombinant viral vectors, active or attenuated or killed wild-type viruses, or a mixture of recombinant viral vectors and wild-type viruses in active or attenuated or killed forms.
[0053] One embodiment of the present invention provides a recombinant Gallid
herpesvirus 3 (MDV-2) vector that comprises a mutated Glycoprotein C (gC or UL44) gene. The term "mutated gC gene" refers to the gC gene of Gallid herpesvirus 3 (MDV- 2) that is altered or engineered which results in a non-functional gC protein upon expression. The alteration or engineering of the gC gene includes mutation or deletion of a segment of the gC gene which is essential for the expression of a functional gC protein. The term "mutated gC gene" also includes deletion of the entire gC gene of Gallid herpesvirus 3 (MDV-2) wherein gC protein is not expressed. Another embodiment of the present invention provides a recombinant Gallid herpesvirus 3 (MDV-2) wherein the Glycoprotein C (gC) gene in the native (wild-type) Gallid herpesvirus 3 (MDV-2) genome encoding the gC protein is deleted. The term "Glycoprotein C (gC) gene" includes any gene or polynucleotide that encodes the Glycoprotein C (gC) of Gallid herpesvirus 3 (MDV-2), and homologs, fragments or variants thereof. The gC gene may encode a gC protein having at least 75%, 80%, 85%, 90%, 95%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity to SEQ ID NO: 35, or a variant thereof. The gC gene having at least 75%, 80%, 85%, 90%, 95%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity to SEQ ID NO:34 is also encompassed in the present invention. [0054] Another embodiment of the invention provides a recombinant Gallid herpesvirus 3 (MDV-2) viral vector comprising one or more heterologous polynucleotides coding for and expressing at least one antigen or polypeptide of an avian pathogen. The Gallid herpesvirus 3 (MDV-2) strains used for the recombinant viral vector may be any SB-1 strains, including, but not limited to, the commercial Marek's Disease Vaccine (SB-1 vaccine) (Merial Select Inc., Gainesville, GA 30503, USA), the SB-1 strain having the genome sequence as defined by GenBank Accession Number HQ840738.1. The Gallid herpesvirus 3 (MDV-2) strains used for the recombinant viral vector may be any other Gallid herpesvirus 3 isolate including the HPRS24 strain having the genome sequence as defined by GenBank Accession Number AB049735.1 , or the HPRS24 strain having the genome sequence as defined by GenBank Accession Number NC_002577.1. The genomes of HPRS24 and SB-1 share 98.4% sequence identity (Spatz and Schat, 201 1 ; Virus Gene 42, 331-338). The Gallid herpesvirus 3 (MDV-2) strains used for the recombinant viral vector may be the 301B/1 isolate described by Witter (1987 Avian Dis 31 , 752-765) or by Witter et al. (1987 Avian Dis 31 , 829-840). The Gallid herpesvirus 3 (MDV-2) strains may be any Gallid herpesvirus 3 (MDV-2) strains comprising the genome sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence as defined in GenBank Accession Number HQ840738.1 (SEQ ID NO: 14), AB049735.1 , or NC 002577.1.
[0055] The genes coding for antigen or polypeptide may be those coding for Newcastle Disease Virus fusion protein (NDV-F), Newcastle Disease Virus hemagglutinin neuraminidase (NDV-HN), Marek's Disease Virus glycoprotein C (gC), Marek's Disease Virus glycoprotein B (gB), Marek's Disease Virus glycoprotein E (gE), Marek's Disease Virus glycoprotein I (gl), Marek's Disease Virus glycoprotein H (gH) or Marek's Disease Virus glycoprotein L (gL), IBDV VP2, IBDV VPX, IBDV VP3, IBDV VP4, ILTV glycoprotein B, ILTV glycoprotein I, ILTV UL32, ILTV glycoprotein D, ILTV glycoprotein E, ILTV glycoprotein C, influenza hemaglutinin (HA), influenza neuraminidase (NA), protective genes derived from Mycoplasma gallisepticum (MG), or Mycoplasma synoviae (MS), or combinations thereof. The antigen or polypeptide may be any antigen from the poultry pathogen selected form the group consisting of avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian metapneumo virus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, chick anemia virus, avian astrovirus, avian parvovirus, coccidiosis (Eimeria sp.), Campylobacter sp., Salmonella sp., Pasteurella sp., Avibacterium sp., Mycoplasma gallisepticum, Mycoplasma synoviae, Clostridium sp., and E. coli.
[0056] Moreover, homologs of aforementioned antigen or polynucleotides are intended to be within the scope of the present invention. As used herein, the term "homologs" includes orthologs, analogs and paralogs. The term "analogs" refers to two
polynucleotides or polypeptides that have the same or similar function, but that have evolved separately in unrelated organisms. The term "orthologs" refers to two
polynucleotides or polypeptides from different species, but that have evolved from a common ancestral gene by speciation. Normally, orthologs encode polypeptides having the same or similar functions. The term "paralogs" refers to two polynucleotides or polypeptides that are related by duplication within a genome. Paralogs usually have different functions, but these functions may be related. Analogs, orthologs, and paralogs of a wild-type polypeptide can differ from the wild-type polypeptide by post-translational modifications, by amino acid sequence differences, or by both. In particular, homologs of the invention will generally exhibit at least 80-85%, 85-90%, 90-95%, or 95%, 96%, 97%), 98%), 99%o sequence identity, with all or part of the polynucleotide or polypeptide sequences of antigens described above, and will exhibit a similar function.
[0057] In one embodiment, the present invention provides a recombinant Gallid
Herpesvirus-3 (MDV-2) viral vector comprising one, two or more heterologous polynucleotides coding for and expressing the NDV-F antigen or polypeptide. In one aspect of the embodiment, the NDV-F antigen or polypeptide has at least 70%>, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2, 9, 50, 52, or 54, or a conservative variant, an allelic variant, a homolog or an immunogenic fragment comprising at least eight or at least ten consecutive amino acids of one of these polypeptides, or a combination of these polypeptides. In another aspect of the embodiment, the heterologous polynucleotide encoding an NDV-F antigen or polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%), 96%), 97%), 98%) or 99% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2, 9, 50, 52, or 54. In yet another aspect of the embodiment, the heterologous polynucleotide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%o or 99%) sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO: l, 8, 49, 51, or 53.
[0058] Variants include allelic variants. The term "allelic variant" refers to a
polynucleotide or a polypeptide containing polymorphisms that lead to changes in the amino acid sequences of a protein and that exist within a natural population (e.g., a virus species or variety). Such natural allelic variations can typically result in 1- 5% variance in a polynucleotide or a polypeptide. Allelic variants can be identified by sequencing the nucleic acid sequence of interest in a number of different species, which can be readily carried out by using hybridization probes to identify the same gene genetic locus in those species. Any and all such nucleic acid variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity of gene of interest, are intended to be within the scope of the invention.
[0059] The term "identity" with respect to sequences can refer to, for example, the number of positions with identical nucleotides or amino acids divided by the number of nucleotides or amino acids in the shorter of the two sequences wherein alignment of the two sequences can be determined in accordance with the Wilbur and Lipman algorithm (Wilbur and Lipman). The sequence identity or sequence similarity of two amino acid sequences, or the sequence identity between two nucleotide sequences can be determined using Vector NTI software package (Invitrogen, 1600 Faraday Ave., Carlsbad, CA). When R A sequences are said to be similar, or have a degree of sequence identity or homology with DNA sequences, thymidine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence. Thus, RNA sequences are within the scope of the invention and can be derived from DNA sequences, by thymidine (T) in the DNA sequence being considered equal to uracil (U) in RNA sequences.
[0060] The polynucleotides of the disclosure include sequences that are degenerate as a result of the genetic code, e.g., optimized codon usage for a specific host. As used herein, "optimized" refers to a polynucleotide that is genetically engineered to increase its expression in a given species. To provide optimized polynucleotides coding for NDV-F polypeptides, the DNA sequence of the NDV-F protein gene can be modified to 1) comprise codons preferred by highly expressed genes in a particular species; 2) comprise an A+T or G+C content in nucleotide base composition to that substantially found in said species; 3) form an initiation sequence of said species; or 4) eliminate sequences that cause destabilization, inappropriate polyadenylation, degradation and termination of RNA, or that form secondary structure hairpins or RNA splice sites. Increased expression of NDV F protein in said species can be achieved by utilizing the distribution frequency of codon usage in eukaryotes and prokaryotes, or in a particular species. The term
"frequency of preferred codon usage" refers to the preference exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the disclosure as long as the amino acid sequence of the NDV-F polypeptide encoded by the nucleotide sequence is functionally unchanged.
61] In another embodiment, the present invention provides a method for producing a recombinant Gallid Herpesvirus-3 or SB-1 viral vector comprising the introduction into the SB-1 genome of one, two or more isolated polynucleotides in a nonessential region of the SB-1 genome. In yet another embodiment, the present invention provides a method for producing a recombinant Gallid Herpesvirus-3 or SB-1 viral vector comprising the steps of altering, engineering, or deleting the gC gene from the SB-1 genome. The term "nonessential region" refers to a region of a virus genome which is not essential for replication and propagation of the virus in tissue culture or in chickens. Any nonessential region or portion thereof can be deleted from the SB-1 genome or a foreign sequence can be inserted in it, and the viability and stability of the recombinant Gallid Herpesvirus-3 or SB-1 vector resulting from the deletion or insertion can be used to ascertain whether a deleted region or portion thereof is indeed nonessential. In one aspect of the embodiment, the non-essential regions are located in the unique long (UL) and unique short (US) regions of the SB-1 genome (see Spatz et al, Virus Genes 42:331-338, 2011). The UL region of SB-1 is about 109,744 bp to about 109,932 bp in length and may extend from positions 12,209 to 121,952 of SEQ ID NO: 14 (GenBank accession No, HQ840738.1) or equivalent positions of other SBl-genomes, for example, from 11,826 bp to 121,757 bp of HPRS24 genome. The US region of SB-1 is about 12,109 bp to about 12,910 bp in length and may extend from positions 143,514 to 156,423 of SEQ ID NO: 14 (GenBank accession No, HQ840738.1) or equivalent positions of other SB 1 -genomes, for example from 142,681bp to 154,789 bp of HPRS24 genome (Spatz et al, 2011). In one aspect of the embodiment, the non-essential region is between ORF of UL55 and ORF of LORF5 in the unique long (UL) region of SB-1. In another aspect, the polynucleotide is inserted into or to replace SB-1 glycoprotein C gene (also designated UL44). The use of the gC locus may allow the generation of recombinant virus unable to produce a functional gC protein and unable to be transmitted horizontally. In yet another embodiment, the nonessential region may be in the intergenic regions between UL7 and UL8, between UL 21 and UL22, between UL40 and UL41, between UL50 and UL51, between UL54 and LORF4, between USIO and SORF4, or within the UL43, US2, USIO or US6 (coding for gD) gene (see GenBank accession No, HQ840738.1). In yet another embodiment, the nonessential regions may be in the region of nucleotide positions 118057-118306 (intergenic UL55-LORF5), 98595-100031 (gC or UL44), 25983-26038 (intergenic UL7- UL8), 49865-50033 (intergenic UL21-UL22), 75880-75948 (intergenic UL35-UL36), 93928-93990 (intergenic UL40-UL41), 109777-109847 (intergenic UL50-UL51), 116466-116571 (intergenic UL54-LORF4), 146548-146697 (intergenic US 10-SORF4), 97141-98385 (UL43), 147857-148672 (US2), 145853..146548 (US10) or 150322-151479 (gD or US6) of SEQ ID NO: 14.
62] Construction of recombinant virus is well known in the art as described in, e.g., US patent Nos. 4,769,330, 4,722,848, 4,603, 112, 5,174, 993, and 5,756,103, 6,719,979. Specifically, a recombinant Gallid Herpesvirus-3 (MDV-2) viral vector may be constructed in two steps. First, the Gallid Herpesvirus-3 (MDV-2) or SB-1 genomic regions flanking the locus of insertion are cloned into an E.coli plasmid construct;
unique(s) restriction site(s) is (are) placed between the two flanking regions (insertion plasmid) in order to allow the insertion of the donor expression cassette DNA.
Separately, the cDNA or DNA gene sequence to be inserted is preceded by a promoter region (gene start region) and a terminator (or poly-adenylation,poly-A) sequence which is specific for the Gallid Herpesvirus-3 (MDV-2) or SB-1 vector and/or eukaryotic cells. The whole expression cassette (promoter-foreign gene-poly-A) is then cloned into the unique(s) restriction site(s) of the insertion plasmid to construct the "donor plasmid" which contains the expression cassette flanked by Gallid Herpesvirus-3 (MDV-2) or SB-1 "arms" flanking the insertion locus. The resulting donor plasmid construct is then amplified by growth within E.coli bacteria and plasmid DNA is extracted. This plasmid is then linearized using a restriction enzyme that cut the plasmid backbone (outside the Gallid Herpesvirus-3 (MDV-2) or SB-1 arms and expression cassette). Chicken embryo fibroblasts are then co-transfected with parental Gallid Herpesvirus-3 (MDV-2) or SB-1 DNA and linearized donor plasmid DNA. The resulting virus population is then cloned by multiple limiting dilution steps where viruses expressing the foreign gene are isolated from the non-expressing viral population. Similarly, another foreign cassette can be inserted in another locus of insertion to create a double Gallid Herpesvirus-3 (MDV-2) or SB-1 recombinant expressing two genes. The second cassette can also be inserted into the same locus. The Gallid Herpesvirus-3 (MDV-2) or SB-1 recombinant is produced in primary chicken embryo fibroblasts similarly to the parental Gallid Herpesvirus-3 (MDV- 2) or SB-1 MD vaccine. After incubation, infected cells are harvested, mixed with a freezing medium allowing survival of infected cells, and frozen usually in cryovial or glass ampoules and stored in liquid nitrogen.
[0063] Successful expression of the inserted cDNA genetic sequence by the modified infectious virus requires two conditions. First, the insertion must be introduced into a region of the genome of the virus in order that the modified virus remains viable. The second condition for expression of inserted cDNA is the presence of a regulatory sequences allowing expression of the gene in the viral background (for instance:
promoter, enhancer, donor and acceptor splicing sites and intron, Kozak translation initiation consensus sequence, polyadenylation signals, untranslated sequence elements).
[0064] In general, it is advantageous to employ a strong promoter functional in
eukaryotic cells. The promoters include, but are not limited to, an immediate early cytomegalovirus (CMV) promoter, guinea pig CMV promoter, an SV40 promoter, Pseudorabies Virus promoters such as that of glycoprotein X promoter, Herpes Simplex Virus- 1 such as the alpha 4 promoter, Marek's Disease Viruses (including MDV-1, MDV-2 and HVT) promoters such as those driving glycoproteins gC, gB, gE, or gl expression, Infectious Laryngotracheitis Virus promoters such as those of glycoprotein gB, gE, gl, gD genes, or other herpesvirus promoters. When the insertion locus consists of a SB-1 gene (for instance, gC, gD, US2 or US 10 genes), the foreign gene can be inserted into the vector with no additional promoter sequence since the promoter of the deleted gene of the vector will drive the transcription of the inserted foreign gene.
[0065] In one embodiment, the present invention relates to a pharmaceutical composition or vaccine comprising one or more recombinant Gallid Herpesvirus-3 (MDV-2) rival vectors of the present invention and a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. The Gallid herpesvirus 3 (MDV-2) strains used for the recombinant Gallid Herpesvirus-3 viral vector may be any SB-1 strains, the HPSR24 strains, or the 301B/1 strains. The Gallid Herpesvirus-3 (MDV-2) strains may also include those described in Witter et al (Avian Diseases 34, 944-957; 1990), Witter (Avian Pathology 21, 601-614, 1992) and Witter (Avian Pathology 24, 665-678, 1995): 280-5/1, 281MI/1, 287C/1, 298B/1, 301A/1, 401/1, 437A/1, 437B/1, 468A/1, 468A/2, 468B/1, 471B/l, or HN-l/l .
[0066] In another embodiment, the present invention provides a composition or vaccine comprising: i) a recombinant Gallid Herpesvirus-3 vector (MDV-2) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; and ii) at least one of: a recombinant HVT vector (or MDV-3 or Meleagrid Herpesvirus- 1) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; or wild type MDV-3; or recombinant MDV-1 vector (or Gallid herpesvirus-2) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; or wild type MDV-1. The composition or vaccine may further comprise a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. This composition may further contain a recombinant fowlpox vector comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen; or wild type fowlpox.
[0067] In one aspect of the embodiment, the composition or vaccine comprises one (or more) recombinant Gallid Herpesvirus-3 (MDV-2) vectors and one or more wild type HVT (MDV-3). In another aspect, the composition or vaccine comprises one (or more) recombinant Gallid Herpesvirus-3 (MDV-2) vectors and one or more recombinant HVT (MDV-3). In another aspect, the composition or vaccine comprises one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors and one or more wild type or genetically modified MDV-1. In another aspect, the composition or vaccine comprises one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors and one or more recombinant MDV-1. In another aspect, the composition or vaccine comprises one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors, one or more wild type HVT (MDV-3) and one or more wild type MDV-1. In another aspect, the composition or vaccine comprises one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors, one or more recombinant HVT (MDV-3) and one or more wild type MDV-1. In another aspect, the composition or vaccine comprises one or more recombinant Gallid
Herpesvirus-3 (MDV-2) vectors, one or more wild type HVT (MDV-3) and one or more recombinant MDV-1. In yet another aspect, the composition or vaccine comprises one or more recombinant Gallid Herpesvirus-3 (MDV-2) vectors, one or more recombinant HVT (MDV-3) and one or more recombinant MDV-1. The wild type HVT (MDV-3) or wild type MDV-1 may be live, attenuated or genetically modified. The heterologous polynucleotides in recombinant Gallid Herpesvirus-3 (MDV-2) vectors, recombinant HVT (MDV-3) vectors, and recombinant MDV-1 vectors may encode same or different antigens from the same or different avian pathogens.
68] The pharmaceutically or veterinarily acceptable carriers or adjuvant or vehicles or excipients are well known to the one skilled in the art. For example, a pharmaceutically or veterinarily acceptable carrier or adjuvant or vehicle or excipient can be Marek's disease vaccine diluent used for MD vaccines. Other pharmaceutically or veterinarily acceptable carrier or adjuvant or vehicle or excipients that can be used for methods of this invention include, but are not limited to, 0.9% NaCl (e.g., saline) solution or a phosphate buffer, poly-(L-glutamate) or polyvinylpyrrolidone. The pharmaceutically or veterinarily acceptable carrier or vehicle or excipients may be any compound or combination of compounds facilitating the administration of the vector (or protein expressed from an inventive vector in vitro), or facilitating transfection or infection and/or improve preservation of the vector (or protein). Doses and dose volumes are herein discussed in the general description and can also be determined by the skilled artisan from this disclosure read in conjunction with the knowledge in the art, without any undue experimentation. [0069] Optionally other compounds may be added as pharmaceutically or veterinarily acceptable carriers or adjuvant or vehicles or excipients, including, but not limited to, alum; CpG oligonucleotides (ODN), in particular ODN 2006, 2007, 2059, or 2135 (Pontarollo R.A. et al., Vet. Immunol. Immunopath, 2002, 84: 43-59; Wernette CM. et al., Vet. Immunol. Immunopath, 2002, 84: 223-236; Mutwiri G. et al., Vet. Immunol. Immunopath, 2003, 91 : 89-103); polyA-polyU, dimethyldioctadecylammonium bromide (DDA) ("Vaccine Design The Subunit and Adjuvant Approach", edited by Michael F. Powell and Mark J. Newman, Pharmaceutical Biotechnology, 6: p.03, p.157); N,N- dioctadecyl-N',N'-bis(2-hydroxy ethyl) propanediamine (such as AVRIDINE®) {Ibid, p. 148); carbomer, chitosan {see US Patent Serial No. 5,980,912 for example).
[0070] The pharmaceutical compositions and vaccines according to the invention may comprise or consist essentially of one or more adjuvants. Suitable adjuvants for use in the practice of the present invention are (1) polymers of acrylic or methacrylic acid, maleic anhydride and alkenyl derivative polymers, (2) immunostimulating sequences (ISS), such as oligodeoxyribonucleotide sequences having one or more non-methylated CpG units (Klinman et al, 1996; W098/16247), (3) an oil in water emulsion, such as the SPT emulsion described on p 147 of "Vaccine Design, The Subunit and Adjuvant Approach" published by M. Powell, M. Newman, Plenum Press 1995, and the emulsion MF59 described on p 183 of the same work, (4) cation lipids containing a quaternary ammonium salt, e.g., DDA (5) cytokines, (6) aluminum hydroxide or aluminum phosphate, (7) saponin or (8) other adjuvants discussed in any document cited and incorporated by reference into the instant application, or (9) any combinations or mixtures thereof.
[0071] Another aspect of the invention relates to a method for inducing an
immunological response in an animal against one or more antigens or a protective response in an animal against one or more avian pathogens, which method comprises inoculating the animal at least once with the vaccine or pharmaceutical composition of the present invention. Yet another aspect of the invention relates to a method for inducing an immunological response in an animal to one or more antigens or a protective response in an animal against one or more avian pathogens in a prime -boost administration regimen, which is comprised of at least one primary administration and at least one booster administration using at least one common polypeptide, antigen, epitope or immunogen. The immunological composition or vaccine used in primary administration may be same, may be different in nature from those used as a booster.
[0072] The avian pathogens may be Newcastle Disease Virus (NDV), Infectious Bursal Disease Virus (i.e., IBDV or Gumboro Disease virus), Marek's Disease Virus (MDV), Infectious Laryngotracheitis Virus (ILTV), avian encephalomyelitis virus and other picornavirus, avian reovirus, avian paramyxovirus, avian metapneumovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, avian parvovirus, avian astrovirus and chick anemia virus, coccidiosis (Eimeria sp.), Campylobacter sp., Salmonella sp., Mycoplasma gallisepticum, Mycoplasma synoviae, Pasteurella sp., Avibacterium sp., E. coli or Clostridium sp.
[0073] Usually, one administration of the vaccine is performed either at one day-of-age by the subcutaneous or intramuscular route or in ovo in 17-19 day-old embryo. A second administration can be done within the first 10 days of age. The animals are preferably at least 17-day-embryo or one day old at the time of the first administration.
[0074] A variety of administration routes in day-old chicks may be used such as subcutaneously or intramuscularly, intradermally, transdermally. The in ovo vaccination can be performed in the amniotic sac and/or the embryo. Commercially available in ovo and SC administration devices can be used for vaccination.
[0075] The invention will now be further described by way of the following non-limiting examples.
EXAMPLES
[0076] Construction of DNA inserts, plasmids and recombinant viral vectors
was carried out using the standard molecular biology techniques described
by J. Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd
Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York,
1989).
Example 1 Construction of recombinant vSBl-004 expressing NDV-F [0077] The aim of the work is to construct a recombinant SB-1 virus in which an expression cassette containing mouse cytomegalovirus (mCMV) promoter, Newcastle disease virus fusion protein (NDV-F), and Simian virus 40 (SV40) poly A tail is inserted into the intergenic site between US 10 and SORF4 site of SB-1 virus (Table 1 and Fig. 2).
Table 1 Characteristics of vSB 1-004
Figure imgf000023_0001
SB-1 *: Merial's commercial Marek's Disease Vaccine SB-l(Merial Select Inc.,
Gainesville, GA 30503, USA). Vaccine Lot# JV505.
[0078] A Newcastle disease virus Fusion Protein (NDV-F) corresponding to genotype Vlld sequence (SEQ ID NO:2 encoded by SEQ ID NO:3) was chemically synthesized (GenScript, Piscataway, NJ, USA). The F protein cleavage site of this synthetic gene was altered to match with a lentogenic F cleavage site sequence and the resultant NDV-F gene sequence has 99% nucleotide as well as 99% amino acid sequence identity to NDV-F sequence deposited in GenBank under accession number AY337464 (for DNA) and AAP97877.1 (for protein), respectively .
Donor plasmid SB-1 USIOmFwt Sbfl construction
[0079] A fragment containing the synthetic NDV-F gene was excised from pUC57 NDV- F Vlld wt plasmid (synthesized by GeneScript) using NotI and inserted into the same site of pCD046 plasmid containing mCMV promoter and SV40 polyA tail. The resultant plasmid, pCD046+NDV-F wt was digested with EcoRl and Sail and blunt ended with Klenow. A 3.3kb fragment was gel extracted and ligated to a Smal digested and dephosphorylated (CIPed) vector (SB1 US10-SORF4 Sbfl pUC57) containing flanking arms. Ligated material was transformed using Top 10 Oneshot kit (Invitrogen, CA, USA). Bacterial colonies were grown in LBamp broth, plasmid extracted by using Qiagens MiniSpin Prep kit, and screened for insert orientation using Pstl digestion. The correct donor plasmid was designated SB-1 lOmFwt Sbfl. Large scale cultures were grown and plasmid extraction was done using Qiagens Maxi Prep kit. Transient expression of the maxi preps was verified using Fugene Transfection Reagent in Chicken Embryo Fibroblast Cells (CEF's) and chicken polyclonal sera against NDV. Recombinant generation
[0080] A standard homologous recombination procedure was followed by co- electroporation of secondary CEF cells using SB-1 USIOmFwt Sbfl donor plasmid and viral DNA isolated from vaccine strain of SB-1 virus. Co-electroporation was performed using lxl 07 2° CEF in 300 μΐ Opti-MEM and shocked at 150 volts with 950 capacitance in a 2 mm electroporation cuvette. The transfected cells were seeded into 96-well plate and incubated for 5-7 days. The cells grown in the 96-well plate were then treated with trypsin and transferred into two "sisters" 96-well plates and incubated for 5 more days. One set of 96-well plates was used for IFA using chicken polyclonal sera against NDV-F to identify positive wells containing recombinants and another set of 96-well plates was used for recovering the infected cells from the positive wells.
[0081] The recombinant viral purification methods were performed first by 96-well plate duplication and IFA selection for the wells containing the most IFA positive plaques with the least amount of IFA negative plaques. Wells matching those criteria were then harvested and adjusted to 1ml in DMEM+2% FBS. From the 1ml stock, 5-20μ1
(depending on the number of visible plaques) were removed and mixed with lxl 07 CEFs in 10ml DMEM+2% FBS and aliquoted onto a new 96-well plate to have single SB-1 plaques per well. The 96-well plates were duplicated after 5 days of incubation and wells that contained plaques were tested for the presence of recombinant SB-1 and absence of parental virus by IFA and PCR. Again the wells that appeared to have more recombinant virus, by comparing the PCR banding results, were harvested and adjusted to 1ml and aliquoted onto new 96-well plates. After three to five rounds of purification of virus infected cells, recombinant SB-1 expressing NDV-F protein was isolated and the purity of the recombinant virus was tested by IFA and PCR to confirm the absence of parental virus. Selected recombinant virus was then passed from one well of a 96-well plate (P0) to 2xT-25 flasks (PI), then 2xT-75 flasks (P2), 2xT-175 flasks (P3), and finally 2x850 cm2 roller bottles (pre-MSV stock or P4). Vials with 2 ml aliquot were stored in liquid nitrogen. Titrations were performed in triplicate on CEFs and a titer of lxl 05 pfu/ml was obtained for SB 1-004.
Expression analysis [0082] For immunofluorescence testing, the P3 material was diluted 1 : 100 in media. Approximately 50 μΐ of the diluted virus was added to 10 ml of DMEM+2% FBS with lxl 07 CEFs and then aliquoted onto a 96 well plate (100 μΐ/well). The plates were incubated for 5 days at 37°C+5%C02 until viral plaques were visible. The plates were fixed with 95% ice-cold acetone for three minutes and washed three times with PBS. Chicken anti-sera against Newcastle Disease Virus (lot#C0139, Charles Rivers
Laboratory) at 1 : 1000 was added and the plates were incubated at 37°C for 1 hour. After one hour incubation, the plates were washed three times with PBS and FITC anti-chicken (cat# F8888, Sigma) was added at 1 :500. Again the plates were incubated at 37°C for 1 hour. After one hour incubation the cells were rinsed three times with PBS and visualized with a fluorescent microscope using fluorescein isothiocyanate (FITC) filter. All examined plaques of vSB 1-004 were found to express NDV-F protein (Fig. 3).
Analysis of recombinant by PCR
[0083] DNA was extracted from a stock virus by phenol/chloroform extraction, ethanol precipitated, and resuspended in 20mM HEPES. PCR primers were designed to specifically identify the NDV-F Vlld gene, the promoter, the SV40 poly A and the SB-1 flanking arms (see Fig. 4). Primers, specific to HVT (strain FC126), MDV serotype 3 (MB080 +MB081) were also included in the analysis to check the purity of the recombinant virus from SB-1 parental virus. PCR was performed using 200 μg of DNA template along with the specified primers pairs.
[0084] The PCR reactions with all primer pairs resulted in the expected PCR products and banding patterns. The PCR results demonstrate that recombinant virus vSB 1-004 carries the intended expression cassette and the virus stock is free from detectable amounts of parental SB-1 virus (Fig. 5).
[0085] The nucleotide sequence of the donor plasmid SB-1 USlOmFwt Sbfl (SEQ ID NO:41) is shown in FIG. 20.
[0086] Based on PCR testing and immunofluorescence analysis, vSB 1-004 is a
recombinant SB-1 expressing a NDV-F gene under the control of mCMV promoter. Recombinant vector vSB 1-004 is free of any detectable parental SB-1 virus or potential HVT contaminant. Example 2 Construction of recombinant vSBl-006 expressing NDV-F
[0087] The aim of the work is to construct a recombinant SB-1 virus in which an expression cassette containing SV40 promoter, Newcastle disease virus fusion protein (NDV-F), and synthetic polyA tail is inserted between the UL55 and LORF5 site of SB-1 virus (Table 2).
Table 2 Characteristics of vSB 1-006
Figure imgf000026_0001
[0088] A Newcastle disease virus Fusion Protein (NDV-F) corresponding to a consensus codon-optimized genotype Vlld sequence (SEQ ID NO:2 encoded by SEQ ID NO: l) was chemically synthesized (Gene Art).
Donor plasmid SB-1 UL55 SV Fopt syn tail Sbfl construction
[0089] A synthetic SB-1 UL55-LOrf5 Sbfl plasmid covering approximately 1 kb sequence on each side of the insertion site (GenScript) was digested with Sbfi and dephosphorylated. A synthetic SV OptF syn tail pUC57 plasmid (Genscript) was digested with Sbfi and a 2239 base pair fragment was gel extracted and ligated to the Sbfi digested vector to create the new SBl UL55 SVFopt syn tail Sbfl donor plasmid.
Recombinant generation, expression analysis and PCR testing
[0090] A standard homologous recombination procedure was followed by co- electroporation of secondary CEF cells using donor plasmid SBl UL55 SV Fopt syn tail Sbfl and viral DNA isolated from vaccine strain of SB-1 virus. Essentially the procedure described in example 1 for vSB 1-004 was followed to generate, plaque purify and characterize recombinants by immunofluorescence and PCR.
[0091] The nucleotide sequence of the donor plasmid SBl UL55 SVFopt syn tail Sbfl (SEQ ID NO:42) is shown in FIG. 20.
Recombinant Generation and Expression Analyses
[0092] Genomic DNA of SB-1 virus was co-electroporated with SB-1 UL55 SV Fopt syn tail Sbfl donor plasmid to generate recombinant SB-1 using homologous recombination technique. Recombinant virus was separated from parental SB-1 virus by
immunofluorescent positive well selection and PCR screening in multiple rounds of plaque purification. A plaque purified recombinant SB-1 virus expressing the NDV-F protein, designated vSB 1-006, was scaled up from tissue culture flasks to 2 x 850 cm2 roller bottles. After about 72 hrs post infection in roller bottles, the infected CEFs were harvested. Aliquots were frozen in liquid nitrogen containing 10% FBS and 10% DMSO. Titrations were performed in triplicate on CEFs and a titer of 8xl05 pfu/ml was obtained for SB 1-006.
[0093] Immunofluorescence was preformed using chicken anti-sera (lot# CO 139, Charles Rivers Laboratories) followed by a FITC labeled anti-chicken IgG (cat# 02-24-06, KPL). All examined plaques of vSB 1-006 were found to express NDV-F protein (Fig. 6).
PCR analysis of vSB 1-006
[0094] Purity of recombinant virus was verified by PCR using primer pairs that are specific to the SB-1 flanking arms, codon-optimized NDV-F Vlld, SV40 promoter as well as primer pairs specific to HVT (see Fig. 7). PCR reactions with all primer pairs resulted in the expected PCR products and banding patterns. In addition, there was no evidence of the parental SB-1 virus in vSB 1-006 (Fig. 8).
[0095] Based on PCR testing and immunofluorescence analysis, it is confirmed that vSB 1-006 is a recombinant SB-1 expressing a codon-optimized NDV-F gene under the control of SV40 promoter. Recombinant vector vSB 1-006 is free of any detectable amount of parental SB-1 virus and potential HVT contaminant.
Example 3 Construction of recombinant vSBl-007 expressing NDV-F
[0096] The aim of the work is to construct a recombinant SB-1 virus in which an
expression cassette containing SV40 promoter, NDV-F gene corresponding to the F sequence of genotype Vlld of NDV is used to replace the coding sequence of
glycoprotein C (gC or UL44) of SB-1 virus (Table 3).
Table 3 Characteristics of vSB 1-007
Figure imgf000027_0001
[0097] A Newcastle disease virus Fusion Protein (NDV-F) corresponding to a consensus codon-optimized genotype Vlld sequence (SEQ ID NO:2 encoded by SEQ ID NO: l) was chemically synthesized (Gene Art).
Donor plasmid pSBl 44 cds SVOptF construction
[0098] A synthetic pSBl 44 cds plasmid containing flanking arms was generated by gene synthesis (GenScript). The pSBl 44 cds was digested with Sbfl, dephosphorylated.
Another plasmid named SV-OptF-syn no polyA tail-pUC57 was digested with Sbfl and 2.1 kb fragment containing SV40 promoter and NDV-F gene was gel extracted, ligated into the Sbfl digested vector and transformed using the Top 10 Oneshot kit (Invitrogen). Bacterial colonies were grown in LB-ampicillin media (lOOug/ml), and plasmids were extracted by using Qiagen Mini Spin Prep kit, and screened for insertions by EcoRI and Ncol digestion. The resultant donor plasmid was designated pSBl 44 cds SVOptF.
[0099] The synthetic plasmid pSBl 44 cds (SEQ ID NO:36 in FIG. 20) can also be used as a donor plasmid without further modification (without inserting NDV-F expression cassette) to generate a recombinant SB-1 lacking the glycoprotein (gC) gene.
Recombinant Generation and Expression Analyses
[0100] A standard homologous recombination procedure was followed by co- electroporation of secondary CEF cells using donor plasmid pSBl 44 cds SVOptF and viral DNA isolated from vaccine strain of SB-1 virus. Essentially the procedure described in example 1 for vSB 1-004 was followed to generate, plaque purify and characterize recombinants by immunofluorescence. A plaque purified recombinant SB-1 virus expressing the NDV-F protein, designated vSB 1-007, was scaled up from T-25 tissue culture flasks to 10xT-150 cm2 flasks. Infected CEF cells were harvested and aliquots were frozen in liquid nitrogen containing 10% FBS and 10% DMSO. Titrations were performed in triplicate on CEFs and a titer of 7.2x104 pfu/ml was obtained for SB 1-007.
[0101] Immunofluorescents was performed using chicken anti-sera (lot# CO 139, Charles Rivers Laboratories) followed by a FITC labeled anti-chicken IgG (cat# 02-24-06, KPL). All examined plaques of vSB 1-007 were found to express NDV-F protein (Fig. 9).
PCR analysis of vSB 1-007
[0102] Viral DNA was extracted from SB 1 -007 from P.1 through P.6 by QIA DNeasy Blood & Tissue Kit (Qiagen). PCR primers were designed to specifically identify the presence of NDV F (codon-optimized), the SV40 promoter and the flanking arms of UL44 (see Fig. 10). PCR amplifications were preformed using 200ng of DNA template along with the specified primer pairs.
[0103] Similarly, a standard homologous recombination procedure using synthetic plasmid pSBl 44 cds and viral DNA isolated from vaccine strain of SB-1 virus will generate a recombinant SB-1 in which the coding region of gC gene is deleted. Two PCR primers (SB1 43. F and SB1 45. R, Table 4) will produce a PCR product of 103 nucleotides for a gC-deleted recombinant SB-1 versus a 1540 nucleotides for the parent SB-1 virus.
[0104] Purity of recombinant virus was verified by PCR using primer pairs that are specific to the SB-1 flanking arms, codon-optimized NDV-F Vlld, SV40 promoter as well as primer pairs (MB080 +MB081) specific to HVT. PCR reactions with all primer pairs resulted in the expected PCR products and banding patterns. In addition, there is no evidence of the parental SB-1 virus in vSB 1-007 (Tables 4-5 and Fig. 11).
Table 4 PCR primers
Figure imgf000029_0001
Table 5 Expected amplicon size
Figure imgf000029_0002
[0105] Based on PCR testing and immunofluorescence analysis, it is confirmed that vSB 1-007 is a recombinant SB-1 expressing a codon-optimized NDV-F gene under the control of SV40 promoter. The NDV-F expression cassette was successfully used to replace the gC gene of SB 1 , demonstrating that gC is dispensable for in vitro propagation of SB-1 virus. Recombinant vector vSB 1-007 is free of any detectable amount of parental SB-1 virus or HVT.
[0106] The nucleotide sequence of the donor plasmid pSBl 44 cds SVOptF (SEQ ID NO:43) is shown in FIG. 20.
Example 4 Construction of recombinant vSBl-008 expressing NDV-F
[0107] The aim of the work is to construct a recombinant SB-1 virus in which an
expression cassette containing SV40 promoter, NDV-F gene corresponding to the F sequence of CA02 strain of NDV, and synthetic polyA tail is inserted between the UL55 and LORF5 site of SB-1 virus (Table 6).
Table 6 Characteristics of vSB 1-008
Figure imgf000030_0001
[0108] An NDV-F corresponding to a codon-optimized genotype V (CA02 strain) sequence (SEQ ID NO: 9 encoded by SEQ ID NO: 8) was chemically synthesized (GeneArt). The F protein cleavage site of this synthetic gene was altered to match a lentogenic F cleavage site sequence and the resultant NDV-F gene sequence has 99% amino acid sequence identity to NDV-F sequence deposited in GenBank (ABS84266). Donor plasmid SB1 UL55 SV CaFopt syn tail Sbfl construction
[0109] A synthetic SB-1 UL55-LOrf5 Sbfl plasmid (Genscript) containing approximately 1 kb sequence of each side of the insertion site was digested with Sbfl and
dephosphorylated. A synthetic SV OptF syn tail pUC57 plasmid (Genscript) was digested with Sbfl and a 2239 base pair fragment containing syn tail was gel extracted and ligated to the Sbfl digested vector to create the new SB1 UL55 SVFopt syn tail Sbfl donor plasmid. This donor plasmid was then digested with Notl, CIPed, and a 5196 base pair fragment was gel extracted. A synthetic NDV-F CA02 CSmut 0813005 pVRlOl donor plasmid (GeneArt) was digested with Notl and a 1677 base pair fragment was gel extracted and ligated to the Notl digested and CIPed UL55 vector resulting in donor plasmid SB1 UL55 SV CaFopt syn tail Sbfl.
Recombinant generation and expression analysis
[0110] A standard homologous recombination procedure was followed by co- electroporation of secondary CEF cells using donor plasmid SB-1 UL55 SV CaFopt syn tail Sbfl and viral DNA isolated from vaccine strain of SB-1 virus. Essentially the procedure described in example 1 was followed to generate and characterize
recombinants by immunofluorescence and PCR.
[0111] Recombinant virus was separated from parental SB-1 virus by immuno fluorescent positive well selection and PCR screening in multiple rounds of plaque purification. A plaque purified recombinant SB-1 virus expressing the NDV-F protein, designated vSBl- 008, was scaled up from tissue culture flasks to 2 x 850 cm2 roller bottles. After about 72 hrs post infection in roller bottles, the infected CEFs were harvested. Aliquots were frozen in liquid nitrogen containing 10% FBS and 10% DMSO.
[0112] Immunofluorescence was performed using chicken anti-sera (Charles Rivers Laboratories) followed by a FITC labeled anti-chicken IgG (KPL) (Fig. 12).
PCR analysis of vSB 1-008
[0113] Purity of recombinant virus was verified by PCR using primer pairs that are specific to the SB-1 flanking arms, codon-optimized NDV-F Vlld, SV40 promoter (see Fig. 13) as well as primer pairs (MB080 +MB081) specific to HVT, MDV serotype 3. PCR reactions with all primer pairs resulted in the expected PCR products and banding patterns. In addition, there is no evidence of the parental SB-1 virus in vSB 1-008 (Fig. 14).
[0114] The nucleotide sequence of the donor plasmid SB-1 UL55 CaFopt syn tail Sbfl
(SEQ ID NO:44) is shown in Fig. 20.
[0115] Based on PCR testing and immunofluorescence analysis, it is confirmed that vSB 1-008 is a recombinant SB-1 expressing a codon-optimized NDV-F gene under the control of SV40 promoter. Recombinant vector vSB 1-008 is free of any detectable parental SB-1 virus or HVT. Example 5 Construction of recombinant vSBl-009 and vSBl-010 expressing NDV-F
[0116] The aim of the study is to construct a recombinant SB-1 viral vector vSB 1-009 in which an expression cassette containing SV40 promoter and Newcastle disease virus fusion (NDV-F) gene is inserted to replace UL44 coding (gC) sequence of SB-1 and to construct a recombinant SB-1 viral vector vSBl-010 in which an additional expression cassette containing guinea pig CMV promoter and NDV-F gene is inserted in SORF-US2 locus of SB 1-009 vector backbone.
Example 5.1 Construction of vSBl-009
[0117] A donor plasmid pSBl 44 cds SV FCAopt was constructed containing UL44 flanking arms of SBl virus, SV40 promoter and NDV F codon optimized gene sequence (SEQ ID NO:8, coding for SEQ ID NO:9) (Table 7).
Table 7 Characteristics of vSB 1-009
Figure imgf000032_0001
Generation of recombinant virus
[0118] A standard homologous recombination procedure was followed by co- electroporation of secondary CEF cells using donor plasmid pSBl 44 cds SV FCAopt and viral DNA isolated from SB-1 virus infected CEFs. Essentially the procedure described in example 1 was followed to generate, plaque purify and characterize recombinants by immunofluorescence.
[0119] After two rounds of plaque purification, pure recombinant virus (vSB 1-009) was isolated and the purity of vSB 1-009 was tested by IFA and PCR to validate the appropriate insertion as well as no remnant parental virus.
PCR analysis
[0120] Viral DNA was extracted from vSB 1-009 pre-master seed virus (pre-MSV) stock by QIA DNeasy Blood & Tissue Kit (Qiagen). PCR primers were designed to identify the presence of the NDV F optimized, the NDV F wild type, the SV40 promoter, the mCMV promoter, the UL44 flanking arms of SB-1 virus and HVT virus. PCR amplifications were performed using approximately 200ng of DNA template along with the primer pairs.
[0121] PCR amplification with various primers confirmed that the vSB 1-009 has the expected amplification patterns and amplicons.
Expression analysis
[0122] Indirect immunofluorescent assay (IF A) was performed on the vSB 1-009 pre- MSV stock to examine the expression of NDV F gene and SB-1 virus antigen. The CEFs that were inoculated with vSB 1-009 were fixed with ice-cold 95% acetone for three minutes at room temperature and air-dried for 10 min. The plates were washed with PBS, then two primary antibodies, chicken anti-Newcastle Disease Virus sera (Charles Rivers Laboratories cat#10100641, lot#C0117A) at 1 :500 dilution and Y5.9 monoclonal antibody against SB-1 virus (Merial Select, Gainesville, GA) at 1 :3000 dilution were added and the plates were incubated for 45 min at 37°C. After three washes with PBS, two secondary antibodies, goat anti-chicken IgG-fluorescein (KPL) at 1 :500 dilution and donkey anti-mouse IgG-Alexa Fluor 568 (Molecular Probe) at 1 :250 dilution were added. The plates were incubated at 37°C for 45 min and followed by three washes with PBS. The wells were screened for IFA positive plaques with a fluorescent microscope using fluorescein isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate (TRITC)- filters of Nikon Eclipse Ti inverted microscope. Similarly, reactivity of vSB 1-009 with NDV F Mab was examined by Dual IFA using anti-MDV serum (Charles River
Laboratories (1/300 dilution) and anti-NDV F monoclonal antibody (1/300 dilution) as primary antibody. The goat anti-chicken IgG-fluorescein (KPL) (1 :500 dilution) and donkey anti-mouse IgG-Alexa Fluor 568 (Molecular Probe) (1 :250 dilution) were used as secondary antibodies. The wells were observed to identify the IFA positive plaques with a fluorescent microscope using FITC- and TRITC-filters of Nikon Eclipse Ti inverted microscope.
[0123] IFA results indicate that vSB 1-009 expresses the NDV F protein in virus-infected CEF. Over 500 vSB 1-009 plaques were counted for NDV F protein expression as well as SB-1 virus specific protein expression with dual IFA. The expression of NDV F protein completely matched with SB-1 virus antigen expression in each virus plaque (Table 8). Table 8 Dual IFA of vSB 1 -009
Figure imgf000034_0001
[0124] NDV F Mab reactivity was confirmed by Dual IFA. Over 200 vSB 1 -009 plaques were examined for NDV F Mab reactivity as well as anti-MDV serum reactivity. The reactivity with NDV F Mab completely matched with anti-MDV serum reactivity in each virus plaque (Table 9).
Table 9 Reactivity of vSB 1 -009 with anti-ND V F Mab
Figure imgf000034_0002
Southern Blot analysis
[0125] Total genomic DNA was extracted from vSB 1-009 pre-MSV stock infected CEFs. The genomic DNA of vSB 1-009, SB-1 virus (negative control), pSBl 44 cds SV FCA opt donor plasmid were digested at 37°C with EcoRI, Ncol, and Kpnl restriction endonucleases separately. The restriction fragments were separated by a 0.8 % agarose gel electrophoresis and transferred onto a positively charged Nylon membrane. After transfer, the membrane was treated with 0.4M NaOH and then neutralized with 2XSSC- HC1 buffer. The membrane was then air dried and UV crosslinked.
[0126] Following the North2South Chemiluminescent Hybridization and Detection Kit (Thermo Scientific cat#89880) manufacturers' instructions, the membrane was pre- hybridized for 1 hr and then hybridized with the probe at 55°C for overnight. For hybridization, two probes were used; 1) the Sbfl fragment of pSBl 44 cds SV FCA opt as NDV F cassette probe, 2) the Smal-EcoRI fragment of pUC57 SB1 44 arm
(GenScript) as recombination arm probe. After the overnight hybridization, several stringency washes were conducted until the membrane was placed in blocking buffer with the addition of Streptavidin-HRP. After rinsing the membrane of any unbound Streptavidin-HRP, the substrate solution of Luminal and peroxide were added. The membrane was then exposed to X-ray film and the film was developed.
[0127] The Southern blot results were as expected based on Vector NTI map analysis. The NDV F cassette (SV40 promoter, NDV-F CA02 codon optimized gene) replaced the UL44 coding sequences of SB-1 virus.
Genomic analysis
[0128] The genomic DNA of vSB 1-009 pre-MSV stock was conducted by nucleotide sequence determination of the region of recombination arm as well as inserted gene cassette. Primers were designed and used to amplify the entire NDV-F gene cassette including the recombination arms.
[0129] The vSB 1 -009 sequence (donor plasmid pSB 1 44 cds SV FCAopt) containing the recombinant arms, SV40 promoter and NDV F codon-optimized gene was confirmed to be correct as shown in SEQ ID NO:37 (FIG. 20).
Western blot analysis
[0130] The CEF monolayer was infected with vSB 1 -009 pre-MSV at MOI - 0.1. After a 5 -day incubation, the CEFs were pelleted and washed with PBS followed by lysis with IP Lysis/Wash buffer of Pierce Classic IP Kit (Thermo Scientific cat#26146) according to the manufacturers' protocols. The lysate was pre-cleared and incubated with 100 ul of anti-NDV F monoclonal antibody to make the immune complex. The immune complex was captured by Protein A/G Plus Agarose and after removing of the un-bounded immune complex by washing steps, the 50 ul of sample buffer was used to elute under non-reducing conditions. The uninfected CEFs were included as a control. The 20 ul of eluted samples were separated in 10% Bis-Tris gels by electrophoresis. After the electrophoresis, the separated proteins in a gel were transferred onto PVDF membrane. The Protein Detection TMB Western Blot Kit (KPL cat#54-l 1-50) was used to detect the NDV antigens onto PVDF membrane with chicken anti-NDV serum (Charles River Laboratories Laboratories cat#l 0100641, lot#C0117A), and goat anti-chicken IgG- peroxidase conjugate (KPL cat#14-24-06) following the manufacturers' protocols. [0131] The NDV F protein expression of vSBl-009 was confirmed by two-step immunodetection. First, the expressed NDV F proteins from vSB 1-009 infected CEF lysate were captured by the immunoprecipitation using anti-NDV F monoclonal antibody 001C3. Subsequently Western blot analysis using anti-NDV polyclonal serum (Charles River Laboratories cat#10100641, lot#C0117 A) was applied to detect the NDV F protein in the captured samples (NDV F protein-monoclonal antibody complex) (Fig.15). An approximately 55 kDa protein in vSB 1-007 pre-MSV lysates was detected by anti-NDV serum that corresponding the expected size of NDV Fl fusion protein (Fig.15).
Example 5.2 Construction of vSBl-010
Donor plasmid SB1US2 gpVIIdwtsyn construction
[0132] Using the plasmid HVT SOrf3-US2 gpVar-Ewt Syn, the gpCMV, Varient E, Syn tail was removed by Sbfl digestion. This fragment was ligated into the SB1 US2 donor plasmid. The Varient E gene was cut out by Notl and replaced by NDV-F Vlld wt. The synthetic NDV-F Vlld wild type gene (SEQ ID NO:3 encoding SEQ ID NO:2) was excised from pUC57 NDV-F Vlld wt plasmid (synthesized by GeneScript) using Notl digestion. Ligated material was transformed using Top 10 Oneshot kit (cat#C404002, Invitrogen). Bacterial colonies were grown in LBamp broth, plasmid extracted by using Qiagens MiniSpin Prep kit, and screened for insert orientation using Ncol+Sall digestion. The correct donor plasmid was designated pSBl US2 gpVIIdwt Syn. Table 10.1 shows the features unique to the construct around the expression cassettes, including the respective sequences. Large scale cultures were grown and plasmid extraction was done by using Qiagens Maxi Prep kit. Transient expression of the maxi preps was verified using Fugene Transfection Reagent in Chicken Embryo Fibroblast Cells (CEF's) and chicken polyclonal sera against NDV-F.
Recombinant generation
[0133] A standard homologous recombination procedure was followed by co- electroporation of secondary CEF cells using pSBl US2 gpVIIdWt Syn donor plasmid and viral DNA isolated from vSB 1-009 (vSB 1-009 is already a recombinant virus expressing CA02 F gene of NDV). Essentially the procedure described in example 1 for was followed to generate, plaque purify and characterize recombinants by
immunofluorescence. [0134] After five rounds of plaque purification, pure recombinant virus (vSB 1-010) was isolated and the purity of vSBl-010 was tested by IFA and PCR to validate the appropriate insertion as well as no remnant parental virus.
Table 10.1 Characteristics of vSB 1-010
Figure imgf000037_0001
[0135] Sequencing of the insert region confirmed that vSB 1-010 contains the correct sequences of guinea pig CMV promoter and the NDV-F Vlld wt gene as shown in the sequence of the donor plasmid SB1US2 gpVIIdwtsyn (SEQ ID NO: 57).
Analysis of recombinant by PCR
[0136] DNA was extracted from a stock virus by phenol/chloroform extraction, ethanol precipitated, and resuspended in 20mM HEPES. PCR primers were designed to specifically identify the NDV-F Vlld wt gene, the promoter, the polyA, as well as, the purity of the recombinant virus from SBl parental virus. PCR was performed using 200 μg of DNA template along with the specified primers pairs indicted in Table 1. PCR cycling conditions are as follows (unless otherwise noted): 94°C - 2 min; 30 cycles of 94°C - 30 sec, 55°C - 30 sec, 68°C - 3 min; 68°C - 5 min.
[0137] Purity of recombinant virus was verified by PCR using primer pairs that are specific to the SBl flanking arms, the gpCMV promoter, the NDV-F Vlld wt gene and the syn tail. Primers, specific to HVT, MDV serotype 3 (MB080 +MB081) were also included in the analysis. The PCR results demonstrate that recombinant virus vSBl-010 carries the intended expression cassette and the virus stock is free from detectable amounts of parental SB 1-009 virus.
Immuno fluorescent staining of recombinant vSBl-010 virus expressing two NDV-F proteins
[0138] For immunofluorescence testing, the P3 material was diluted 1 : 100 in media. Approximately 50 μΐ of the diluted virus was added to 10 ml of DMEM+2% FBS with lxl 07 CEFs and then aliquoted onto a 96 well plate (100 μΐ/well). The plates were incubated for 5 days at 37°C+5% C02 until viral plaques were visible. The plates were fixed with 95% ice-cold acetone for three minutes and washed three times with PBS. Chicken anti-sera against Newcastle Disease Virus (lot#C0139, Charles Rivers
Laboratory) at 1 : 1000 was added and the plates were incubated at 37°C for 1 hour. After one hour incubation, the plates were washed three times with PBS and FITC anti-chicken (cat# F8888, Sigma) was added at 1 :500. Again the plates were incubated at 37°C for 1 hour. After one hour incubation the cells were rinsed three times with PBS and visualized with a fluorescent microscope using fluorescein isothiocyanate (FITC) filter.
[0139] The immuno fluorescent staining results indicate that vSBl-010 exhibited a very strong expression of the NDV-F protein when the polyclonal sera against both CA02 and Vlld F proteins of NDV were used.
Conclusion
[0140] Based on PCR testing and immunofluorescence analysis, vSBl-010 is a
recombinant SB-1 in which VII d-F gene of NDV under the control of gpCMV promoter was successfully inserted into a vSB 1-009, which already expresses the CA02-F gene of NDV. Consequently vSBl-010 carries both Vlld and CA02 F genes of NDV genotypes and it is free of any detectable parental vSB 1-009.
Example 6 Construction of recombinant vHVT vectors expressing NDV-F
Preparation of donor plasmid pHM103+Fopt for vHVTl 14
[0141] The plasmid pHM103 (Merial Limited) containing the Intergenic I arms of HVT FC126, SV40 promoter and SV40 poly A was digested with NotI, dephosphorylated, and the 5.6kb fragment was gel extracted. A NotI flanked 1.7 kb fragment of a chemically synthesized codon-optimized genotype Vlld NDV-F gene (SEQ ID NO: l, coding for SEQ ID NO:2) was also NotI digested and the 1.7kb fragment was gel extracted. The 5.6 and 1.7kb fragments were ligated to create pHM103+Fopt (Table 10.2).
Table 10.2 Characteristics of vHVTl 14
Figure imgf000038_0001
Generation of recombinant HVT viral vector [0142] A standard homologous recombination procedure was followed by co- electroporation of secondary CEF cells using donor plasmid pHM103+Fopt and viral DNA isolated from the HVT strain FC126 (Igarashi T. et al, J. Gen. Virol. 70, 1789- 1804, 1989). Essentially the procedure described in example 1 was followed to generate, plaque purify and characterize recombinants by immunofluorescence.
[0143] After five rounds of plaque purification, a recombinant virus designated as vHVTl 14 was isolated and the purity was tested by IF A and PCR to confirm NDV-F expression and the absence of parental virus.
PCR analysis of recombinant vHVTl 14
[0144] DNA was extracted from vHVTl 14 by phenol/chloroform extraction, ethanol precipitated, and was resuspended in 20mM HEPES. PCR primers were designed to specifically identify the presence of the codon optimized NDV-F, the SV40 promoter, as well as, the purity of the recombinant virus from FC126 CL2 parental virus.
[0145] The PCR results showed that the sizes of PCR products after gel electrophoresis correspond well with the expected sizes and the banding patterns.
Sequence analysis of the inserted region in recombinant vHVTl 14
[0146] Analysis of vHVTl 14 genomic DNA region was performed by PCR
amplification. Total of 10 primers were used to amplify the entire cassette, as well as, beyond the flanking BamHI-I arms used in the donor plasmid. The 4.727 kb PCR product was gel purified and the entire fragment was sequenced using the sequencing primers. The sequence result confirmed that the vHVTl 14 contains the correct SV40 promoter, the codon-optimized NDV-F and the SV40 polyA sequences that match exactly the sequence described for the donor plasmid pHM103+Fopt in SEQ ID NO:38 (see Fig. 20).
Western blot analysis of recombinant vHVTl 14
[0147] Approximately 2xl06 chicken fibroblast cells were infected at ~0.1 MOI with vHVTl 14 Pre-MSV. After two days of incubation at 37°C, infected as well as uninfected cells were harvested using a cell scraper after removing the media and rinsing with PBS. The cells were harvested with 1ml of PBS and centrifuged. The cell pellets were lysed by following the Pierce Classic IP Kit (Thermo Scientific). 100 μΐ of the anti-NDV-F monoclonal antibody 001C3 (Merial Limited) was used to form the immune complex. The antibody/lysate sample was added to Protein A/G Plus Agarose to capture the immune complex. The immune complex was washed three times to remove non-bound material and then eluted in 50ul volume using sample buffer elution under non-reducing condition. After boiling for 5 minutes, 10 μΐ of the samples were loaded into a 10% Acrylamide gel (Invitrogen). The PAGE gel was run in MOPS buffer (Invitrogen) at 200volts for 1 hour. Then the gel was transferred onto a PVDF membrane.
[0148] The Protein Detector Western Blot Kit TMB System (KPL, cat# 54- 11-50) was used for blotting the PVDF membrane by using the reagents and following
manufacturer's directions. After blocking the membrane for 1 hour at room temperature, the membrane was then rinsed three times in IX Wash Buffer, five minutes each and then soaked in blocking buffer containing 1 : 1000 dilution of chicken serum raised against NDV virus (Lot # CO 139, Charles River Laboratories). After washing three times in a washing buffer, the membrane was incubated with a peroxidase labeled goat anti-chicken IgG (KPL, cat# 14-24-06) at a dilution of 1 :2000 for 1 hour at room temperature. The membrane was then rinsed three times in IX Wash Buffer, five minutes each. 5ml of TMB membrane peroxidase substrate was added to the membrane and gently rocked for about 1 minute. The developing reaction was stopped by placing the membrane into water.
[0149] The immunoprecipitation and Western blot technique detected an approximately 55 kD protein in vHVTl 14 sample that corresponds to the expected size of Fl component ofthe NDV-F protein (Fig. 16).
Generation and characterization of other HVT recombinants
[0150] Generation and characterization of other HVT recombinants, such as vHVT039, vHVTl 10, vHVTl 11, vHVTl 12, vHVTl 13, and vHVTl 16 were essentially done in the same way as for vHVTl 14 described above. The generation and characterization of recombinant HVT viral vectors were also described in US patent application serial No.
US filed on (Merial limited), which is incorporated herein by reference in its entirety. Table 11 shows the features unique to each construct around the expression cassettes, including the respective sequences.
Table 11 Characteristics of the expression cassettes
of single HVT recombinants Name Parental Promoter F gene Poly-A Locus
virus
vHVT039 HVT MDV gB Wtnm-Texas SV40 IG1
vHVTl lO HVT mCMV IE Wt-VIId SV40 IG1
vHVTl l l HVT SV40 Wt-VIId SV40 IG1
vHVTl 12 HVT MCMV IE Wt-YZCQ SV40 IG1
vH VT 113 HVT MCMV IE Wt-Texas SV40 IG1
vHVT114 HVT SV40 Opt-VIId SV40 IG1
vH VT 116 HVT SV40 Opt-NDV-F SV40 IG1
of CA02
Example 7 Construction of double HVT vectors expressing NDV-F and IBDV
VP2,and double HVT vectors expressing IBDV VP2 variants
Preparation of donor plasmid pHVT US2 SV- Fopt-synPA for vHVT306
[0151] The donor plasmid pHVT US2 SV- Fopt-synPA was constructed containing SV40 promoter, synthetic NDV F codon optimized VII gene, synthetic polyA tail flanked by the SORF3 and US2 arm sequences of HVT FC126.
Generation of recombinant virus
[0152] A standard homologous recombination procedure was followed by co- electroporation of secondary CEF cells using donor plasmid pHVT US2 SV-Fopt-synPA and viral DNA isolated from vHVT13 (an HVT vector expressing the IBDV VP2 gene,
Merial Limited). Essentially the procedure described in example 1 was followed to generate, plaque purify and characterize recombinants by immunofluorescence.
[0153] After two rounds of plaque purification, pure recombinant virus (VHVT306) was isolated and the purity of vHVT306 was tested and confirmed by IF A and PCR.
PCR analysis
[0154] Viral DNA was extracted from vHVT306 pre-master seed virus (pre-MSV) stock by QIA DNeasy Blood & Tissue Kit (Qiagen). PCR primers were designed to identify the presence of the NDV F optimized, the NDV F wild type, the SV40 promoter, the mCMV promoter, the flanking arms of US2 HVT virus and SB-1 virus.
[0155] PCR amplification with various primers confirmed that the vHVT306 had the expected amplification patterns and amplicons.
Genomic analysis [0156] The genomic DNA of vHVT306 pre-MSV stock was sequenced to verify the sequence of the recombination arm region as well as inserted gene cassette.
[0157] Primers were designed to amplify the entire inserted gene cassette including recombination arm used in donor plasmid. Analysis of vHVT306 genomic DNA was performed by PCR amplification and followed by nucleotide sequence determination.
[0158] The vHVT306 (donor plasmid pHVT US2 SV- Fopt-synPA) containing the recombinant arms, SV40 promoter and NDV F codon-optimized gene was confirmed to be correct as shown in SEQ ID NO:45 (Fig. 20).
Western blot analysis
[0159] The NDV F protein expression of vHVT306 was confirmed by two-step
immunodetection. First, the expressed NDV F proteins from vHVT306 infected CEF were captured by the immunoprecipitation using anti-NDV F monoclonal antibody 001C3 (Merial Limited). Subsequently Western blot analysis using anti-NDV polyclonal serum (Charles River Laboratories) was applied to detect the NDV F protein in the captured samples (NDV F protein-monoclonal antibody complex). A 55 kDa protein in vHVT306 pre-MSV lysates was detected by anti-NDV serum which corresponds to the expected size of NDV Fl fusion protein.
Generation and characterization of other double HVT recombinants
[0160] Generation and characterization of double HVT recombinants, such as vHVT301, vHVT302, vHVT303, vHVT304, vHVT202, and vHVT307 were essentially done in the same way as for vHVT306 described above. The generation and characterization of recombinant HVT viral vectors were also described in US patent application serial No.
US filed on (Merial limited), which is incorporated herein by reference in its entirety. Table 12 shows the features unique to each construct around the expression cassettes, including the respective sequences.
Table 12 Characteristics of the expression cassettes
of double HVT recombinants
Figure imgf000042_0001
Figure imgf000043_0001
Example 8 Lack of horizontal transmission of gC-deleted SB-1 mutant
[0161] The objective of the study was to compare the level of viremia and horizontal transmission induced by the parental SB-1 with that of a recombinant SB-1 virus in which the gC gene was deleted (see example 3).
[0162] Two groups (A and B) of thirty one-day-old specific pathogen free (SPF) white Leghorn chicks were randomly constituted. Twenty birds from groups A were vaccinated (DO) by the subcutaneous route (nape of the neck; 0.2ml/bird) with 2000 PFU of parental SB-1 and twenty from groups B with 2000 PFU of the SB-1 gC-deleted mutant. Ten birds were kept unvaccinated in the same isolator as the vaccinated birds (groups Ac and Be). At 2-weeks-of-age (D14), the spleen as well as 2 feathers of twenty vaccinated birds of groups A and B were removed after euthanasia. At 4-weeks-of-age (D28) the spleen of the 10 contact birds of groups Ac and Be were also removed for viral isolation. White blood cells were collected from the buffy coat of ground spleens which had added to lymphocyte separation medium and centrifuged. For each bird, 106 leucocytes were added to a 60mm tissue culture dish that contained confluent monolayers of primary chicken embryo fibroblasts (CEF) prepared the day before. Five days postinfection, MDV plaques were counted on each dish and the number of positive birds and mean number of plaques was calculated. For feather follicles samples, the feather pulp was added to SPGA medium and sonicated for 10 seconds before placing on confluent monolayers of primary CEF from which the media had been removed. The pulp suspension was allowed to absorb for 45 minutes prior to adding fresh media with 1% calf serum.
[0163] Results of virus isolation from spleen and from feather follicles of vaccinated birds at D14 are reported in Table 13. All birds from both groups were positive for virus isolation from spleen with a similar mean number of plaques of 142.5 and 176.0 for groups A and B, respectively. Virus could be isolated from feather follicles of all birds in group A and from 90% of birds in group B.
[0164] Results of virus isolation from spleen of unvaccinated contact birds at D28 are reported in Table 14. Seven out of ten birds from group Ac were positive for virus isolation from spleen indicating that the parental SB-1 spread horizontally to contact birds. Virus could not be isolated from birds of group Be suggesting that the gC-deleted mutant did not spread to contact birds.
Table 13 Results of viral isolation from spleen buffy coat (BC) and from feather follicles (FF) of vaccinated birds from groups A and B at D14
Figure imgf000044_0001
15 155 + 80 +
16 226 + TNTC (563) +
17 145 + 145 +
18 114 + 224 +
19 88 + 181 +
20 TNTC*** (462) + 78 +
Mean or 142.5 20/20 176.0 18/20 positive/total
Standard 103.3 137.6 - deviation
* Average plaque counts from spleen buffy coat (BC)
** positive sample from feather follicles
*** TNTC too numerous to count
Results of viral isolation from spleen buffy coat (BC) of unvaccinated contact birds from groups Ac and Be at D28
Figure imgf000045_0001
* Average plaque counts [0165] This study indicates that the level of viremia of the gC-deleted SB-1 mutant measured at D14 post- vaccination was similar to that of the parental SB-1 virus suggesting that the gC deletion did not impair the ability of the SB-1 virus to replicate in vaccinated birds. The level of virus at the feather follicle was slightly lower with the gC- deleted mutant since 2/20 birds did not have detectable amount of virus. Horizontal transmission could be detected in 7/10 birds in contact with birds vaccinated with the parental SB-1. In contrast, no virus could be detected from the birds in contacts with birds vaccinated with the gC-deleted mutant indicating that the gC deletion severely impaired horizontal transmission.
Example 9 ND efficacy induced by SB-1 recombinant alone or in combination with an HVT-IBD vector vaccine in one day-old SPF chickens
[0166] The objective of the study was to evaluate the efficacy of the vSB 1-004
recombinant expressing NDV F gene against an ND challenge performed at 4 week-of- age in SPF chicks vaccinated with vSB 1-004 alone or in combination with an HVT-IBD vector vaccine.
[0167] Three groups (1, 2 and 3) of fifteen one-day-old specific pathogen free (SPF) white Leghorn chicks were randomly constituted. Two vectored vaccines were used: the vSB 1-004 described in example 1 and vHVT13, an herpesvirus of turkey (HVT) vector expressing the VP2 gene of infectious bursal disease virus Faragher 52/70 strain (active ingredient of the Merial licensed VAXXITEK® HVT+IBD vaccine, US 5,980,906 and EP 0 719 864). Birds from groups 1, 2 and 3 received vHVT13 only (control group), vSBl-004 only and a mix of vHVT13 and vSBl-004, respectively (see Table 6). All birds were vaccinated by the subcutaneous route (nape of the neck) with 2000 PFU of vSBl- 004 and/or vHVT13 (DO). Twenty seven days after vaccination (D27), birds of each group were challenged with the genotype V Mexican Chimalhuacan (Mex V) velogenic NDV strain. The challenge was performed by the intramuscular (IM) route using 105 Egg Infectious Dose 50 (EID50) diluted in 0.2 ml of physiological sterile water. Birds were observed daily during 14 days after challenge for clinical signs and mortality.
Oropharyngeal swabs were also sampled from 10 birds per group 5, 7 and 9 days after challenge. The viral RNA load was evaluated in these swabs after RNA extraction by using a quantitative reverse transcriptase real time polymerase chain reaction (qRT-PCR) based on the M gene and described by Wise et al. (2004; Development of a Real-Time Reverse-Transcription PCR for Detection of Newcastle Disease Virus RNA in Clinical Samples; J. Clin. Microbiol. 42, 328-338). Shedding levels were expressed as loglO egg infectious dose 50% (EID50) per mL. Blood was also sampled at the time of challenge (D27). The serums were tested with the anti-IBD ELISA (Synbiotics ELISA ProFlok PLUS IBD) to evaluate the impact of vSBA-004 on the vHVT 13 -induced IBDV antibodies.
[0168] Results of protection and serology are summarized in Table 15. All control birds died within 5 days after ND challenge. The vSB 1-004 recombinant virus induced full clinical protection either alone or when combined with vHVT13. The number of birds shedding detectable amount of challenge ND virus was very low in both vaccinated groups. The mean IBD ELISA titers in groups 1 and 3 were nearly identical indicating the lack of vSB 1-004 interference on vHVT 13 -induced IBDV antibodies.
Results of ND protection induced by SB-1 recombinants expressing NDV F gene in SPF day-old chicks (15/group) challenged at D27
Figure imgf000047_0001
* Standard deviation
** number of birds shedding/total (mean loglO EID50 equivalent/mL)
*** day post-challenge
**** all birds of group 1 died before D5 and therefore, shedding was not evaluated in this group
[0169] The ND challenge model with the genotype V Chimalhuacan velogenic NDV is very severe. In these severe challenge conditions, vSB 1-004 induced full clinical protection and excellent protection against shedding of challenge virus by the oropharyngeal route. It is worth noting that the F gene inserted in vSB 1-004 is from a genotype Vlld NDV strain and the challenge strain used here is a genotype V. It shows therefore that the genotype Vlld F gene inserted into the SB-1 vector is cross-protecting birds against a genotype V challenge. The addition of vHVT13 did not impair the ND protection induced by vSB 1-004 and the vSB 1-004 did not interfere on vHVT 13 -induced IBD antibody titers, demonstrating compatibility of SB-1 vector with HVT vector.
Example 10 ND early efficacy induced by SB-1 recombinant in
one-day-old SPF chickens
[0170] The objective of the study was to evaluate the efficacy of the vSB 1-004
recombinant expressing NDV F gene against an early (D14) ND challenge in SPF chicks performed with two different NDV challenge strains.
[0171] Two groups (1 and 2) of twenty one-day-old specific pathogen free (SPF) white Leghorn chicks were randomly constituted. Birds from group 2 were vaccinated by the subcutaneous route (nape of the neck) with 2000 PFU of vSB 1-004. Chicks from group 1 were not vaccinated and were kept as control birds. At 2 week-of-age, half of the birds of each group were challenged with the genotype V Mexican Chimalhuacan (Mex V) velogenic NDV strain and the other half with the genotype Vlld Malaysia 04-1 (Mai Vlld) velogenic NDV strain. The challenge was performed by the intramuscular (IM) route using 105 Egg Infectious Dose 50 (EID50) diluted in 0.2 ml of physiological sterile water. Birds were observed daily during 14 days after challenge for clinical signs and mortality.
[0172] Results of protection are summarized in Table 16. All control birds died within 5 days after ND challenges. The vSB 1-004 recombinant virus induced partial protection against mortality (70% and 40% protection after challenge with Mai Vlld and Mex V, respectively) and against morbidity (50% and 30% protection after challenge with Mai Vlld and Mex V, respectively) in these severe early challenge conditions.
Results of early ND protection induced by SB-1 recombinants expressing NDV F gene in SPF day-old chicks
Figure imgf000048_0001
Mai Vlld 0/10 0/10
1 -
Mex V 0/9 0/9
Mai Vlld 7/10 5/10
2 vSB 1-004
Mex V 4/10 3/10
[0173] The early ND challenge model that was used to evaluate the efficacy of vSB 1-004 recombinant was chosen because Marek's disease virus vectors expressing NDV F gene do not generally provide full protection in this model. Indeed, their onset of immunity is delayed compared to live NDV vaccines (Morgan et al. (1993) Avian Dis 37, 1032-40; Heckert et al. (1996) Avian Dis 40, 770-777). It is therefore a good model to evaluate and compare the vaccine candidates. In these severe early challenge conditions, vSB 1-004 recombinant induced partial protection that was only slightly higher against the
Malaysian genotype Vlld challenge than against the Mexican Chimalhuacan genotype V one indicating a broad protection against the 2 most prevalent genotypes circulating in the Americas and Eurasia/ Africa, respectively.
Example 11 ND efficacy induced by SB-1 recombinant alone or in combination with an HVT-IBD vector vaccine in 1 day-old broiler chickens with maternal antibodies
[0174] The objective of the study was to evaluate the efficacy of the vSB 1-004
recombinant expressing NDV F gene against two ND challenges performed at 4 week of age in broiler chicks vaccinated with vSB 1-004 alone or in combination with an HVT- IBD vector vaccine.
[0175] Six groups (la, lb, 2a, 2b, 3a, 3b) of twelve one-day-old broilers (Hubbard JA957 line) were randomly constituted. Two vectored vaccines were used: the vSB 1-004 described in example 1 and vHVT13, an herpesvirus of turkey (HVT) vector expressing the VP2 gene of infectious bursal disease virus Faragher 52/70 strain (active ingredient of the Merial licensed VAXXITEK® HVT+IBD vaccine). Birds from groups 1 (la & lb) were vaccinated with vHVT13 only (control group); those from groups 2 with vSB 1-004 only and those from groups 3 with a mix of vHVT13 and vSB 1-004 (see Table 17). All birds were vaccinated by the subcutaneous route (nape of the neck) with 2000 PFU of vSBl-004 and/or vHVT13 (DO). Twenty eight days after vaccination (D28), all birds of each subgroup "a" were challenged with the genotype Vlld Malaysia 04-1 (Mai Vlld) velogenic NDV strain and all birds of each subgroup "b" with the genotype V Mexican Chimalhuacan (Mex V) velogenic NDV strain. The challenge was performed by the intramuscular (IM) route using 105 Egg Infectious Dose 50 (EID50) diluted in 0.2 ml of physiological sterile water. Birds were observed daily during 14 days after challenge for clinical signs and mortality. Blood was also sampled from 5 birds in each group at the time of challenge (D28). The serums were tested with the anti-IBD ELISA (Synbiotics ELISA ProFlok PLUS IBD) to evaluate the impact of vSBl-004 on the vHVT 13 -induced IBDV antibodies in broilers.
[0176] Results of protection and serology are summarized in Table 17. All control birds died within 5 days after ND challenges. The vSB 1-004 recombinant virus induced significant level of clinical protection when combined or not with vHVT13. The number of birds shedding detectable amount of virus was very low in both vaccinated groups. The mean IBD antibody titers in groups 2 was still high (3 log 10) at D27 indicating a high level of maternally-derived IBD antibodies; nevertheless, vHVT13 induced a clear IBD antibody response which was not affected when mixed with vSB 1-004.
Table 17 Results of ND protection induced by SB-1 recombinants expressing NDV F gene in broiler day-old chicks (12 per group except group lb: 11) challenged at D28
Figure imgf000050_0001
* Standard deviation
[0177] Results of this study indicated significant levels of protection induced by vSB 1 - 004 in broilers with NDV MDA. The addition of vHVT13 did not have negative impact on vSB l-004-induced ND protection indicating the lack of vHVT13 interference.
Furthermore, vSB 1-004 did not interfere on vHVT 13 -induced IBD antibodies,
confirming in broilers the compatibility between these two vectors.
Example 12 Lack of interference of vSBl-004 on IBD early efficacy induced by an
HVT-IBD vector vaccine in 1 day-old SPF chicks
[0178] The objective of the study was to evaluate the potential interference of the vSB l- 004 recombinant on the IBD efficacy induced by an HVT-IBD vector vaccine (vHVT13) in an early (D14) IBD challenge model in SPF chicks.
[0179] Three groups (1 to 3) of ten one-day-old specific pathogen free (SPF) white
Leghorn chicks were randomly constituted. Birds from group 1 were vaccinated by the subcutaneous route (nape of the neck) with 2000 PFU of vSB 1-004 (control group).
Chicks from group 2 were vaccinated with 2000 PFU of vHVT13 and birds from group 3 were vaccinated with 2000 PFU of vHVT13 and 2000 PFU of vSB 1-004. At 2 week of age, all birds of each group were challenged by the ocular route with 50μΙ, containing 2.5 loglO EID50 of the IBDV classical strain Faragher 52/70. Birds were observed daily during 10 days after challenge for clinical signs and mortality. All birds were euthanized 10 days after challenge and body and bursa of Fabricius weights were recorded in order to evaluate the bursa/body weight ratio. Their bursa was also checked for histological lesions typical of IBD. A score was assigned to each bursa based on the severity of the lesions as shown in Table 18. The number of affected birds (non-protected) in each group was calculated. A bird was considered as affected if it died and/or showed notable sign of disease and/or intermediate or severe lesions of the bursa of Fabricius (i.e., histology score >3).
Table 18 Scoring scale of histological lesions of the bursa of Fabricius
Score Histology observation/lesions
0 No lesion, normal bursa
j 1% to 25% of the follicles show lymphoid depletion (i.e., less than 50% of depletion in 1 affected follicle), influx of heterophils in lesions
26%o to 50%o of the follicles show nearly complete lymphoid depletion (i.e., with
2 more than 75% of depletion in 1 affected follicle), the affected follicles show necrosis lesions and severe influx of heterophils may be detected 51% to 75% of the follicles show lymphoid depletion; affected follicles show necrosis lesions and a severe influx of heterophils is detected
76%o to 100%) of the follicles show nearly complete lymphoid depletion; hyperplasia and cyst structures are detected; affected follicles show necrosis lesions and severe influx of heterophils is detected
100%) of the follicles show nearly complete lymphoid depletion; complete loss of
5
follicular structure; thickened and folded epithelium; fibrosis of bursal tissue
[0180] Results of protection are summarized in Table 19. All control birds became sick and one died after challenge whereas all vaccinated birds remained healthy. The bursal body weight ratios of groups 2 and 3 were similar and significantly higher than that of group 1. All 8 birds that survived challenge from group 1 had bursa lesion scores of 4 or 5.
Table 19 Results of early (D14) IBD protection induced by vHVT13 alone or in combination with vSB 1-004 recombinant expressing NDV F gene in SPF day-old chicks.
* One bird in these groups died before challenge.
[0181] The early IBD challenge model that was used to evaluate the lack of interference of vSB 1-004 recombinant on vHVT 13 -induced IBD protection was chosen because it is very sensitive to detect interference on vHVT13 protection. Results obtained with vSBl- 004+vHVT13 indicated an excellent level of IBD protection (89%) indicating
compatibility between vSB 1-004 and vHVT13 even when measured in an early IBD challenge. Example 13 Efficacy of vHVT114, vHVT116, vSBl-007, vSBl-008 (alone or with vHVT13) and vHVT 304 against challenges with NDV ZJ1 (genotype Vlld) and
California/02 (genotype V) at 21 days of age in SPF chickens
[0182] The aim of the study was to assess the efficacy of 2 single HVT recombinant constructs (vHVTl 14 and vHVTl 16), 2 SB1 recombinant constructs (vSB 1-007 & vSB 1-008) expressing the NDV F gene and a double HVT recombinant (vHVT304) against Newcastle disease challenge with NDV ZJ1 (genotype Vlld) and California/02 (genotype V) performed at 21 days of age in SPF chickens.
[0183] The characteristics of these 5 vaccine candidates are described in Table 20 below.
Table 20 Characteristics of the vectors used in the challenge study
Figure imgf000053_0001
*vHVT13 is the active ingredient of the licensed Vaxxitek HVT-IBD vaccine based on an HVT vector expressing the IBDV VP2 gene (see US 5,980,906 and EP 0 719 864).
[0184] On DO, 158 one-day-old SPF chickens were randomly allocated into 6 groups of 24 birds (vaccinated) and 1 group of 12 birds (non- vaccinated controls). The birds were injected by subcutaneous injection in the neck at DO with 0.2 mL of recombinant vaccines containing a target dose of 1000 pfu as described in Table 21 below. The birds were then separated into two sub-groups, each sub-group being challenged by the intramuscular route on D21 with 5 log 10 EID50 of either NDV ZJ1 (genotype Vlld) or California/02 (genotype V) velogenic strain.
Table 21 Results of efficacy
% clinical protection
Vaccine at
Group
day-old (DO)
CA/02 (genotype V) ZJ1 (genotype Vlld)
Gl - 0% 0%
G2 vHVTl 14 100% 100%
G3 vHVTl 16 100% 90%
G4 vSB 1-007 92% 100%
G5 vSB 1-008 100% 100%
G6 vSBl-008+vHVT13 100% 83% G7 vHVT304 92% 75%
[0185] Each group was monitored before and after challenge. Technical problems observed with isolators reduced the number of birds in group 2 (vHVTl 14: from 24 to 14) and in group 3 (vHVTl 16: from 24 to 20). NDV clinical signs were recorded after challenge. Serum was collected from blood samples taken from birds of groups 2 and 7 before challenge (D21) for NDV serology by HI test using each challenge strains as antigen.
[0186] Percentages of protection against mortality and morbidity are reported in the table above. Full susceptibility was observed in the non-vaccinated challenged control group Gl thus validating the high severity of both challenges. All vaccines induced high levels (>75%) of protection against both challenges. Full clinical protection against both challenges was induced by vHVTl 14 and vSB 1-008.
[0187] The shedding was evaluated after challenge by real time RT-PCR in oral and cloacal swabs taken 2 and 4 days post-challenge. Percentage of positive (Ct<40) birds are shown for both challenges in Figs. 17A and 17B. Note that all 6 birds were dead at 4 dpch in the control group challenged with the CA/02 isolate and only one bird (out of 6) was still alive at 4 dpch in the control group challenged with ZJl . Shedding was detected in all control birds. Reduction of the percentage of birds positive for shedding was observed in all vaccinated groups.
[0188] In conclusion, the results of this study showed the very good ND protection at 3 weeks of age induced by tested Marek's disease vector vaccines.
Example 14 Efficacy of vHVTl 14, vSBl-007, vSBl-009, vHVT306 and vHVT307 vaccines against challenges with NDV Texas GB strain at 28 days of age in SPF chickens
[0189] The aim of the study was to assess the efficacy of combinations of different
Marek's disease vector vaccines expressing the NDV F and/or the IBDV VP2 gene against Newcastle disease challenge (Texas GB strain, genotype II) performed at 28 days of age in SPF chickens. [0190] The characteristics of the 5 recombinant vaccine candidates tested in this study are described in Table 22 below.
Table 22 Characteristics of the vectors used in the challenge study
Figure imgf000055_0001
[0191] The Marek's disease virus serotype 1 (CVI988 (or Rispens) strain; Gallid
herpesvirus 2) and serotype 2 (SB-1 strain; gallid herpesvirus 3) vaccines were used also in combination with recombinant viruses in some of the groups.
[0192] On DO, 135 one-day-old SPF chickens were randomly allocated into 9 groups of 15 birds. The birds were injected by subcutaneous injection in the neck at DO with 0.2 mL containing a target dose of 2000 pfu for recombinant vaccines (vSB 1-007, vSB 1-009, vHVT13, vHVT306, vHVT307, vHVTl 14), and 1000 pfu for parental Marek's disease vaccine strains (SB-1 and CVI988). The design of the study is shown in Table 23 below. The birds were challenged by the intramuscular route on D28 with 4.0 loglO EID50 velogenic ND Texas GB (genotype II) strain.
Table 23 Results of efficacy
% ND protection after Newcastle
Vaccine at
Group disease challenge at 28 days of
day-old (DO)
age
Gl - 0%
G2 vSBl-007+vHVT13 80%
G3 vSB 1-009 100%
G4 vSBl-009+vHVT13 86%
G5 vSB 1 -009+vHVT 13+CVI988 93%
G6 vHVT306+SB-l 100%
G7 vHVT307 100%
G8 vHVT307+SB-l 93%
G9 vHVTl 14+vHVT13+SB-l 100% [0193] Each group was monitored before and after challenge. NDV clinical signs after challenge were recorded.
[0194] Percentages of protection against mortality and morbidity are reported in the table 23 above. Full susceptibility was observed in the non-vaccinated challenged control group Gl thus validating the high severity of challenge. Excellent levels of protection were observed in all vaccinated groups. Birds from G3, G6, G7 and G9 were fully protected. This study shows that the vSBl-ND candidates can be co-administered with vHVT13 and CVI988 and still provide a very good ND protection. Similarly, double HVT-IBD+ND are compatible with SB-1 and vHVT-ND (vHVTl 14) is compatible with vH VT 13 and SB-1.
[0195] In conclusion, the results of this study showed the lack of interference on ND protection induced by the tested Marek's disease parental and vector vaccines.
Example 15 Efficacy of vHVT114, vHVT307, vSBl-007 and vSBl-009 in combination with vHVT13 against challenges with NDV Chimalhuacan strain
(genotype V) at D28 in SPF chickens
[0196] The aim of the study was to assess the efficacy of one HVT recombinant construct (vHVTl 14) and two SBl recombinant constructs (vSB 1-007 and vSB 1-009) expressing the NDV F gene in combination with vHVT-IBD (vHVT13), as well as a double HVT vHVT307 expressing both NDV F and IBDV VP2 against Newcastle disease challenge (Chimalhuacan, genotype V) performed at 28 days of age in SPF chickens.
[0197] The characteristics of these 4 vaccine candidates are described in Table 24 below.
Table 24 Characteristics of the vectors used in the challenge study
Figure imgf000056_0001
[0198] On DO, 45 one-day-old SPF chickens were randomly allocated into 4 groups of 10 birds and 1 group of 5 birds (unvaccinated control group). The birds were injected by subcutaneous injection in the neck at DO with 0.2 mL of recombinant vaccines containing a target dose of 2000 pfu as described in Table 25 below. The birds were challenged by the intramuscular route on D28 with 5.0 loglO EID50 velogenic Chimalhuacan (genotype V) strain.
Table 25 Study design and results of ND efficacy
Vaccine at % protection % protection against
Group
day-old (DO) against mortality morbidity
Gl - 0% 0%
G2 vHVT114+vHVT13 100% 100%
G3 vHVT307 80% 80%
G4 vSBl-007+vHVT13 90% 90%
G5 vSBl-009+vHVT13 90% 90%
[0199] Each group was monitored before and after challenge. NDV clinical signs were recorded after challenge. Oropharyngeal swabs were taken in the vaccinated groups at 5 and 7 days post-challenge to evaluate the viral load by real time RT-PCR.
[0200] Percentages of protection against mortality and morbidity are reported in the table above. Full susceptibility was observed in the non-vaccinated challenged control group Gl thus validating the high severity of challenge. Very good protection was observed in all 4 vaccinated groups, a full clinical protection being induced by vHVTl 14+vHVT13. The percentage of positive birds and the mean shedding titer (expressed as log 10 EID50 equivalent per mL) are shown in Figs. 18A and 18B. Surprisingly, no shedding was detected in G2 indicating a complete (against both clinical signs and shedding) ND protection induced by vHVTl 14 even if co-administered with vHVT13, in the tested conditions. The shedding levels detected in the other vaccinated groups were low with a slightly higher level detected in G3 (vHVT307) at 5 days post-infection (pi) only.
[0201] In conclusion, this example further illustrates the excellent ND protection induced by double HVT-IBD+ND recombinant or a combination of SB1-ND or HVT-ND and HVT-IBD (vHVT13) recombinant viruses. Contrary to the general belief in the field that a second HVT vaccine (regular HVT vaccines or recombinant HVT vaccines) interferes with the immunity to the foreign genes inserted into the first recombinant HVT vaccine, the present invention showed surprising result that vHVTl 14 in combination with vHVT13 offered excellent protection against NDV and no interference effect was observed.
Example 16 Efficacy of vHVT306, vSBl-008 in combination with vHVT13 administered by SC or in ovo route against challenge with NDV Chimalhuacan strain (genotype V) at D28 in SPF chickens
[0202] The aim of the study was to assess the efficacy of the vHVT306 double HVT expressing both NDV F and IBDV VP2 genes, and the vSB 1-008 SB1 recombinant expressing the NDV F gene in combination with vHVT-IBD (vHVT13), administered by the in ovo or by the subcutaneous route against Newcastle disease challenge
(Chimalhuacan, genotype V) performed at 28 days of age in SPF chickens.
[0203] The design of the groups is shown on Table 26. Sixty SPF embryonated eggs (after approximately 18 days and 18 hours of incubation; D-3) were used for the in ovo administration (20 per group for Gl, G2 and G3). Fifty microliters of vaccine containing 2000 PFU were administered by the in ovo route using the IntelliLab System device from AviTech LLC (Salisbury, MD, USA). Hatchability and survival were recorded after in ovo administration. On DO, 20 one-day-old SPF chickens were randomly allocated into 2 groups of 10 birds (G4 and G5). The birds were injected by subcutaneous (SC) injection in the neck at DO with 0.2 mL of recombinant vaccines containing a target dose of 2000 pfu as described in Table 26 below. Ten birds per group were challenged by the intramuscular route on D28 with 5.0 loglO EID50 velogenic Chimalhuacan (genotype V) strain.
Table 26 Study design and results of ND efficacy
Admin, % protection
Vaccine at % protection against
Group route against
day-old (DO) morbidity
mortality
Gl vHVT13 In ovo 0% 0%
G2 vHVT306 In ovo 100% 100%
G3 vSBl-008+vHVT13 In ovo 78% 68%
G4 vHVT306 SC 100% 100%
G5 vSB l -008 VI IV 13 SC 100% 70% [0204] Each group was monitored before and after challenge. NDV clinical signs were recorded after challenge. Oropharyngeal swabs were taken in the vaccinated groups at 5 and 7 days post-challenge to evaluate the viral load by real time RT-PCR.
[0205] Full hatchability and viability were recorded up to D28 (challenge day) for birds of groups Gl and G2. Hatchability in G3 was 85% and one additional bird died after hatching in this group. The lower hatchability of that group may be due to egg incubator problems. Body weights of males and females in Gl, G2 and G3 were similar at Dl and at D28.
[0206] Percentages of protection against mortality and morbidity are reported in the table 26. Full susceptibility was observed in the non- vaccinated challenged control group Gl thus validating the high severity of challenge. Very good protection was observed in all 4 vaccinated groups, a full clinical protection being induced by vHVT306 administered by both routes.
[0207] The percentage of positive birds and the mean shedding titer (expressed as log 10 EID50 equivalent per mL) are shown in Table 27. Absence of detectable or very low shedding was observed in G2 and G4 vaccinated with vHVT306. The shedding levels detected in the groups vaccinated with vSBl-008+vHVT13 were higher especially at 5 days post-infection (pi).
Table 27 Results of protection against shedding (percentage of birds with detectable shedding and mean viral load in log 10) evaluated at D5 and D7 after NDV challenge
Admin. Percent of
Vaccine at Route positive Mean viral load*
Group
day-old (DO) birds (D5/D7 pi)
(D5/D7 pi)
G2 vHVT306 In ovo 0/0% 2.7/2.7
G3 vSBl-008+vHVT13 In ovo 100/38% 5.2/3.2
G4 vHVT306 SC 20/10% 3.2/2.9
G5 vSBl-008+vHVT13 SC 80/50% 4.6/3.4
* Mean quantitative real time PCR value expressed in equivalent loglO EID50; the threshold is set at 2.7 loglO.
[0208] In conclusion, this example shows excellent ND protection induced by vHVT306 double HVT recombinant administered either by in ovo or by SC routes. The performance of vSBl-008+vHVT13 was slightly lower especially after in ovo administration, but it may be at least partially due to egg incubator problems. Indeed, the in ovo safety testing of another SB1-ND recombinant (vSB 1-009) at 1000 or 4000 PFU associated with 6000 PFU of vHVT13 did not show any difference in hatchability and early survival with a group receiving 6000 PFU of vHVT13 only.
Example 17 Efficacy of vHVT304, vHVT306, vSBl-007 and vSBl-008 in combination with vHVT13 against challenge with NDV Chimalhuacan strain
(genotype V) at D42 in commercial broiler chickens
[0209] The aim of the study was to assess the efficacy of two double HVT (vHVT304 and vHVT306) expressing both NDV F and IBDV VP2 genes, and two SB1
recombinants (vSB 1-007 and vSB 1-008) expressing the NDV F gene in combination with vHVT-IBD (vHVT13) against Newcastle disease challenge (Chimalhuacan, genotype V) performed at 42 days of age in commercial broiler chickens.
[0210] The design of the groups is shown on Table 28. On DO, 55 one-day-old
commercial broiler chickens were randomly allocated into 5 groups of 11 birds. The birds were injected by subcutaneous (SC) injection in the neck at DO with 0.2 mL of recombinant vaccines containing a target dose of 2000 pfu as described in Table 28 below. Ten birds per group were challenged by the intramuscular route on D42 with 5.0 log 10 EID50 velogenic Chimalhuacan (genotype V) strain.
Table 28 Study design and results of ND efficacy
% protection
Vaccine at % protection against
Group against
day-old (DO) morbidity
mortality
Gl vHVT13 0% 0%
G2 vHVT304 82% 82%
G3 vHVT306 100% 100%
G4 vSBl-007+vHVT13 100% 100%
G5 vSBl-008+vHVT13 91% 91%
[0211] Each group was monitored before and after challenge. NDV clinical signs were recorded during 14 days after challenge. Oropharyngeal swabs were taken in the vaccinated groups at 5 and 7 days post-challenge to evaluate the viral load by real time RT-PCR. [0212] Percentages of protection against mortality and morbidity are reported in the table 28. Full susceptibility was observed in the non- vaccinated challenged control group Gl thus validating the high severity of challenge. Very good protection was observed in all 4 vaccinated groups, a full clinical protection being induced by vHVT306 and by vSBl- 007+vHVT13.
[0213] The percentage of positive birds and the mean shedding titer (expressed as loglO EID50 equivalent per mL) are shown in Table 29. The best reduction of shedding was induced by vHVT306 and vSBl-007+vHVT13, which were also the best candidates for clinical protection.
Table 29 Results of protection against shedding (percentage of birds with detectable shedding and mean viral load in log 10) evaluated at D5 and D7 after NDV challenge (pi)
Vaccine at Percent of positive Mean viral load*
Group
day-old (DO) birds (D5/D7 pi) (D5/D7 pi)
G2 vHVT304 100/100% 5.4/4.6
G3 vHVT306 40/50% 3.5/3.7
G4 vSBl-007+vHVT13 80/70% 3.8/4.8
G5 vSBl-008+vHVT13 100/100% 4.8/4.3
* Mean quantitative real time PCR value expressed in equivalent loglO EID50; the threshold is set at 2.7 loglO.
[0214] The vSBl-007+vHVT13 performed better than vSBl-008+vHVT13. The vSBl- 007 genomic structure differs from that of vSB 1-008 in different aspects: locus of insertion, promoter, poly-adenylation signal and F gene origin. The combination of these foreign sequences and locus of insertion in vSB 1-007 were likely responsible for its better ND protection performances.
[0215] In summary, this example illustrates the importance of the locus of insertion and other regulatory sequences of the NDV expression cassette in the ND protection induced by HVT and MDV serotype 2 vectors.
Example 18 Efficacy of double HVT-ND+IBD (vHVT304 and vHVT306) or SB1- ND (vSBl-008) in combination with vHVT13 recombinant vaccines, against challenge with a classical IBDV isolate on D14 in SPF chickens [0216] The aim of the study was to assess the early IBD efficacy of double HVT recombinants vHVT304 and vHVT306 as well as that of vHVT13 co-administered with a SB1-ND (vSB 1-008) recombinant constructs against a virulent infectious bursal disease virus (vIBDV) challenge (Faragher 52/70 strain) performed at 14 days of age in SPF chickens.
[0217] On DO, 95 one-day-old SPF chickens were randomly allocated into 9 groups of 10 birds and 1 group of 5 birds (unvaccinated unchallenged control group). The birds were injected by subcutaneous injection in the neck at DO with 0.2 mL of recombinant vaccines containing a target dose of 300 or 1000 pfu as described in the Table 30 below. On D14, blood sample was collected from 5 birds per group for serological testing with the Kit ProFLOK® plus IBD (Synbiotics Corp). The birds (10 birds per group except for group 7 in which 1 bird died before challenge) were challenged by the eye drop (0.05 mL per bird) with 2.5 loglO EID50.
Table 30 Study design and results of IBD efficacy
IBD+ Number Mean
%
Vaccine at ELISA Dead bursal/body
Group protectday-old (dose in PFU) titer at /Sick2 weight
ion3
D141 ratio4
Gl vSBl-008 (1000) 0.2 7/10 0% 0.0013
G2 vH VT 13 (300) 2.7 0/0 100% 0.0051
G3 vH VT 13 (1000) 2.7 0/0 90% 0.0049
G4 vHVT13+vSB 1-008 (300) 1.9 1/1 60% 0.0041
G5 vHVT13+vSB 1-008 (1000) 2.4 0/0 70% 0.0041
G6 vHVT304 (300) 2.9 0/0 60% 0.0037
G7 VHVT304 (1000) 2.2 0/0 67% 0.0047
G8 vHVT306 (300) 2.4 0/0 80% 0.0033
G9 vHVT306 (1000) 2.7 0/0 40% 0.0026
1 Mean IBD+ ELISA titers expressed in log 10 in the serum of 5 birds per group sampled at D14 before challenge;
2 Birds sick for more than 2 days or still sick on D25 were considered as sick.
3 Protection against clinical signs and severe bursal lesion (bursal score <3)
4 The bursal/body weight ratio of the unvaccinated/unchallenged group was 0.0047.
[0218] Each group was monitored before and after challenge. IBDV clinical signs were recorded for 11 days after challenge (from D15 to D25). At the end of the post-challenge observation period (D25), all the surviving birds were euthanized and necropsied. Body and bursal weights were recorded. Each bursa of Fabricius (BF) was weighted then stored in individual recipients containing 4% formaldehyde for histology. Histological lesions of the bursa were scored according to the scale presented in Table 31.
Table 31 Scoring scale of histological lesions of the bursa of Fabricius*
Score Histology observation/lesions
0 No lesion, normal bursa
j 1% to 25% of the follicles show lymphoid depletion (i.e. less than 50% of depletion in 1 affected follicle), influx of heterophils in lesions
26% to 50% of the follicles show nearly complete lymphoid depletion (i.e.
2 more than 75% of depletion in 1 affected follicle), affected follicles show necrosis and severe influx of heterophils may be detected
^ 51%) to 75%) of the follicles show lymphoid depletion; affected follicles show necrosis lesions and a severe influx of heterophils is detected
76%o to 100%) of the follicles show nearly complete lymphoid depletion;
4 hyperplasia and cyst structures are detected; affected follicles show necrosis and severe influx of heterophils is detected
100% of the follicles show nearly complete lymphoid depletion; complete
5 loss of follicular structure, thickened and folded epithelium, fibrosis of bursal tissue
* sourced from Monograph No. 01/2008:0587 of EU Pharmacopoeia "Avian Infectious Bursal Disease vaccine (live)
[0219] A bird was considered as affected if it died and/or showed notable sign of disease and/or severe lesions of the bursa of Fabricius (i.e., histology score >3).
[0220] The mean ELISA IBD+ antibody titer expressed in log 10 before challenge is shown in Table 30. Significant titers were detected in all vaccinated groups that were significantly higher than that of the control group Gl . The serology titer was not dose- dependent.
[0221] Severe clinical signs were observed after challenge in all birds of the control group Gl . Seven out of 10 birds of that group died within the 11 days observation period indicating the high severity of challenge. None of the vaccinated birds showed severe clinical signs after challenge except 1 bird of G4 that died. Percentages of protection against severe bursal lesions are shown in the table 30 above. Significant IBD protection was observed in all groups, the best protection being observed in G2 and G3 (vHVT13 alone). The co-administration of vSBl-008+vHVT13 and the double vHVT304 and vHVT306 constructs induced similar levels of IBD protection. The protection was not dose-dependent at the tested doses. The mean bursal/body weight ratios are also shown in Table 30. Ratios in all vaccinated groups were higher than those of the challenged control group.
[0222] In conclusion, these data indicate that both the combination of a SB1-ND vector with a single HVT-IBD or double HVT expressing both NDV-F and IBDV-VP2 induce IBD antibodies and early IBD protection in a severe IBDV challenge model.
Example 19 Efficacy of single HVT-ND (vHVT114) or SB1-ND (vSBl-007 and vSBl-009) in combination with vHVT13 recombinant vaccines, against challenge with a very virulent IBDV isolate on D23 in commercial broiler chickens
[0223] The aim of the study was to assess the IBD efficacy of vHVT13 co-administered with an HVT-ND (vHVTl 14) or SB1-ND (vSB 1-007 and vSB 1-009) recombinant constructs against a very virulent infectious bursal disease virus (wIBDV) challenge (91- 168/980702 isolate) performed at 23 days of age in commercial broiler chickens.
[0224] On DO, 90 one-day-old broiler chickens were randomly allocated into 7 groups of 12 birds and 1 group of 6 birds (unvaccinated unchallenged control group). The birds were injected by subcutaneous injection in the neck at DO with 0.2 mL of recombinant vaccines containing a target dose of 3000 pfu as described in the Table 32. On D14, blood sample was collected from 5 birds per group for serological testing with the Kit ProFLOK® plus IBD (Synbiotics Corp). The serum of 10 extra one-day-old broiler chickens was tested at DO with the same kit to evaluate the level of IBDV maternal antibody. The birds (10 birds per group) were challenged by the eye drop (0.05 mL per bird) on D23 with 4.3 loglO EID50 of the wIBDV 91-168 isolate.
[0225] Each group was monitored before and after challenge. IBDV clinical signs were recorded for 11 days after challenge (from D23 to D33). At the end of the post-challenge observation period (D33), all the surviving birds were euthanized and necropsied. Body and bursal weights were recorded. Each bursa of Fabricius (BF) was weighted then stored in individual recipients containing 4% formaldehyde for histology. Histological lesions of the bursa were scored according to the scale presented in Table 31.
[0226] A bird was considered as affected if it died and/or showed notable signs of disease and/or severe lesions of the bursa of Fabricius (i.e., histology score >3).
Table 32 Study design and serology results Mean
Vaccine at IBD+ ELISA bursal/body
Group
day-old (DO) titer at D231 weight
ratio2
Gl - 3.9 0.0007
G2 vH VT 13 4.0 0.0015
G3 vHVT114+vHVT13 4.1 0.0015
G4 vSBl-007+vHVT13 3.8 0.0018
G5 vSBl-009+vHVT13 4.0 0.0019
1 Mean IBD+ ELISA titers expressed in log 10 in the serum of 5 birds per group sampled at D23 before challenge;
2 The bursal/body weight ratio of the unvaccinated/unchallenged group was 0.0047
[0227] The mean ELISA IBD+ serological titer at DO was 4.36±0.01 loglO indicating a very high level of IBD maternal antibody at hatch. At D23, the mean ELISA IBD+ titer was still high (3.9) in the control Gl . ELISA mean titers in the vaccinated groups were not significantly different from those of the control group.
[0228] Neither morbidity nor mortality was observed in any of the groups after
challenge. Percentages of protection against severe bursal lesions are shown in Table 32 above. The result showed that co-administration of vHVTl 14, vSB 1-007 or vSB 1-009 did not interfere with vHVT 13 -induced IBD protection indicating a lack of interference. Similarly, the mean bursal/body weight ratios of the vaccinated groups were similar and clearly higher than that of the control group, indicating IBD protection and no difference between the vaccination regimens.
[0229] In conclusion, the data indicate the compatibility between vHVTl 14, vSB 1-007 or vSB 1-009 and vHVT13 for IBD protection.
Example 20 Efficacy of double HVT-ND+IBD (vHVT304 and vHVT306) associated or not with SB-1 and of SB1-ND (vSBl-007 and vSBl-008) in combination with vHVT13 recombinant vaccines, against challenge with a variant E IBDV isolate on
D28 in SPF chickens
[0230] The aim of the study was to assess the efficacy of two double HVT (HVT- ND+IBD: vHVT304 and vHVT306) or two vSB-l-NDV in combination with vHVT13 (vSBl-007+vHVT13, vSBl-008+vHVT13) vectored vaccines administered subcutaneously (SC) to day-old SPF chicks and challenged with IBDV- Variant (VAR-E) 28 days post-vaccination.
[0231] On DO, 105 one-day-old SPF chickens were randomly allocated into 7 groups of 15 birds including a group of challenged controls (G6) and unchallenged controls (G7). The birds of groups Gl to G5 were injected by subcutaneous injection in the neck at DO with 0.2 mL of recombinant and/or SB-1 vaccines containing each a target dose of 2000 pfu. The design of the study is shown in Table 33 below. On D28, all birds from groups Gl to G6 were challenged by the eye drop (0.03 mL containing 3 loglO EID50 per bird) of the IBDV variant E isolate from University of Delaware (USA). Each group was monitored before and after challenge. Eleven days post-challenge, birds were weighed and necropsied. The bursa were collected and weighed. The bursal/body weight ratio (bursa weight/body weight ratio X 100) was calculated.
Table 33 Study design and results of IBD efficacy
Vaccine at Mean bursal/body weight
Group
day-old ratio (*100)
Gl vHVT304 0.33
G2 vHVT304+SB-l 0.33
G3 vHVT306 0.29
G4 vHVT13+vSB 1-007 0.49
G5 vHVT13+vSB 1-008 0.47
G6 - (challenged) 0.13
G7 - (unchallenged) 0.46
[0232] The mean bursal/body weight ratios are shown in Table 33. The challenged control birds had a severe bursal atrophy compared to unchallenged ones. The vSB 1-007 and vSB 1-008 vaccines did not interfere on vHVT 13 -induced protection (G4 and G5). The bursal/body weight ratios of birds vaccinated with the double HVT (HVT-ND+IBD) were slightly lower than the unchallenged control group but were clearly higher than the challenged control groups. Furthermore, the SB-1 serotype 2 Marek's disease vaccine did not interfere with vHVT304-induced IBD protection. [0233] In conclusion, these data indicate that both the combination of a SB1-ND vector with a single HVT-IBD or double HVT expressing both NDV-F and IBDV-VP2 induce IBD protection in a variant E IBDV challenge model.
Example 21 Lack of interference of vHVT114, vSBl-009 and/or SB-1 on vHVT13 induced variant E IBD protection in SPF chickens
[0234] The aim of the study was to assess the IBD efficacy of vHVT13 when
administered by SC or in ovo route concomitantly with vHVTl 14, vSB 1-009 and/or SB- 1 in SPF chicks in an IBDV- Variant (VAR-E) at D28 challenge model.
[0235] 75 one-day-old SPF chickens and 75 SPF 18 to 19 day-old chicken embryo were randomly allocated into 5 groups (Gl to G5 and G6 to G10, respectively) including a group of challenged controls (G4 and G9, respectively) and unchallenged controls (G5 and G10, respectively). The birds of groups Gl to G3 were injected by subcutaneous injection in the neck at DO with 0.2 mL of vaccines containing each a target dose of 3000 pfu except for SB-1 which had a target dose of 1000 PFU. Birds from G6 to G8 received the same vaccine doses but in 0.05 mL volume by the in ovo route 2-3 days before hatch. The design of the study is shown in Table 34 below. At 28 days of age, all birds from groups Gl to G4 and G6 to G9 were challenged by the eye drop (0.03 mL containing 3 log 10 EID50 per bird) of the IBDV variant E isolate from University of Delaware (USA). Each group was monitored before and after challenge. Eleven days post-challenge, birds were weighed and necropsied. The bursa were collected and weighed. The bursal/body weight ratio (bursa weight/body weight ratio X 100) was calculated.
Table 34 Study design and results of IBD efficacy
Vaccine at Administration Mean bursal/body
Group
day-old route weight ratio (*100)
Gl vHVT13+vHVTl 14+SB-l SC 0.56
G2 vHVT13+vHVTl 14+vSB 1-009 sc 0.58
G3 vHVT13+vSB 1-009 sc 0.52
G4 - (challenged) SC 0.13
G5 - (unchallenged) SC 0.51
G6 vHVT13+vHVTl 14+SB-l In ovo 0.54
G7 vHVT13+vHVTl 14+vSB 1-009 In ovo 0.47 G8 vHVT13+vSB 1-009 In ovo 0.53
G9 - (challenged) In ovo 0.14
G10 - (unchallenged) In ovo 0.58
[0236] The mean bursal/body weight ratios are shown in Table 34. The challenged control birds (G4 and G9) had a severe bursal atrophy compared to unchallenged ones. The bursal/body weight ratios of the vaccinated groups (Gl to G3 and G6 to G8) were similar to those of the unchallenged control groups (G5 and G10) and well above those of the challenged control groups (G4 and G9). The lack of interference of vHVTl 14 on vHVT 13 -induced IBD protection after both SC or in ovo routes was surprising and confirmed data obtained in examples 15 and 19.
[0237] In conclusion, these data indicate clearly the compatibility of vHVTl 14+vSBl- 009 or +SB-1 and of vSB 1-009 with vHVT13 when administered by SC or in ovo route in a variant E IBDV challenge model.
Example 22 Efficacy of vHVT114 and vHVT13 and SB1 or vSBl-009 vectors against very virulent plus Marek's disease challenge
[0238] The aim of this study was to evaluate the Marek's disease efficacy induced by different combinations of vaccines including vHVTl 14, vHVT13, SB-1 and/or vSB 1-009 administered by the SC route to one-day-old SPF chicks and challenged 4 days later with the very virulent plus Marek's disease virus (w+MDV) T-King isolate.
[0239] On DO, 100 one-day-old SPF chickens were randomly allocated into 5 groups of 20 birds. The birds from groups 1 to 3 were injected by subcutaneous injection in the neck at DO with 0.2 mL of vaccines containing a target dose of 2000 pfu for each vaccine except for SB-1 for which the target dose was 1000 pfu. Birds from groups 4 and 5 were non-vaccinated and were used as sham controls challenged (group 4) or unchallenged (group 5). The study design is shown in the Table 35. On D4, All birds from groups 1 to 4 were challenged with 0.2 mL of the w+MDV T-King isolate using the intraperitoneal route of administration.
Table 35 Study design and MD protection results
Vaccine at Number of MD Percentage of
Group
day-old (DO) positive/total protection Gl vHVT13+SB-l 7/20 65%
G2 VHVT114+SB-1 7/20 65%
G3 vHVT13+vHVTl 14+vSB 1-009 7/20 65%
G4 (challenged) 20/20 0%
G5 (unchallenged) 0/20 100%
[0240] Each group was monitored daily for any unfavourable reactions before and after challenge. At day 49, all live birds were terminated and necropsied to examine for gross lesions associated with Marek's disease. Chickens were classified as positive for infection with Marek's disease if nervous signs, such as paralysis, locomotive signs attributable to the disease, and severe emaciation or depression are observed, if mortality directly attributable to Marek's Disease occurs, or if gross lesions are observed at necropsy. Lesions might include, but not be limited to, the following: liver, heart, spleen, gonads, kidneys, and muscle lesions
[0241] Results of protection are shown in the Table 35 above. All vaccinated groups (Gl to G3) performed equally, inducing a partial (65%>) MD protection as expected in this very severe and early challenge model. These results indicated that the vector vaccine candidates retain their ability to protect against Marek's disease.
Example 23 Evaluation of Marek's disease efficacy of the SBl-ND vector combined with HVT-IBD vector
[0242] The synergy between parental HVT and SB-1 in inducing a protection against Marek's disease is well known. The SB-1 vector expressing a foreign gene can therefore be mixed with either parental HVT or vectored HVT expressing another foreign gene in order to get a bivalent or a trivalent vaccine solution, respectively. An example of evaluation of Marek's disease efficacy induced by a combination of vSB 1-009 with vHVTl 14 and vHVT13 is shown above (example 22). Marek's disease (MD) efficacy is also demonstrated for Marek's disease vectored recombinants either alone or in combination in other MD challenge models including virulent Marek's disease (vMD) challenge such as GA22, very virulent Marek's disease (wMD) challenge such as RB1B and/or very virulent plus Marek's disease (w+MD) challenge such as the T. King virus. One-day-old chickens are inoculated subcutaneously or 18-19-day-old embryonated eggs are inoculated with a 0.2 ml dose or 0.05 ml dose, respectively, of the test viruses. At five days of age the vaccinated chickens and naive controls are challenged with the relevant Marek's challenge virus (v, w, or w+ MDV). The challenged birds are observed until seven weeks of age. All birds are terminated and necropsied to observe for grossly visible lesions associated with Marek's disease as described in Example 22.
Example 24 Efficacy of vSBl-004, vSBl-006, vSBl-007, vSBl-008, SBl-vectored ND vaccine alone or in association with vHVT13 HVT-vectored IBD vaccine, and the vHVT302 and vHVT304 vaccines against challenges with NDV Texas GB strain at 14 and/or 28 days of age in SPF chickens
[0243] The aim of the study was to assess the efficacy of combinations of different
Marek's disease vector vaccines expressing the NDV F and/or the IBDV VP2 gene against Newcastle disease challenge (Texas GB strain, genotype II) performed at 14 and/or 28 days of age in SPF chickens.
[0244] The characteristics of the 6 NDV recombinant vaccine candidates tested in this study are described in the Table 36 below.
characteristics of the 6 NDV recombinant vaccine candidates tested in this study
Figure imgf000070_0001
[0245] On DO, 225 one-day-old SPF chickens were randomly allocated into 9 groups of 15 birds (Gla to G9a challenged at D14) and 6 groups of 15 birds (Gib, G3b, G4b, G5b, G8b, G9b challenged at D28). The birds were injected by subcutaneous injection in the neck at DO with 0.2 mL containing a target dose of 2000 pfu for recombinant vaccines. The design of the study is shown in Table 37 below. The birds were challenged by the intramuscular route on D14 or D28 with 4.3 and 4.2 loglO EID50 (0.1 mL) velogenic ND Texas GB (genotype II) strain, respectively.
Table 37 Results of ND efficacy % ND protection % ND protection
Vaccine at
Group after ND challenge at after ND challenge day-old (DO)
14 days of age at 28 days of age
Gla & lb - 0% 0%
G2a vSB 1-004 20% ND*
G3a & 3b vSB 1-006 26.6% 73.3%
G4a & 4b vSB 1-007 33.3% 93.3%
G5a & 5b vSB 1-008 46.6% 86.6%
G6a vSBl-006+vHVT13 14% ND
G7a vSBl-008+vHVT13 21.4% ND
G8a & 8b vHVT302 13.3% 80%
G9a & 9b vHVT304 33.3% 93.3%
*ND = not done
[0246] Each group was monitored before and after challenge. NDV clinical signs after challenge were recorded. One bird died in G6 and G7 before challenge reducing the number of birds from 15 to 14 in these groups.
[0247] Percentages of clinical protection (including protection against both mortality and morbidity) are reported in Table 37 above. Full susceptibility was observed in the non- vaccinated challenged control group Gla and Gib thus validating the high severity of challenge. Partial protections ranging from 13.3 to 46.6% were observed after challenge at D14, the highest levels of protection being induced by vSBl-008, vSBl-007 and vHVT304. Protection levels after ND challenge at D28 were much higher for all
vaccinated groups and were again slightly higher in the groups vaccinates with vSBl- 008, vSB 1-007 or vHVT304. These results indicated that ND protection levels were dependent on the date of challenge and on the construct. The vSB 1-008 and vSB 1-007 constructs performed slightly better than vSB 1-004 and vSB 1-006, and the vHVT304 performed slightly better than vHVT302, indicating that different characteristics of the constructs are playing a role in the performances of MDV-based vector vaccines.
[0248] In conclusion, the results of this study showed that ND protection levels induced by Marek's disease vectors expressing NDV F gene may depend on different parameters including the vector, the locus of insertion, the F gene, the promoter, the poly-adenylation site and the challenge conditions. Example 25 Efficacy of double HVT-ND+IBD vHVT304 and vHVT306 vaccines against challenges with NDV Texas GB strain at 14 and/or 28 days
of age in SPF chickens
[0249] The aim of the study was to assess the efficacy of HVT -vectored vaccine
expressing both NDV F and IBD V VP2 genes against Newcastle disease challenge
(Texas GB strain, genotype II) performed at 14 and/or 28 days of age in SPF chickens.
[0250] The characteristics of the 2 recombinant vaccine candidates tested in this study are described in the Table 38 below.
Table 38 Characteristics of the recombinant vaccine candidates
used in this study
Figure imgf000072_0001
[0251] On DO, 90 one-day-old SPF chickens were randomly allocated into 3 groups of 15 birds (Gla to G3 a challenged at D14) and 3 groups of 15 birds (Gib to G3b challenged at D28). The birds were injected by subcutaneous injection in the neck at DO with 0.2 mL containing a target dose of 2000 pfu for recombinant vaccines. The design of the study is shown in Table 39 below. The birds were challenged by the intramuscular route on D14 or D28 with a target dose of 4.0 loglO EID50 (0.1 mL) velogenic ND Texas GB
(genotype II) strain.
Table 39 Results of ND efficacy
% ND protection % ND protection
Vaccine at
Group after ND challenge at after ND challenge day-old (DO)
14 days of age at 28 days of age
Gla & lb 0% 0%
G2a & 2b vHVT304 26.7% 92.9%
G3 a & 3 b vl IVT306 33.3% 86.7%
[0252] Each group was monitored before and after challenge. NDV clinical signs after challenge were recorded. One bird died in G2b before challenge reducing the number of birds from 15 to 14 in this group. [0253] Percentages of clinical protection (including protection against both mortality and morbidity) are reported in Table 39 above. Full susceptibility was observed in the non- vaccinated challenged control group Gla and Gib thus validating the high severity of challenge. Protections levels after challenge at D14 were much lower than those obtained after challenge at D28. These vaccine candidates had the same NDV F expression cassette inserted into 2 different loci of vHVT13 genome. They performed equally in terms of ND protection in the tested conditions, indicating that both insertion loci (IG2 and SORF3-US2) are equally suitable for NDV F cassette insertion.
[0254] In conclusion, the results of this study showed that ND protection levels induced by Marek's disease vectors expressing NDV F gene depend on different parameters including the vector, the locus of insertion, the F gene, the promoter, the poly-adenylation site and the challenge conditions.
Example 26 ND early efficacy induced by double HVT-ND+IBD (vHVT302, VHVT303, and vHVT304) or SBl-vectors (vSBl-006 and vSBl-007) in one day-old
SPF chickens against a velogenic genotype V NDV challenge
[0255] The objective of the study was to evaluate the efficacy of three double HVT- ND+IBD (vHVT302, vHVT303, and vHVT304) and two SB1-ND vectors (vSBl-006 and vSB 1-007) in one day-old SPF chickens against a velogenic genotype V
(Chimalhuacan) NDV challenge performed at D14.
[0256] The characteristics of the 5 recombinant vaccine candidates tested in this study are described in the Table 40 below.
Table 40 Characteristics of the recombinant vaccine candidates
used in this study
Figure imgf000073_0001
[0257] Six groups (1 and 2) of ten one-day-old specific pathogen free (SPF) white
Leghorn chicks were randomly constituted. Birds from groups 2 to 6 were vaccinated by the subcutaneous route (nape of the neck) with a target dose of 2000 PFU as shown in the Table 41 below. Chicks from group 1 were not vaccinated and were kept as control birds. At 2 week-of-age, all birds were challenged with the genotype V Mexican Chimalhuacan (Mex V) velogenic NDV strain. The challenge was performed by the intramuscular (IM) route using 105 Egg Infectious Dose 50 (EID50) diluted in 0.2 ml of physiological sterile water. All birds were monitored until 14 days post-challenge. After challenge, health status of each bird was scored daily as follows: healthy / with specific symptoms (ruffled feathers, prostration, torticollis, tremor) / dead. Any bird that showed specific symptoms for more than 2 days or was noted sick on D28 was taken into account for calculation of morbidity.
Table 41 Results of early ND protection induced by different MDV vectored candidates expressing NDV F gene in SPF day-old chicks
Figure imgf000074_0001
[0258] Results of protection are summarized in Table 41. All control birds died after ND challenge. Variable levels of ND protection were induced by the different tested vaccines ranging from 10% to 80% and from 0% and 60% in terms of protection against mortality and morbidity, respectively. The vHVT304 candidate induced a better protection than the vHVT303 and vHVT302 candidates; this may be due to the exogenous SV40 promoter placed in front of the NDV F gene. The vSB 1-007 performed slightly better than the vSB 1-006. Furthermore, performances obtained with vHVT304 were comparable to those obtained with vSB 1-007 indicating that different Marek's disease vectors can reach the same level of ND protection.
[0259] In conclusion, this study demonstrates that both double HVT-ND+IBD and SB1- ND vectored vaccines can reach significant levels of ND protection in a very severe and early NDV challenge model.
Example 27 ND efficacy induced by the double HVT-ND+IBD vHVT306 administered by in ovo or SC route to one day-old SPF chickens against a velogenic genotype V NDV challenge performed at D28
[0260] The objective of the study was to evaluate the efficacy of one double HVT- ND+IBD (vHVT306) administered by the in ovo or SC route to SPF chickens against a velogenic genotype V (Chimalhuacan) NDV challenge performed at 28 days of age.
[0261] The characteristics of the vHVT306 recombinant vaccine candidate tested in this study are described in Table 42 below. The single HVT-IBD vector vaccine vHVT13 was used as a control.
Table 42 Characteristics of the recombinant vaccine candidate used in this study
Figure imgf000075_0001
[0262] On day -3, 40 SPF embryonated eggs aged around 18 days and 18 hours of incubation were randomly allocated into 2 groups of 20 eggs each. On DO, one group of 12 day-old SPF chicks was added. The definition of groups is given in Table 43 below. The vaccination was performed on D-3 (in ovo route) or on DO (SC route, in the back of the neck) and the target dose of vHVT306 and vHVT13 was 2000PFU/bird. For the in ovo route, hatchability, viability (until D28) and growth of the birds (between hatching and D28) were monitored.
[0263] On D28, 10 birds per group were challenged with virulent ND Chimalhuacan strain. The challenge was performed by the intramuscular (IM) route using 105 Egg Infectious Dose 50 (EID50) diluted in 0.2 ml of physiological sterile water. Birds were monitored until 14 days post-challenge. Specific clinical signs and mortality were recorded. Any bird that showed specific symptoms for more than 2 days or was noted sick on D42 was taken into account for calculation of morbidity. Five and seven days post-challenge (i.e. on D33 and D35), oropharyngeal swab was taken from each surviving bird. All the swabs were analyzed by specific NDV qRT-PCR.
Table 43 Results of ND protection induced by vHVT306 MDV vectored candidate expressing both NDV F and IBDV VP2 genes administered by the SC or in ovo route into SPF chicks
Figure imgf000076_0001
* The threshold titer of the real time RT PCR was set at 2.7 log 10 equivalent EID50
[0264] Full hatchability was recorded after in ovo vaccination in groups 1 and 2 and all hatched birds survived up to D28. No difference in body weights was detected between the two groups at both DO and D28 confirming the perfect safety of vHVT306 when administered in ovo. Results of protection are summarized in Table 43. All vHVT13- vaccinated control birds died by 4 days after ND challenge. Full clinical ND protection was induced by vHVT306 administered by both routes. Furthermore, no shedding was detected after in ovo administration whereas only a few birds shed detectable amount of challenge virus after SC administration.
[0265] In conclusion, this study demonstrates that the double HVT-ND+IBD vHVT306 induce excellent level of ND protection by SC or in ovo administration routes in a very severe heterologous NDV challenge model.
Example 28 Efficacy of double HVT-ND+IBD (vHVT302, vHVT303 and vHVT304) recombinant vaccines, against challenge with a classical
IBDV isolate on D15 in SPF chickens
[0266] The aim of the study was to assess the early IBD efficacy of double HVT
recombinants vHVT302, vHVT303 and vHVT304 recombinant constructs against a virulent infectious bursal disease virus (vIBDV) challenge (Faragher 52/70 strain) performed at 15 days of age in SPF chickens.
[0267] The characteristics of the 3 double HVT-ND+IBD recombinant vaccine
candidates tested in this study are described in the Table 44 below.
Table 44 Characteristics of the expression cassettes
of double HVT recombinants
Figure imgf000077_0001
[0268] On DO, 40 one-day-old SPF chickens were randomly allocated into 4 groups of 10 birds including one control groups (Gl) that was vaccinated with vSB 1-004, a SB-1 vector expressing NDV F gene. Five other SPF birds were kept unvaccinated and unchallenged for bursal/body weights evaluation. The birds were injected by
subcutaneous injection in the neck at DO with 0.2 mL of recombinant vaccines containing a target dose of 2000 pfu as described in the Table 45 below. On D15, blood sample was collected from all birds per group (10 birds per group except for groups 1 and 3 in which 1 bird died before blood sampling) for serological testing with the Kit ProFLOK® plus
IBD (Synbiotics Corp). On D15, birds from all 4 groups were challenged by the eye drop (0.05 mL per bird) with 2.5 loglO EID50.
Table 45 Study design and results of IBD efficacy
ELISA Number
Vaccine at % Mean bursal/body
Group IBD+ titer Dead /Sick
day-old protection2 weight ratio4
(loglO) (total)1
Gl vSB 1-004 0.25 1/9 (9) 0% 0.0014
G2 vHVT302 2.6 0/1 (10) 0.0043
G3 vHVT303 3.0 0/0 (9) 100% 0.0053
G4 vHVT304 2.4 0/0 (10) 80% 0.0034
Birds sick for more than 2 days or still sick on D25 were considered as sick. The number in brackets is the total number of birds in the group that were challenged.
2 Protection against clinical signs and severe bursal lesion (bursal score <3)
4 The bursal/body weight ratio of the unvaccinated/unchallenged group was 0.0043. [0269] Each group was monitored before and after challenge. IBDV clinical signs were recorded for 11 days after challenge (from D15 to D25). At the end of the post-challenge observation period (D25), all the surviving birds were euthanized and necropsied. Body and bursal weights were recorded. Each bursa of Fabricius (BF) was weighted then stored in individual recipients containing 4% formaldehyde for histology. Histological lesions of the bursa were scored according to the scale presented in Table 46.
Table 46 Scoring scale of histological lesions of the bursa of Fabricius*
Score Histology observation/lesions
0 No lesion, normal bursa
1 1% to 25% of the follicles show lymphoid depletion (i.e. less than 50% of
1
depletion in 1 affected follicle), influx of heterophils in lesions
26% to 50% of the follicles show nearly complete lymphoid depletion (i.e. 2 more than 75% of depletion in 1 affected follicle), affected follicles show necrosis and severe influx of heterophils may be detected
^ 51%) to 75%) of the follicles show lymphoid depletion; affected follicles show necrosis lesions and a severe influx of heterophils is detected
76%o to 100%) of the follicles show nearly complete lymphoid depletion;
4 hyperplasia and cyst structures are detected; affected follicles show necrosis and severe influx of heterophils is detected
100% of the follicles show nearly complete lymphoid depletion; complete
5 loss of follicular structure, thickened and folded epithelium, fibrosis of bursal tissue
* sourced from Monograph No. 01/2008:0587 of EU Pharmacopoeia "Avian Infectious Bursal Disease vaccine (live)
[0270] A bird was considered as affected if it died and/or showed notable sign of disease and/or severe lesions of the bursa of Fabricius (i.e., histology score >3).
[0271] The mean ELISA IBD+ antibody titer expressed in loglO before challenge is shown in Table 45. Significant titers were detected in all vaccinated groups that were significantly higher than that of the control group Gl . The serology titer was slightly higher in G3 (vHVT303).
[0272] Severe clinical signs were observed after challenge in all 9 birds of the control group Gl, which lead to the death of 1 bird. Only one vaccinated bird in G2 (vHVT302) showed clinical signs after challenge. Percentages of protection against severe bursal lesions are shown in Table 45 above. Significant IBD protection was observed in all vaccinated groups, a full protection being observed in G3 (vHVT303). The mean bursal/body weight ratios are also shown in Table 45. Ratios in all vaccinated groups were higher than those of the challenged control group Gl and not significantly different from the unvaccinated and unchallenged control group.
[0273] In conclusion, these data indicate that the three double HVT-IBD+ND tested in this study induced IBD antibodies and early IBD protection in a severe IBDV challenge model.
Example 29 Efficacy of five different HVT-ND vaccine candidates against challenges with velogenic NDV ZJ1 (genotype Vlld) isolate at
14 days of age in SPF chickens
[0274] The aim of the study was to assess the efficacy of 5 single HVT recombinant constructs (vHVT39, vHVTl 10, vHVTl 11, vHVTl 12 and vHVTl 13) expressing the NDV F gene against Newcastle disease challenge with velogenic NDV ZJ1 (genotype Vlld) isolate performed at 14 days of age in SPF chickens.
[0275] The characteristics of these 5 vaccine candidates are described in Table 47 below.
Table 47 Characteristics of the HVT-ND recombinant viruses
used in the challenge study
Figure imgf000079_0001
*Wt means that the wild type velogenic F gene sequence was used but the cleavage site was modified to that of a lentogenic virus. Wtnm means that the cleavage site of the wild type sequence was not modified. The Texas velogenic strain belongs to genotype IV and YZCQ to the genotype Vlld.
[0276] On DO, 72 one-day-old SPF chickens were randomly allocated into 5 groups of 12 birds (vaccinated) and 1 group of 12 birds (non- vaccinated controls). The birds were injected by subcutaneous injection in the neck at DO with 0.2 mL of recombinant vaccines containing a target dose of 6000 pfu as described in Table 48 below. The birds were challenged by the intramuscular route on D14 with 5 log 10 EID50 of NDV
ZJ1/2000 (genotype Vlld) velogenic strain. Table 48 Results of ND efficacy
% clinical protection
Vaccine at
Group
day-old (DO) Protection against Mean shedding titer
mortality/morbidity (loglO) at 2/4 dpi
Gl - 0%/0% 3.5/- (all dead)
G2 vHVT039 25%/8% 2.5/4.8
G3 vHVTHO 100%/83% 1.8/2.0
G4 vHVTl l l 100%/67% 1.8/2.8
G5 vHVTl 12 75%/42% 1.7/3.4
G6 vHVTl 13 83%/25% 1.4/3.3
[0277] Each group was monitored before and after challenge. NDV clinical signs and mortality were recorded after challenge. Oropharyngeal swabs were taken at 2 and 4 days post-infection (dpi) for evaluation of viral load by real time RT-PCR using the method described by Wise et al. (2004; Development of a Real-Time Reverse-Transcription PCR for Detection of Newcastle Disease Virus RNA in Clinical Samples. J Clin Microbiol 42, 329-338).
[0278] Percentages of protection against mortality and morbidity are reported in Table 48 above. Full susceptibility was observed in the non-vaccinated challenged control group Gl thus validating the high severity of the challenge. Vaccines induced variable levels of protection against mortality (25-100%) or against morbidity (8%-83%). The best protection level was induced by vHVTl 10 whereas the lowest one was induced by vHVT039, the other candidates giving intermediate results. Results of oropharyngeal shedding at 2 and 4 dpi are also shown in Table 48 above and are in line with those of clinical protection. These vaccine candidates differ in their promoter and F gene sequence. These results show that both of these parameters are important for the design of optimal HVT-ND vaccine candidate.
[0279] In conclusion, the results of this study showed the importance of promoter and F gene sequence in the ND efficacy induced by HVT -vectored ND vaccine candidates.
Example 30 Evaluation of the Newcastle disease efficacy induced by double SB1 constructs expressing IBDV VP2 and NDV F [0280] The aim of the study is to assess the efficacy of double SB1 constructs expressing IBDV VP2 and NDV F against Newcastle disease challenge.
[0281] On DO, one-day-old SPF chickens are randomly allocated into several groups of 10-20 birds, including vaccinated and non- vaccinated groups. The birds of the vaccinated groups are injected by subcutaneous injection in the neck at DO with 0.2 mL containing a target dose of 1000 to 5000 pfu of recombinant vaccines. Alternatively, the same dose in 0.05 mL may be administered in ovo 2 or 3 days before hatch. The birds (at least one vaccinated and one non vaccinated group) are challenged by the intramuscular route at different time after vaccination: for instance, D14, D28 or D42 with about 4.0 loglO EID50 (0.1 mL) of a velogenic NDV strain such as Texas GB (genotype II), ZJ1 (genotype Vlld), Chimalhuacan (genotype V) strain.
[0282] Each group is monitored clinically before and after challenge. NDV clinical signs (morbidity) and mortality are recorded after challenge. Percentages of clinical protection in all groups are calculated. At least 90% of non-vaccinated challenged SPF birds should die or be severely sick after challenge to validate the severity of challenge.
Oropharyngeal and cloacal swabs can be samples at different times after challenge such as 3, 5, 7 and 9 days post-challenge and the viral load can be estimated by real-time RT- PCR. The best candidates will be those who induced the highest level of clinical protection and the lowest level of viral load in the swabs. A similar study can be performed in broilers containing NDV maternal antibodies; however, these maternal antibodies may potentially protect the non- vaccinated birds if the challenge is performed early. The double SB1 construct may also be tested in combination with other Marek's disease vaccine or vector vaccines.
Example 31 Evaluation of the infectious bursal disease efficacy induced by double
SB1 constructs expressing IBDV VP2 and NDV F
[0283] The aim of the study is to assess the IBD efficacy of double SB1 expressing both the IBDV VP2 and the NDV F.
[0284] One-day-old SPF chickens are randomly allocated into several groups of 10 to 20 birds including vaccinated and non- vaccinated controls. Non- vaccinated controls will be separated into 2 subgroups including challenged and unchallenged birds. The birds of vaccinated groups are injected by subcutaneous injection in the neck at DO with 0.2 mL of vaccines containing each a target dose of 1000 to 5000 pfu. Alternatively, the same dose in 0.05 mL may be administered in ovo 2 or 3 days before hatch. At different times after vaccination such as 14, 21, 28 or 42 days post- vaccination, all birds from vaccinated groups and the challenged controls are challenged by the eye drop (0.03 mL containing 2 to 4 log 10 EID50 per bird) of a virulent IBDV (such as the Faragher or the US standard strain), a very virulent IBDV such as the 91-168 isolate or a variant IBDV isolate such as the US Delaware variant E isolate. Each group is clinically monitored before and after challenge. Birds can be necropsied 4 or 5 days post-challenge for bursal gross lesions evaluation. They can also be necropsied 10 to 11 days post-challenge. Gross and/or histological lesions can be evaluated. Furthermore, birds and bursa are weighed the bursal/body weight ratios (bursa weight/body weight ratio X 100) are calculated compared to those of the non- vaccinated unchallenged group. Control SPF challenged birds must show clinical signs and/or have significant gross and/or histological lesions, and/or should have a bursal/body weight ratio significantly lower than the unvaccinated unchallenged control birds to validate the severity of challenge. The efficacy of the vaccine is evaluated by comparing these parameters with unvaccinated/challenged and unvaccinated/unchallenged groups. Such study may be performed in broiler chickens containing IBDV maternal antibodies; however, these maternal antibodies may potentially protect the non-vaccinated birds if the challenge is performed early. The double SB1 construct may also be tested in combination with other Marek's disease vaccine or vector vaccines.
Example 32 Evaluation of the Marek's disease efficacy induced by double SB1 constructs expressing IBDV VP2 and NDV F
[0285] The aim of the study is to evaluate Marek's disease efficacy induced by the SB1 vectors expressing both IBDV VP2 and NDVF.
[0286] One-day-old SPF chickens are randomly allocated into several groups of 20 to 50 birds including vaccinated and non- vaccinated controls. Non- vaccinated controls may be separated into 2 subgroups including challenged and unchallenged birds. The birds of vaccinated groups are injected by subcutaneous injection in the neck at DO with 0.2 mL of vaccines containing each a target dose of 1000 to 5000 pfu. Alternatively, the same dose in 0.05 mL may be administered in ovo 2 or 3 days before hatch. At different times after vaccination such as 3 to 10 days post- vaccination, all birds from vaccinated groups and the challenged controls are challenged by the intraperitoneal route with 0.2 mL of a Marek's disease virus (MDV) strain. MDV strain may be of several pathotypes such as virulent MDV (vMDV) including the JM or GA22 isolate, very virulent MDV (wMDV) such as the RB-1B or Md5 isolate, very virulent plus (w+MDV) such as the T-King or 648A isolate. MDV challenge strain inoculum are prepared by infecting chickens, harvesting and freezing their blood cells into liquid nitrogen in presence of a
cryopreservative such as DMSO. The chicken infectious dose 50 (CID50) is established for each challenge batch before performing vaccination/challenge studies. Each group is clinically monitored before and after challenge. Birds are necropsied after at least 7 weeks post-vaccination and the presence Marek's disease gross lesions is checked in each bird. Lesions might include, but not be limited to, the following: liver, heart, spleen, gonads, kidneys, nerve and muscle lesions. Such study may be performed in broiler chickens containing MDV maternal antibodies. The double SB1 construct may also be tested in combination with other Marek's disease vaccine (for insance HVT and or CVI988 Rispens strains) or MD vector vaccines. MD challenge may also be performed by contact between vaccinated birds and MDV infected non- vaccinated SPF chicks.
[0287] Having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the above examples is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.
[0288] All documents cited or referenced herein ("herein cited documents"), and all documents cited or referenced in herein cited documents, together with any
manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention.

Claims

CLAIMS What we claim is:
1. A composition or vaccine comprising one or more recombinant Gallid herpesvirus 3 (MDV-2) vectors comprising one or more heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen, or a composition or vaccine comprising one or more recombinant Gallid herpesvirus 3 (MDV-2) vectors comprising a mutated glycoprotein C (gC) gene.
2. The composition of claim 1 further comprising one or more compositions or vaccines selected from the group consisting of a recombinant HVT vector (or MDV-3 or Meleagrid herpesvirus- 1) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen, wild type HVT (MDV-3), recombinant MDV-1 vector (or Gallid herpesvirus-2) comprising heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen, wild type MDV-1, and a combination thereof.
3. The composition or vaccine of claim 2 comprising wild type HVT (MDV-3).
4. The composition or vaccine of claim 2 comprising recombinant HVT (MDV-3).
5. The composition or vaccine of claim 2 comprising wild type MDV-1.
6. The composition or vaccine of claim 2 comprising recombinant MDV-1.
7. The composition or vaccine of claim 2 comprising wild type HVT (MDV-3) and wild type MDV-1.
8. The composition or vaccine of claim 2 comprising recombinant HVT (MDV-3) and wild type MDV-1.
9. The composition or vaccine of claim 2 comprising wild type HVT (MDV-3) and recombinant MD V- 1.
10. The composition or vaccine of claim 2 comprising recombinant HVT (MDV-3) and recombinant MD V- 1.
11. The composition or vaccine of any one of claims 1- 10, wherein the heterologous polynucleotide in Gallid herpesvirus 3 is inserted into the region between ORF UL55 and ORF LORF5 in the unique long (UL) region of the Gallid herpesvirus 3 vector.
12. The composition or vaccine of any one of claims 1-10, wherein the heterologous polynucleotide in Gallid herpesvirus 3 is inserted into or to replace Gallid herpesvirus 3 glycoprotein C.
13. The composition or vaccine of any one of claims 1-12, wherein the heterologous polynucleotide in any recombinant vector corresponds to the gene for the poultry pathogen Newcastle Disease Virus F (NDV-F).
14. The composition or vaccine of any one of claims 1-12, wherein the heterologous polynucleotide in any recombinant vector corresponds to the gene for the poultry pathogen Newcastle Disease Virus hemagglutinin neuraminidase (NDV-FiN).
15. The composition or vaccine of any one of claims 1-12, wherein the heterologous polynucleotide in any recombinant vector correspond to one or more gene(s) from the poultry pathogen Marek's Disease Virus.
16. The composition or vaccine of any one of claims 1-12, wherein the heterologous polynucleotide in any recombinant vector corresponds to the gene selected from the group consisting of Marek's Disease Virus glycoprotein C (gC), Marek's Disease Virus glycoprotein B (gB), Marek's Disease Virus glycoprotein E (gE), Marek's Disease Virus glycoprotein I (gl), Marek's Disease Virus glycoprotein H (gH) or Marek's Disease Virus glycoprotein L (gL), and combinations thereof.
17. The composition or vaccine of any one of claims 1-12, wherein the heterologous polynucleotide in any recombinant vector corresponds to the gene for the poultry pathogen Infectious Bursal Disease Virus (i.e., IBDV or Gumboro Disease virus).
18. The composition or vaccine of any one of claims 1-12, wherein the heterologous polynucleotide corresponds to the gene for poultry pathogen IBDV VP2, IBDV VPX, IBDV VP3, and/or IBDV VP4.
19. The composition or vaccine of any one of claims 1-12, wherein the heterologous polynucleotide in any recombinant vector corresponds to the gene for the poultry pathogen infectious laryngotracheitis virus (ILTV).
20. The composition or vaccine of any one of claims 1-12, wherein the heterologous polynucleotide in any recombinant vector corresponds to the gene for the poultry pathogen ILTV glycoprotein B, ILTV glycoprotein I, ILTV glycoprotein D, ILTV glycoprotein E, ILTV glycoprotein C, or combinations thereof.
21. The composition or vaccine of any one of claims 1-12, wherein the heterologous polynucleotide in any recombinant vector corresponds to the gene for the poultry pathogen selected form the group consisting of avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, avian parvovirus, avian astrovirus and chick anemia virus and coccidiosis (Eimeria sp.), Campylobacter sp., Salmonella sp., Mycoplasma gallisepticum and synoviae, Escherichia coli, Pasteurella sp.,
Avibacterium sp., Clostridium sp..
22. The composition or vaccine of any one of claims 1-12, wherein the heterologous polynucleotide in any recombinant vector corresponds to the gene for the poultry pathogen selected form the group consisting of influenza hemaglutinnin (HA), influenza neuraminidase (NA), protective genes from Mycoplasma gallisepticum (MG) and/or Mycoplasma synoviae (MS).
23. The composition or vaccine of any one of claims 1-12, wherein the heterologous polynucleotides in any recombinant vector coding for and expressing one or more antigens of an avian pathogen in recombinant Gallid herpesvirus 3, recombinant HVT (MDV-3), and recombinant MDV-1 encode different antigens.
24. The composition or vaccine of any one of claims 1-23, wherein the recombinant Gallid herpesvirus 3 vector comprises a promoter.
25. The composition or vaccine of any one of claims 1-23 further comprising a
pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant.
26. A recombinant Gallid herpesvirus 3 vector comprising one or more heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen, or a recombinant Gallid herpesvirus 3 vector comprising a mutated gC gene.
27. The recombinant Gallid herpesvirus 3 vector of claim 26, wherein the heterologous polynucleotide in any recombinant vector corresponds to the gene for the poultry pathogen Newcastle Disease Virus F (NDV-F).
28. The recombinant Gallid herpesvirus 3 vector of claim 26, wherein the heterologous polynucleotide in any recombinant vector corresponds to the gene for the poultry pathogen Marek's Disease Virus.
29. The recombinant Gallid herpesvirus 3 vector of claim 26, wherein the heterologous polynucleotide corresponds to the gene selected from the group consisting of Marek's Disease Virus glycoprotein C (gC), Marek's Disease Virus glycoprotein B (gB), Marek's Disease Virus glycoprotein E (gE), Marek's Disease Virus glycoprotein I (gl), Marek's Disease Virus glycoprotein H (gH) or Marek's Disease Virus glycoprotein L (gL), and combinations thereof.
30. The recombinant Gallid herpesvirus 3 vector of claim 26, wherein the heterologous polynucleotide corresponds to the gene for the poultry pathogen Infectious Bursal Disease Virus (i.e., IBDV or Gumboro Disease virus).
31. The recombinant Gallid herpesvirus 3 vector of claim 26, wherein the heterologous polynucleotide corresponds to the gene for poultry pathogen IBDV VP2, IBDV VPX, IBDV VP3, and/or IBDV VP4.
32. The recombinant Gallid herpesvirus 3 vector of claim 26, wherein the heterologous polynucleotide corresponds to the gene for the poultry pathogen infectious laryngotracheitis virus (ILTV).
33. The recombinant Gallid herpesvirus 3 vector of claim 26, wherein the heterologous polynucleotide corresponds to the gene for the poultry pathogen ILTV glycoprotein B, ILTV glycoprotein I, ILTV glycoprotein D, ILTV glycoprotein E, ILTV glycoprotein C, or combinations thereof.
34. The recombinant Gallid herpesvirus 3 vector of claim 26, wherein the heterologous polynucleotide corresponds to the gene for the poultry pathogen selected form the group consisting of avian encephalomyelitis virus, avian reovirus, avian
paramyxovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, avian parvovirus, avian astrovirus and chick anemia virus and coccidiosis (Eimeria sp.), Campylobacter sp., Salmonella sp., Mycoplasma gallisepticum, Mycoplasma synoviae, Escherichia coli, Pasteurella sp., Avibacterium sp., and Clostridium sp.
35. The recombinant Gallid herpesvirus 3 vector of claim 26, wherein the heterologous polynucleotide corresponds to the gene for the poultry pathogen selected form the group consisting of influenza hemaglutinnin (HA), influenza neuraminidase (NA), or both.
36. The recombinant Gallid herpesvirus 3 vector of any one of claims 26-35, wherein the recombinant Gallid herpesvirus 3 vector comprises a promoter.
37. The recombinant Gallid herpesvirus 3 vector of claim 36, wherein the promoter is selected from the group consisting of an immediate early CMV promoter, guinea pig CMV promoter, SV40 promoter, Pseudorabies Virus glycoprotein X promoter, Herpes Simplex Virus- 1 alpha 4 promoter, Marek's Disease Virus glycoprotein A (or gC) promoter, Marek's Disease Virus glycoprotein B promoter, Marek's Disease Virus glycoprotein E promoter, Infectious Laryngotracheitis Virus glycoprotein B, Infectious Laryngotracheitis Virus glycoprotein E, Infectious Laryngotracheitis Virus glycoprotein D or Infectious Laryngotracheitis Virus glycoprotein I promoter, and Bovine Herpesvirus 1.1 VP8 promoter.
38. A method of vaccinating an animal comprising at least one administration of the composition or vector of any one of claims 1-37.
39. The method of claim 38, wherein the method comprises a prime-boost administration regime.
40. A method for inducing an immunogenic or protective response in an animal against one or more avian pathogens comprising at least one administration of the composition or vector of any one of claims 1-37.
41. The method of any one of claims 38-41, wherein the animal is avian.
42. A method for producing a recombinant SB-1 viral vector comprising the introduction into the SB-1 genome one or more isolated heterologous polynucleotide in a nonessential region of the SB-1 genome.
43. The method of claim 42, wherein the heterologous polynucleotide is inserted in the unique long (UL) region, or the unique short (US) region, or to replace SB-1 glycoprotein C gene.
PCT/US2012/067123 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof WO2013082317A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
RS20190443A RS58610B1 (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
DK12805843.5T DK2785374T3 (en) 2011-11-30 2012-11-29 RECOMBINANT GALLID HERPES VIRUS 3 (MDV SEROTYPE 2) VECTORS EXPRESSING ANTIGEN OF PATH CREATURES AND APPLICATIONS THEREOF
ES12805843T ES2719409T5 (en) 2011-11-30 2012-11-29 Recombinant Gallid herpesvirus 3 (mdv serotype 2) vectors expressing avian pathogen antigens and uses thereof
MEP-2019-103A ME03433B (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
LTEP12805843.5T LT2785374T (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
MX2014006361A MX361893B (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof.
IN4833CHN2014 IN2014CN04833A (en) 2011-11-30 2012-11-29
KR1020147017914A KR102013135B1 (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
JP2014544892A JP6149301B2 (en) 2011-11-30 2012-11-29 Recombinant Gallidoherpesvirus 3 (MDV serotype 2) vector expressing avian pathogen antigen and use thereof
HRP20190525TT HRP20190525T4 (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
CN201280066324.4A CN104159605B (en) 2011-11-30 2012-11-29 Express 3 type of recombination avian herpetoviruses (2 type of MDV serotype) carrier of antigen and application thereof of avian pathogens
SI201231570T SI2785374T1 (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
EP12805843.5A EP2785374B2 (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
PL12805843.5T PL2785374T5 (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
HK15100455.1A HK1200018A1 (en) 2011-11-30 2015-01-15 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof 3(mdv 2)
CY20191100394T CY1121528T1 (en) 2011-11-30 2019-04-09 RECOMMENDATED GALLID 3 HARPETIC CARRIERS (MDV SEROTYP 2) EXPRESSING ANTIGENS OF BIRD PATHOGENS AND THEIR USES

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564877P 2011-11-30 2011-11-30
US61/564,877 2011-11-30
US201261694957P 2012-08-30 2012-08-30
US61/694,957 2012-08-30

Publications (3)

Publication Number Publication Date
WO2013082317A2 true WO2013082317A2 (en) 2013-06-06
WO2013082317A3 WO2013082317A3 (en) 2013-08-15
WO2013082317A8 WO2013082317A8 (en) 2014-07-10

Family

ID=47358292

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2012/067123 WO2013082317A2 (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
PCT/US2012/067135 WO2013082327A1 (en) 2011-11-30 2012-11-29 Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2012/067135 WO2013082327A1 (en) 2011-11-30 2012-11-29 Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

Country Status (28)

Country Link
EP (7) EP3578199A1 (en)
JP (1) JP6149301B2 (en)
KR (1) KR102013135B1 (en)
CN (3) CN105920598A (en)
AR (2) AR090401A1 (en)
BR (1) BR112014013276B1 (en)
CA (1) CA2857025C (en)
CO (1) CO7061033A2 (en)
CY (3) CY1121528T1 (en)
DK (3) DK2785373T3 (en)
ES (3) ES2775218T3 (en)
HK (4) HK1247832A1 (en)
HR (3) HRP20190525T4 (en)
HU (3) HUE042471T2 (en)
IN (1) IN2014CN04833A (en)
LT (3) LT2785373T (en)
ME (1) ME03433B (en)
MX (2) MX365984B (en)
PE (1) PE20141482A1 (en)
PH (2) PH12014501174A1 (en)
PL (3) PL3251691T3 (en)
PT (3) PT2785373T (en)
RS (3) RS58610B1 (en)
RU (1) RU2620936C2 (en)
SI (3) SI2785373T1 (en)
UA (1) UA118651C2 (en)
WO (2) WO2013082317A2 (en)
ZA (1) ZA201403804B (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015032909A1 (en) * 2013-09-06 2015-03-12 Ceva Sante Animale Combination vaccines comprising recombinant mov1 vectors and recombinant hvt vectors
EP2831246B1 (en) 2012-03-30 2017-05-03 Ceva Sante Animale Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species
JP6246985B1 (en) * 2014-12-24 2017-12-13 インターベット インターナショナル ベー． フェー． Improved HVT vector ND-IBD vaccine
WO2018112051A1 (en) 2016-12-14 2018-06-21 Merial, Inc. Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
EP3391903A1 (en) * 2017-04-21 2018-10-24 The Pirbright Institute Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens
EP2785374B1 (en) 2011-11-30 2019-01-09 Merial, Inc. Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
WO2019121888A1 (en) 2017-12-20 2019-06-27 Intervet International B.V. Improved diluent for cell-associated alphaherpesvirus vaccine
WO2020127964A1 (en) 2018-12-21 2020-06-25 Ceva Sante Animale Recombinant avian herpes viruses containing multiple foreign genes
CN111542599A (en) * 2017-10-12 2020-08-14 英特维特国际股份有限公司 Recombinant non-pathogenic markholderia virus constructs encoding multiple heterologous antigens
WO2021050701A1 (en) * 2019-09-11 2021-03-18 Zoetis Services Llc Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof
WO2021211553A1 (en) * 2020-04-15 2021-10-21 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant vaccine against marek's disease and newcastle disease
WO2021257706A1 (en) 2020-06-17 2021-12-23 Boehringer Ingelheim Animal Health USA Inc. Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof
WO2022079160A2 (en) 2020-10-15 2022-04-21 Ceva Sante Animale Recombinant hvt and uses thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2851658C (en) 2011-10-21 2022-03-15 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
AR097029A1 (en) * 2013-07-26 2016-02-17 Intervet Int Bv ACCELERATION OF THE IMMUNE RESPONSE INDUCED BY VECTOR VIRUS IN BIRDS, COMPOSITION, USE, VACCINATION METHOD AND METHOD FOR ACCELERATING THE IMMUNE RESPONSE
EP3334833A4 (en) 2015-08-10 2019-04-24 The Texas A&M University System Recombinant turkey herpesvirus vaccines and uses thereof
WO2017216287A1 (en) 2016-06-17 2017-12-21 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens
JOP20190088A1 (en) * 2016-10-21 2019-04-21 Us Agriculture Recombinant vectors expressing antigens of avian influenza virus and uses thereof
CN106929483B (en) * 2017-01-19 2020-09-25 北京邦卓生物科技有限公司 Construction and application of recombinant turkey herpesvirus expressing newcastle disease virus F gene
CN106701693A (en) * 2017-01-19 2017-05-24 北京邦卓生物科技有限公司 Construction and application of recombinant herpesvirus of turkey for expressing GB gene of serum I type Marek's disease virus
CN107099513B (en) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 Construction and application of HVT co-expressing NDV HN and IBDV VP2 genes
CN107254450A (en) * 2017-07-20 2017-10-17 扬州大学 The chimeric Newcastle Disease Virus Vaccine carrier Candidate Strain and construction method for overcoming newcastle disease maternal antibody to influence
CN107603958A (en) * 2017-09-29 2018-01-19 天津农学院 The construction method and recombined adhenovirus of the genes of amalgamation and expression TM 1 and gD gene recombinant adenovirus and application
CN108543067A (en) * 2017-12-25 2018-09-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Co-express the recombinant herpesvirus of turkeys vaccine strain of H5 subtype avian influenza HA albumen and infectious bursa of Fabricius VP2 albumen
US20210046130A1 (en) * 2018-01-24 2021-02-18 Virogin Biotech Canada Ltd Recombinant viral vaccines
CN109468315B (en) * 2018-12-07 2021-09-07 袁隆平农业高科技股份有限公司 Rice flooding-resistant gene Sub1 codominant molecular marker and application thereof
CN110872578B (en) * 2019-11-29 2022-09-16 扬州优邦生物药品有限公司 Variant infectious bursal disease virus, subunit vaccine, preparation method and application thereof
CN112206317B (en) * 2020-10-12 2023-09-22 浙江省淡水水产研究所 Preparation method of grass carp hemorrhagic disease bivalent nucleic acid bacterial ghost vaccine
CN114317827B (en) * 2022-01-07 2023-03-24 河南省农业科学院 Multiplex PCR (polymerase chain reaction) primer, method and application for identifying infection and immunity of Marek's disease viruses of different serotypes

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
WO1987004463A1 (en) 1986-01-27 1987-07-30 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
EP0517292A1 (en) 1991-05-27 1992-12-09 SOLVAY (Société Anonyme) Recombinant Avipox virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5187087A (en) 1989-12-04 1993-02-16 Akzo N.V. Recominbant herpesvirus of turkeys and live vector vaccines derived thereof
EP0719864A2 (en) 1994-12-30 1996-07-03 Rhone Merieux Recombinant live avian vaccin, using an avian herpes virus as vector
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5756103A (en) 1991-03-07 1998-05-26 Virogenetics Corporation Alvac canarypox virus recombinants comprising heterlogous inserts
US5853733A (en) 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
US6183753B1 (en) 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
US6719979B2 (en) 1998-06-19 2004-04-13 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Newcastle disease virus infectious clones, vaccines and diagnostic assays

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2779447B2 (en) 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 Method for producing recombinant gene using attenuated Marek's disease virus vector and recombinant of the virus
FR2719056B1 (en) 1994-04-20 1996-09-06 Rhone Merieux Herpesvirus transformed to express gD in vitro.
PT776361E (en) * 1994-08-09 2007-04-30 Schering Plough Ltd Recombinant herpesvirus of turkeys and uses thereof
RU2059414C1 (en) * 1994-12-09 1996-05-10 Государственная Курская биофабрика - Фирма "БИОК" Multipartial vaccine for mareck disease prophylaxis and a method of its preparing
JPH104956A (en) * 1996-06-21 1998-01-13 Univ Michigan State Improvement in maintainable cell strain in order to produce vaccine for marek's disease
FR2751225B1 (en) * 1996-07-19 1998-11-27 Rhone Merieux AVIAN POLYNUCLEOTIDE VACCINE FORMULA
EP1026246B1 (en) * 1997-10-03 2006-11-29 Zeon Corporation Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
KR100354972B1 (en) * 2000-04-11 2002-10-05 대한민국 Recombinant Marek's disease virus type 2 expressing the S1 glycoprotein of infectious bronchitis virus and a method for constructing thereof
US6764684B2 (en) * 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
US6866852B2 (en) 2002-01-31 2005-03-15 Zeon Corporation Recombinant herpesvirus of turkeys and use thereof
KR100801180B1 (en) * 2006-09-26 2008-02-05 주식회사 고려비엔피 Attenuated recombinant newcastle disease virus and vaccine containing the same
WO2010119112A1 (en) * 2009-04-15 2010-10-21 Ceva Sante Animale Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
CA2857025C (en) 2011-11-30 2021-08-03 Merial Limited Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1987004463A1 (en) 1986-01-27 1987-07-30 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
US5187087A (en) 1989-12-04 1993-02-16 Akzo N.V. Recominbant herpesvirus of turkeys and live vector vaccines derived thereof
US5756103A (en) 1991-03-07 1998-05-26 Virogenetics Corporation Alvac canarypox virus recombinants comprising heterlogous inserts
EP0517292A1 (en) 1991-05-27 1992-12-09 SOLVAY (Société Anonyme) Recombinant Avipox virus
US5853733A (en) 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US6183753B1 (en) 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
EP0719864A2 (en) 1994-12-30 1996-07-03 Rhone Merieux Recombinant live avian vaccin, using an avian herpes virus as vector
US5980906A (en) 1994-12-30 1999-11-09 Rhone Merieux Live recombinant avian vaccine using an avian herpesvirus as vector
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
US6719979B2 (en) 1998-06-19 2004-04-13 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Newcastle disease virus infectious clones, vaccines and diagnostic assays

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical Biotechnology", vol. 6, article "Vaccine Design The Subunit and Adjuvant Approach", pages: 03,157
BENJAMIN LEWIN: "Genes V.", 1994, OXFORD UNIVERSITY PRESS
BUBLOT ET AL., J.COMP. PATH., vol. 137, 2007, pages S81 - S84
GLENN E. MORRIS,: "Epitope Mapping Protocols in Methods in Molecular Biology", vol. 66, 1996
HECKERT ET AL., AVIAN DIS, vol. 40, 1996, pages 770 - 777
IGARASHI T. ET AL., J. GEN. VIROL., vol. 70, 1989, pages 1789 - 1804
J. SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual, 2nd Edition", 1989, COLD SPRING HARBOR LABORATORY
JAROSINSKI ET AL., J. OF VIROLOGY, vol. 81, 2007, pages 10575 - 10587
JAROSINSKI ET AL., J. OF VIROLOGY, vol. 84, 2010, pages 7911 - 7916
JOHNSON ET AL., AVIAN DIS, vol. 54, 2010, pages 1251 - 1259
KENDREW ET AL.: "The Encyclopedia of Molecular Biology", 1994, BLACKWELL SCIENCE LTD.
M. POWELL, M.: "Vaccine Design, The Subunit and Adjuvant Approach", 1995, PLENUM PRESS
MORGAN ET AL., AVIAN DIS, vol. 37, 1993, pages 1032 - 40
MORGAN ET AL., AVIAN DIS., vol. 36, 1992, pages 858 - 70
MUTWIRI G. ET AL., VET. IMMUNOL. IMMUNOPATH, vol. 91, 2003, pages 89 - 103
PETHERBRIDGE ET AL., J. VIROL. METHODS, vol. 158, 2009, pages 11 - 17
PETHERBRIDGE ET AL.: "158", J. VIROL. METHODS, 2009, pages 11 - 17
PONTAROLLO R.A. ET AL., VET. IMMUNOL. IMMUNOPATH, vol. 84, 2002, pages 43 - 59
ROBERT A. MEYERS: "Molecular Biology and Biotechnology: a Comprehensive Desk Reference", 1995, VCH PUBLISHERS, INC.
RUDOLF HEINE: "Issues of the Poultry Recombinant Viral Vector Vaccines which May Cause an Effect on the Economic Benefits of those Vaccines", CONGRESS IN CANCUN, MEXICO, 2011
SINGH ET AL., RESEARCH IN VETERINARY SCIENCE, vol. 89, 2010, pages 140 - 145
SLACUM G; HEIN R; LYNCH P: "The compatibility of HVT recombinants with other Marek's disease vaccines", 58TH WESTERN POULTRY DISEASE CONFERENCE, 2009, pages 84, XP009167868
SPATZ ET AL., VIRUS GENES, vol. 42, 2011, pages 331 - 338
SPATZ; SCHAT, VIRUS GENE, vol. 42, 2011, pages 331 - 338
WERNETTE C.M. ET AL., VET. IMMUNOL. IMMUNOPATH, vol. 84, 2002, pages 223 - 236
WISE ET AL.: "Development of a Real-Time Reverse-Transcription PCR for Detection of Newcastle Disease Virus RNA in Clinical Samples", J CLIN MICROBIOL, vol. 42, 2004, pages 329 - 338
WISE ET AL.: "Development of a Real-Time Reverse-Transcription PCR for Detection of Newcastle Disease Virus RNA in Clinical Samples", J. CLIN. MICROBIOL., vol. 42, 2004, pages 328 - 338
WITTER ET AL., AVIAN DIS, vol. 31, 1987, pages 829 - 840
WITTER ET AL., AVIAN DISEASES, vol. 34, 1990, pages 944 - 957
WITTER, AVIAN DIS, vol. 31, 1987, pages 752 - 765
WITTER, AVIAN PATHOLOGY, vol. 21, 1992, pages 601 - 614
WITTER, AVIAN PATHOLOGY, vol. 24, 1995, pages 665 - 678
WITTER; LEE, AVIAN PATHOLOGY, vol. 13, 1984, pages 75 - 92

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2785374B1 (en) 2011-11-30 2019-01-09 Merial, Inc. Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
EP2831246B1 (en) 2012-03-30 2017-05-03 Ceva Sante Animale Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species
US10245315B2 (en) 2012-03-30 2019-04-02 Ceva Sante Animale Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species
WO2015032909A1 (en) * 2013-09-06 2015-03-12 Ceva Sante Animale Combination vaccines comprising recombinant mov1 vectors and recombinant hvt vectors
JP6246985B1 (en) * 2014-12-24 2017-12-13 インターベット インターナショナル ベー． フェー． Improved HVT vector ND-IBD vaccine
EP3744342A1 (en) 2016-12-14 2020-12-02 Boehringer Ingelheim Animal Health USA Inc. Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
EP3854415A1 (en) 2016-12-14 2021-07-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
KR102617503B1 (en) * 2016-12-14 2023-12-29 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 Recombinant HVT vectors expressing multiple antigens of avian pathogens and vaccines containing them
KR20190098168A (en) * 2016-12-14 2019-08-21 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 Recombinant HVT vectors expressing multiple antigens of avian pathogens and vaccines comprising the same
EP4112072A1 (en) 2016-12-14 2023-01-04 Boehringer Ingelheim Animal Health USA Inc. Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
WO2018112051A1 (en) 2016-12-14 2018-06-21 Merial, Inc. Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
EP4085928A1 (en) 2016-12-14 2022-11-09 Boehringer Ingelheim Animal Health USA Inc. Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them
EP3391903A1 (en) * 2017-04-21 2018-10-24 The Pirbright Institute Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens
WO2018193110A1 (en) * 2017-04-21 2018-10-25 The Pirbright Institute Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens
CN111542599A (en) * 2017-10-12 2020-08-14 英特维特国际股份有限公司 Recombinant non-pathogenic markholderia virus constructs encoding multiple heterologous antigens
US11229698B2 (en) * 2017-10-12 2022-01-25 Intervet Inc. Recombinant non-pathogenic Marek's Disease virus constructs encoding multiple heterologous antigens
WO2019121888A1 (en) 2017-12-20 2019-06-27 Intervet International B.V. Improved diluent for cell-associated alphaherpesvirus vaccine
WO2020127964A1 (en) 2018-12-21 2020-06-25 Ceva Sante Animale Recombinant avian herpes viruses containing multiple foreign genes
CN114616325A (en) * 2019-09-11 2022-06-10 硕腾服务有限责任公司 Recombinant herpesvirus of turkeys vector expressing avian pathogen antigen and uses thereof
US11464849B2 (en) 2019-09-11 2022-10-11 Zoetis Services Llc Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof
WO2021050701A1 (en) * 2019-09-11 2021-03-18 Zoetis Services Llc Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof
US11883481B2 (en) 2019-09-11 2024-01-30 Zoetis Services Llc Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof
WO2021211553A1 (en) * 2020-04-15 2021-10-21 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant vaccine against marek's disease and newcastle disease
WO2021257706A1 (en) 2020-06-17 2021-12-23 Boehringer Ingelheim Animal Health USA Inc. Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof
EP4378474A2 (en) 2020-06-17 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof
EP4378474A3 (en) * 2020-06-17 2024-08-28 Boehringer Ingelheim Vetmedica GmbH Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof
WO2022079160A2 (en) 2020-10-15 2022-04-21 Ceva Sante Animale Recombinant hvt and uses thereof

Also Published As

Publication number Publication date
AR090401A1 (en) 2014-11-12
CN105920598A (en) 2016-09-07
MX2014006360A (en) 2015-03-05
HUE047724T2 (en) 2020-05-28
HRP20192215T1 (en) 2020-02-21
CA2857025A1 (en) 2013-06-06
HRP20192241T1 (en) 2020-03-06
MX2014006361A (en) 2015-03-05
SI2785373T1 (en) 2020-02-28
DK3251691T3 (en) 2020-02-10
BR112014013276A2 (en) 2018-05-15
HRP20190525T8 (en) 2023-01-20
HRP20190525T1 (en) 2019-05-03
EP3251691B1 (en) 2019-11-20
PL3251691T3 (en) 2020-06-01
PH12015502790B1 (en) 2017-07-10
EP2785374B1 (en) 2019-01-09
PT2785373T (en) 2020-01-27
RS58610B1 (en) 2019-05-31
EP3251691A1 (en) 2017-12-06
EP3263130A1 (en) 2018-01-03
SI2785374T1 (en) 2019-04-30
KR102013135B1 (en) 2019-08-22
PH12015502790A1 (en) 2017-07-10
WO2013082327A8 (en) 2014-07-03
SI3251691T1 (en) 2020-02-28
PL2785374T5 (en) 2023-01-09
PT2785374T (en) 2019-05-09
CO7061033A2 (en) 2014-09-19
AR089039A1 (en) 2014-07-23
CY1121528T1 (en) 2020-05-29
CY1124618T1 (en) 2022-03-24
CN104159604A (en) 2014-11-19
CY1122872T1 (en) 2021-05-05
LT3251691T (en) 2020-02-10
HUE047909T2 (en) 2020-05-28
ES2719409T5 (en) 2022-12-07
WO2013082317A3 (en) 2013-08-15
HK1248566A1 (en) 2018-10-19
RS59893B1 (en) 2020-03-31
PL2785374T3 (en) 2019-07-31
ME03433B (en) 2020-01-20
CN104159605A (en) 2014-11-19
KR20140097515A (en) 2014-08-06
JP2015500806A (en) 2015-01-08
EP3572092A1 (en) 2019-11-27
RU2014126375A (en) 2016-01-27
PL2785373T3 (en) 2020-06-01
EP2785374A2 (en) 2014-10-08
RS59892B1 (en) 2020-03-31
EP4112073A1 (en) 2023-01-04
JP6149301B2 (en) 2017-06-21
DK2785373T3 (en) 2020-02-03
EP3578199A1 (en) 2019-12-11
DK2785374T3 (en) 2019-04-08
MX361893B (en) 2018-12-18
IN2014CN04833A (en) 2015-09-18
RU2620936C2 (en) 2017-05-30
PH12014501174B1 (en) 2014-09-08
EP2785373A1 (en) 2014-10-08
LT2785373T (en) 2020-02-10
HK1247832A1 (en) 2018-10-05
ZA201403804B (en) 2015-04-29
HK1197175A1 (en) 2015-01-09
ES2785045T3 (en) 2020-10-05
PH12014501174A1 (en) 2014-09-08
CN104159605B (en) 2019-04-19
HRP20190525T4 (en) 2023-01-20
PE20141482A1 (en) 2014-11-08
ES2719409T3 (en) 2019-07-10
WO2013082327A1 (en) 2013-06-06
CN104159604B (en) 2016-08-24
WO2013082317A8 (en) 2014-07-10
BR112014013276B1 (en) 2021-07-27
UA118651C2 (en) 2019-02-25
EP2785373B1 (en) 2019-11-20
EP2785374B2 (en) 2022-08-17
HK1200018A1 (en) 2015-07-31
HUE042471T2 (en) 2019-07-29
ES2775218T3 (en) 2020-07-24
LT2785374T (en) 2019-04-25
PT3251691T (en) 2020-01-28
CA2857025C (en) 2021-08-03
MX365984B (en) 2019-06-21

Similar Documents

Publication Publication Date Title
EP2785374B2 (en) Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
US9770502B2 (en) Recombinant gallid herpesvirus 3 (MDV serotype 2) vectors expressing antigens of avian pathogens and uses thereof
US11421249B2 (en) Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof
US9555096B2 (en) Recombinant HVT vectors expressing antigens of avian pathogens and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12805843

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/006361

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014544892

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20147017914

Country of ref document: KR

Kind code of ref document: A